Serotonin receptor modulators for the treatment of addictions and overdoses

Abstract

Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of using them for treating and preventing addictions and overdoses.

Description

[0001] SEROTONIN RECEPTOR MODULATORS FOR THE TREATMENT OF ADDICTIONS AND

[0002] OVERDOSES

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS

[0004] This application claims priority to U.S. Application No. 63 / 642,831 , filed May 5, 2024, U.S. Application No. 63 / 593,604, filed October 27, 2023, U.S. Application No. 63 / 588,341 , filed October 6, 2023, and U.S. Application No. 63 / 520,868, filed August 21 , 2023, the entire contents of each being incorporated by reference herein for all purposes.

[0005] TECHNICAL FIELD

[0006] This disclosure relates to hallucinogenic and non-hallucinogenic serotonin receptor agonist compounds, combinations thereof, and methods of using them for treating and preventing addictions and overdoses.

[0007] BACKGROUND

[0008] Presently, there is no cure for drug addiction. Indeed, the overwhelming majority (up to 85%) of patients undergoing modern day drug rehabilitation relapse back into compulsive drug taking. This relapse is motivated by the intense craving for the drug that is experienced by the drug-withdrawn addict even after years of being drug free. Psychosocial therapy is widely employed for the long-term treatment of drug addiction, but there remains an exceptionally high incidence of relapse to drug taking in the drug-withdrawn addict.

[0009] Methamphetamine ("METH") is an increasingly popular psychostimulant / hallucinogenic drug with an extremely high abuse liability. METH ('meth', 'speed', 'ice', 'crystal', and 'crank') is a Schedule II stimulant that "on the street" comes in forms amenable to smoking, snorting, oral ingestion or injection. METH often is abused in a relatively drawn out "binge and crash" pattern known as a "run". This typically lasts for several days, during which time the user foregoes food and sleep. Long-term, heavy use can initiate violent rages, induce anxiety, confusion and insomnia, and evoke a number of psychotic features, including intense paranoia, hallucinations, and delusions that endure for years after drug use has ceased. When METH use is stopped, the user experiences a particularly intense craving for the drug that is protracted. There currently is no approved medication or efficacious pharmacotherapy for METH abuse.

[0010] To date, very little work has been done in developing novel serotonergic drugs that may be capable of treating addiction or overdose. Given that modulation of the serotonin receptors 5-HT2A and 5-HT2C have shown promise in some addiction models, there remains a need to develop “multifunctional” serotonergic drugs that can selectively modulate target receptors for treating a variety of addictions and drug overdoses.

[0011] SUMMARY

[0012] Disclosed herein are methods of treating a disease or condition comprising

[0013] 1 01312-0021-00PCT administering, to a subject in need thereof, a compound of Formula I: wherein is a single or double bond as needed to satisfy atom valences; Y are each independently selected from hydrogen, deuterium, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2- C8 alkynyl, or Y is taken together with X and the nitrogen atom therebetween to form a 3- to 7- membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9; W1 is selected from O, Se, Se(O), SeO2, S, S(O), NR1a, C(R50)(R51), and SO2 when the to which W1is attached is a single bond, and W1is selected from C(R50) and N when the to which W1is attached is a double bond; W2 is selected from –C(R30)(R31)– and –(C(R30)(R31))2–; W4 is selected from C(R2)(R2’) and NR1c when a to which W4 is attached is a single bond, and W4 is selected from C(R2) and N when a to which W4 is attached is a double bond; W5 is selected from C(R51’) and N when the to which W5 is attached is a single bond, and W5 is C when the to which W5 is attached is a double bond; Z4is selected from N and CR4; Z5is selected from N and CR5; Z6is selected from N and CR6; Z7 is selected from N and CR7; 2 01312-0021-00PCT R1a and R1c are each independently selected from hydrogen, deuterium, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, -C(O)R8, -C(O)OR8, -P(O)(OR9)2, -C(O)N(R9)2, -SOR8, and -SO2R8; R2, R2’, R3, R3’, R4, R5, R6, R7, R30, R31, R50, R51, and R51’are each independently selected from hydrogen, deuterium, -N(R9)2, -C(O)R8, -OC(O)OR8, -C(O)OR8, -OC(O)R8, -SR9, -P(O)(OR9)2, -C(O)N(R9)2, halo, hydroxyl, optionally substituted C1- C8alkyl, optionally substituted -C1-C8alkoxy, optionally substituted C2-C8alkenyl and optionally substituted C2-C8alkynyl, or Y is absent and R3is taken together with the carbon to which it is attached and the nitrogen atom to which X is attached to form an optionally substituted 3- to 9- membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9, or Y is absent and R2 is taken together with the carbon to which it is attached and the nitrogen atom to which X is attached to form an optionally substituted 5- to 9-membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9; R8 is, independently for each occurrence, selected from hydrogen, optionally substituted C1-C8alkyl, optionally substituted C2-C8alkenyl, optionally substituted C2-C8alkynyl, optionally substituted heteroaryl, and optionally substituted aryl; and R9 is, independently for each occurrence, selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted heteroaryl, and optionally substituted aryl; and and salts, solvates, hydrates, and prodrugs thereof. In certain embodiments, the disease or condition is chosen from addiction and overdose. The disclosure also relates to methods of treating a disease or condition comprising administering, to a subject in need thereof, compositions comprising, consisting of, or consisting essentially of a compound of Formula I and an excipient, wherein the disease or condition is chosen from addiction and overdose. The disclosure further relates to methods of treating a disease or condition comprising administering, to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I and an excipient, wherein the excipient is a pharmaceutically acceptable carrier and wherein the disease or condition is chosen from addiction and overdose. Embodiments of the disclosure also relate to methods of treating a disease or condition comprising administering, to a subject in need thereof, a composition comprising, consisting of, 3 01312-0021-00PCT or consisting essentially of a first compound selected from compounds of Formula I; and a second active compound, wherein the disease or condition is chosen from addiction and overdose. In certain embodiments, the second active compound comprises a serotonergic compound. In certain embodiments, the compound of Formula I is not: Unless context indicates differently, reference to a compound of Formula I includes all subgenera of Formula I (e.g., Formulae Ia, Ib, II, etc.). DETAILED DESCRIPTION COMPOUNDS 4 01312-0021-00PCT Disclosed herein are compounds of Formula I: wherein is a single or double bond as needed to satisfy atom valences; X and Y are each independently selected from hydrogen, deuterium, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2- C8 alkynyl, or Y is taken together with X and the nitrogen atom therebetween to form a 3- to 7- membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9; W1 is selected from O, Se, Se(O), SeO2, S, S(O), NR1a, C(R50)(R51), and SO2 when the to which W1 is attached is a single bond, and W1 is selected from C(R50) and N when the to which W1 is attached is a double bond; W2 is selected from –C(R30)(R31)– and –(C(R30)(R31))2–; W4 is selected from C(R2)(R2’) and NR1c when a to which W4 is attached is a single bond, and W4 is selected from C(R2) and N when a to which W4 is attached is a double bond; W5 is selected from C(R51’) and N when the to which W5 is attached is a single bond, and W5 is C when the to which W5 is attached is a double bond; Z4is selected from N and CR4; Z5is selected from N and CR5; Z6 is selected from N and CR6; 5 01312-0021-00PCT Z7 is selected from N and CR7; R1aand R1care each independently selected from hydrogen, deuterium, optionally substituted C1-C8alkyl, optionally substituted C2-C8alkenyl, optionally substituted C2-C8alkynyl, -C(O)R8, -C(O)OR8, -P(O)(OR9)2, -C(O)N(R9)2, -SOR8, and -SO2R8; R2, R2’, R3, R3’, R4, R5, R6, R7, R30, R31, R50, R51, and R51’are each independently selected from hydrogen, deuterium, -N(R9)2, -C(O)R8, -OC(O)OR8, -C(O)OR8, -OC(O)R8, -SR9, -P(O)(OR9)2, -C(O)N(R9)2, halo, hydroxyl, optionally substituted C1- C8alkyl, optionally substituted -C1-C8alkoxy, optionally substituted C2-C8alkenyl and optionally substituted C2-C8alkynyl, or Y is absent and R3is taken together with the carbon to which it is attached and the nitrogen atom to which X is attached to form an optionally substituted 3- to 9- membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9, or Y is absent and R2 is taken together with the carbon to which it is attached and the nitrogen atom to which X is attached to form an optionally substituted 5- to 9-membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9; R8 is, independently for each occurrence, selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted heteroaryl, and optionally substituted aryl; and R9 is, independently for each occurrence, selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted heteroaryl, and optionally substituted aryl; and salts, solvates, hydrates, and prodrugs thereof. As used herein, the term “alkyl” refers to straight, branched or cyclic saturated hydrocarbon group. As used herein, alkyl has 1 to 20 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms or 1 to 3 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl. When an alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl, isobutyl, sec-butyl, and tert-butyl; and “propyl” includes n-propyl and isopropyl. In some embodiments, a deuterium atom maybe be a replacement for a hydrogen atom. When the alkyl groups described herein are said to be “substituted,” they may be substituted with any substituent or substituents found in the exemplary compounds and embodiments disclosed herein, as well as deuterium, aryl, 6 01312-0021-00PCT heteroaryl, hydroxy, -C(O)R8, -C(O)OR8, alkoxy, alkyl sulfonamido, aryl sulfonamido, and halo. In certain embodiments, at least one hydrogen for a compound of Formula I, II, II, IV, or V is replaced with a deuterium. As used herein, the term “alkenyl” refers to an alkyl group that contains one or more carbon-carbon double bonds. An “alkynyl” group is an alkyl group that contains one or more carbon-carbon triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, allyl, -CH=CH(CH3), -CH=C(CH3)2, -C(CH3)=CH2, -C(CH3)=CH(CH3), -C(CH2CH3)=CH2, -C≡CH, -C≡C(CH3), -C≡C(CH2CH3), -CH2C≡CH, -CH2C≡C(CH3) and -CH2C≡C(CH2CH3), among others. When the alkenyl and alkynyl groups described herein are said to be “substituted,” they may be substituted with any substituent or substituents found in the exemplary compounds and embodiments disclosed herein, as well as deuterium, aryl, heteroaryl, hydroxy, -C(O)R8, -C(O)OR8, alkoxy, alkyl sulfonamido, aryl sulfonamido, and halo. As used herein, the term “cycloalkenyl” refers to a cyclic alkyl group that is partially saturated. As used herein, the term “alkoxy” refers to -O-(alkyl), wherein alkyl is as defined above. As used herein, the term “aryl” refers to an aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl). In some embodiments, aryl groups contain 6-14 carbons and in others from 6 to 12 or even 6 to 10 carbon atoms in the ring portions of the groups. Particular aryls include phenyl, biphenyl, naphthyl and the like. The phrase “aryl groups” also includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like). When the aryl groups described herein are said to be “substituted,” they may be substituted with any substituent or substituents found in the exemplary compounds and embodiments disclosed herein, as well as deuterium, aryl, alkyl, heteroaryl, hydroxyl, and halo. As used herein, the term “heteroaryl” refers to an aromatic ring system having one to four heteroatoms as ring atoms in a heteroaromatic ring system, wherein the remainder of the atoms are carbon atoms. In some embodiments, heteroaryl groups contain 3 to 6 ring atoms, and in others from 6 to 9 or even 6 to 10 atoms in the ring portions of the groups. Suitable heteroatoms include oxygen, sulfur and nitrogen. In certain embodiments, the heteroaryl ring system is monocyclic or bicyclic. As used herein, the term “heterocyclic ring” or “heterocyclyl” or “heterocycloalkyl” refers to a non-aromatic cycloalkyl in which one to four of the ring carbon atoms are independently replaced with a heteroatom selected from O, S and N. In some embodiments, heterocyclyl groups include 3 to 10 ring members, whereas other such groups have 3 to 5, 3 to 6, or 3 to 8 7 01312-0021-00PCT ring members. Heterocyclyls can also be bonded to other groups at any ring atom (i.e., at any carbon atom or heteroatom of the heterocyclic ring). A heterocycloalkyl group can be substituted or unsubstituted. When the heterocyclyl groups described herein are said to be “substituted,” they may be substituted with any substituent or substituents found in the exemplary compounds and embodiments disclosed herein, as well as deuterium, alkyl, alkenyl, aryl, heteroaryl, hydroxy, alkoxy, -C(O)R8, -C(O)OR8, alkyl sulfonamido, aryl sulfonamido, and halo. Heterocyclyl groups encompass saturated and partially saturated ring systems. Further, the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to an aryl or heteroaryl ring, regardless of the attachment to the remainder of the molecule. The phrase also includes bridged polycyclic ring systems containing a heteroatom. As used herein, the term “heteromoieties” refers to any groups containing a heteroatom, for example, amino, O, Se, Se(O), SeO2, S, S(O), and SO2. As used herein, the term “halo” or “halogen” refers to a fluorine, chlorine, bromine or iodine atom. As used herein, the term “hydroxyl” refers to -OH group. As used herein, the term “alkyl sulfonamido” refers to a moiety containing -S(=O)2-N(R)2, wherein each R group is chosen from an alkyl and H. As used herein, the term “aryl sulfonamido” refers to a moiety containing -S(=O)2-N(R)2, wherein each R group is chosen from an aryl and H. In some embodiments, the compound of Formula I contains one or more stereocenters. In some circumstances, the compound of Formula I comprises a racemic mixture. In some embodiments, the compound of Formula I comprises the (S) enantiomer. In some embodiments, the compound of Formula I comprises the (R) enantiomer. In some embodiments, the (S) and (R) designations refer to the absolute stereochemistry of a compound having more than one stereocenter. In such cases, the conformation of one of those stereocenters may be referred to in terms of its relative (D) or (L) configuration. In some embodiments, X and Y are independently selected from hydrogen, deuterium, and optionally substituted C1-C8 alkyl, wherein the alkyl group comprises a cycloalkyl moiety (e.g., cyclopropyl, cyclobutyl, etc.). In some embodiments, R2, R2’, R3, R3’, R4, R5, R6, R7, R30, R31, R50, R51, R51’, R60 and R61 are each independently selected from hydrogen, deuterium, -N(R9)2, -C(O)R8, -OC(O)OR8, - C(O)OR8, 8 01312-0021-00PCT -OC(O)R8, -SR9, -P(O)(OR9)2, -C(O)N(R9)2, halo, hydroxyl, optionally substituted C1- C8alkyl, optionally substituted -C1-C8alkoxy, optionally substituted C2-C8alkenyl and optionally substituted C2-C8alkynyl. In some embodiments, Y is absent and R3 is taken together with the carbon to which it is attached and the nitrogen atom to which X is attached to form an optionally substituted 3- to 9- membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9. In some embodiments, Y is absent and W4is C(R2)(R2’), C(R2) or NR1cwherein R1cor R2is taken together with the nitrogen or carbon to which it is attached, respectively, and the nitrogen atom to which X is attached to form an optionally substituted 5- to 9-membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9. Exemplary compounds of such embodiments include, but are not limited to, those compounds of Formula II. In some embodiments, R4 and R5 are each independently selected from hydrogen, deuterium, -N(R9)2, -SR9, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, halo, hydroxyl, -C1-C8 alkoxy, -C(O)R8, -OC(O)R8, - OC(O)OR8, -OP(O)(OR9)2, and -OSO2R8. In some embodiments, R4 and R5 are each independently selected from hydrogen, deuterium, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, halo, hydroxyl, -C1-C8 alkoxy, -OC(O)R8, -OC(O)OR8, -OP(O)(OR9)2, and -OSO2R8. In certain embodiments, R5is hydroxyl. In certain embodiments, R5is -OC(O)R8. In certain embodiments, R5 is hydrogen. In certain embodiments, at least one of R4 or R5 is deuterium. In certain embodiments, at least one of R4 and R5 is selected from C1-C5 alkoxy group, or in some embodiments, a C2-C4 alkoxy group, wherein it may be a straight chain or branched C1-C5 alkoxy group or C2-C4 alkoxy group, for example a straight chain, and may be methoxy or ethoxy. In some embodiments, R5is C1-C5alkoxy. In some embodiments, R4is selected from hydrogen and fluorine, and R5is C1-C5alkoxy. In some embodiments, at least one of R4and R5is selected from C1-C5alkyl or C1-C4alkyl, for example a straight chain C1-C4alkyl. In some embodiments, R5 is selected from methyl, ethyl, n-propyl or n-butyl, and for example methyl or ethyl. In some embodiments, at least one of R4 and R5 is halo. In some embodiments, R4 is fluoro. In some embodiments, R4 is fluoro and R5 is selected from hydrogen and C1-C5 alkoxy. In some embodiments, at least one of R4 or R5 is -OC(O)R8. In some embodiments, R4 is selected from -OC(O)R8and R5is hydrogen or fluoro. In some embodiments, R8 is selected from optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and 9 01312-0021-00PCT optionally substituted heteroaryl. In some embodiments, R9 is selected from hydrogen, deuterium, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted heteroaryl and optionally substituted aryl. In some embodiments, R8 is selected from methyl, ethyl, propyl, and isopropyl. In some embodiments, R9 is selected from methyl, ethyl, propyl, and isopropyl. Exemplary halo residues for compounds of Formula I include chloro, bromo, fluoro, and iodo. In certain embodiments, the compounds of Formula I comprise at least one fluoro residue. In some embodiments, W1 is selected from O, Se, Se(O), SeO2, S, S(O), NR1a, C(R50)(R51), and SO2 when the to which W1 is attached is a single bond, and W1 is selected from C(R50) and N when the to which W1is attached is a double bond; In some embodiments, W1 is selected from NR1a, O, Se, Se(O), SeO2 S, S(O), and SO2. In some embodiments, W1 is NR1a. In some embodiments, W1 is O. In some embodiments, W1 is S. In some embodiments, W1 is Se. In some embodiments, the to which W1 is attached is a double bond and W1is N. In some embodiments, the to which W1is attached is a single bond and W1is NR1a. In some embodiments, the to which W1is attached is a double bond and W1is CR50. In some embodiments, the to which W1is attached is a single bond and W1 is C(R50)(R51). In some embodiments, Z6is selected from N and CR6; and Z7is selected from N and CR7. In some embodiments, Z6 is N. In some embodiments, Z7 is N. In some embodiments, R1aand R1care each independently selected from hydrogen, deuterium, optionally substituted C1-C8alkyl, optionally substituted C2-C8alkenyl, optionally substituted C2-C8alkynyl, -C(O)R8, -C(O)OR8, -P(O)(OR9)2, -C(O)N(R9)2, -SOR8, and -SO2R8. In some embodiments, R1ais hydrogen. In some embodiments, R1is optionally substituted C1- C8 alkyl. In some embodiments, R1 is optionally substituted C2-C4 alkyl. In some embodiments, R1 is methyl. In some embodiments, R1 is ethyl. In some embodiments, R1 is isopropyl. In some embodiments, W2 is selected from -CD2-, -CDH-, –(CD2)2-, -CH2-, and –(CH2)2-. In some embodiments, W2 is selected from -CH2-. In some embodiments, W2 is selected from – (CH2)2-. In some embodiments, W2 is selected from -CD2-. In some embodiments, W2 is selected from –(CD2)2-. In some embodiments, W2is -CDH-. In some embodiments, when W2is -CDH-, W2represents a stereocenter in the I or (S) conformation. In certain embodiments, W4is selected from C(R2)(R2’) and NR1cwhen a to which W4is attached is a single bond, and W4is selected from C(R2) and N when a to which W4is attached is a double bond. In certain embodiments, W5is selected from C(R51’) and N when the to which W5 is attached is a single bond, and W5 is C when the to which W5 is 10 01312-0021-00PCT attached is a double bond. In certain embodiments, the between W4 and W5 is a double bond, wherein W5 is C and W4 is N or C(R2). In certain embodiments, the alkyl groups of Formula I are selected from C1-C8alkyl, C2- C8alkyl, C3-C8alkyl, and C4-C8alkyl, or methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert-butyl pentyl, isopentyl, hexyl, heptyl, octyl, etc. In certain embodiments, the alkenyl groups of Formula I are selected from C2-C8alkenyl, C3-C8alkenyl, and C4-C8alkenyl, or ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, etc. In certain embodiments, the alkyl and alkenyl groups of Formula I may be unsubstituted or substituted with one or more groups selected from deuterium, aryl, heteroaryl, hydroxy, alkoxy, alkyl sulfonamido, aryl sulfonamido, and halo. In certain embodiments, the cycloalkenyl and heterocyclyl groups of Formula I may be unsubstituted or substituted with one or more groups selected from deuterium, alkyl, alkenyl, aryl, heteroaryl, hydroxy, alkoxy, alkyl sulfonamido, aryl sulfonamido, and halo. In certain embodiments, the aryl and heteroaryl groups of Formula I may be unsubstituted or substituted with one or more groups selected from deuterium, aryl, alkyl, heteroaryl, hydroxyl, and halo. In certain embodiments, the alkoxy groups of Formula I may be unsubstituted or substituted with one or more groups selected from deuterium, aryl, alkyl, heteroaryl, hydroxyl, and halo. In some embodiments, X and / or Y may be a straight chain C1-C4 alkyl, or a C2-C4 alkenyl. In some embodiments, X and Y are each methyl, X and Y are each ethyl, or X is methyl and Y is ethyl. In certain embodiments, X and / or Y are an C1-C8 alkyl or C2-C8 alkenyl optionally substituted with at least one halo group, such as fluorine. In certain embodiments, at least one of X or Y comprises a group selected from -CF3, -CHF2, -CH2F, -CH2CF3, -CH2CHF2, and -CH2CH2F. In certain embodiments, at least one of X or Y comprises a group selected from -CD3, -CH2CD3, -CD2CH3, and -CD2CD3. In some embodiments, X is unsubstituted C1-C8 alkyl. In some embodiments, X is methyl. In some embodiments, X is ethyl. In some embodiments, X is n-propyl. In some embodiments, X is isopropyl. In some embodiments, X is cyclopropyl. In some embodiments, Y is hydrogen. In some embodiments, Y is unsubstituted C1-C8 alkyl. In some embodiments, Y is methyl. In some embodiments, Y is ethyl. In some embodiments, Y is n-propyl. In some embodiments, Y is isopropyl. In some embodiments, Y is cyclopropyl. In some embodiments, R2, R3, R3’, R6 and R7 are each independently selected from 11 01312-0021-00PCT hydrogen, deuterium, halo, or C1-C4 alkyl, for example a straight chain C1-C4 alkyl. In some embodiments, R2, R3, R3’, R6 and R7 are each independently selected from hydrogen, deuterium, halo, methyl, ethyl, n-propyl, isopropyl, n-butyl and isobutyl. In other embodiments, R2, R3, R3’, R6 and R7 are each independently selected from hydrogen, deuterium, methyl, and ethyl. In some embodiments, R2 is hydrogen. In some embodiments, R3 and R3’ are each independently selected from hydrogen, methyl, and ethyl. In some embodiments, R3is hydrogen. In some embodiments, R3is methyl and R3’is hydrogen. In some embodiments, R3and R3’are both hydrogen. In some embodiments, R3and R3’are both deuterium. In some embodiments, R3 is hydrogen and R3’ is deuterium. In some embodiments, when R3 and R3’ are not the same, it represents a stereocenter wherein the compound of Formula I comprises a racemic mixture. In some embodiments, when R3 and R3’ are not the same, it represents a stereocenter wherein the compound of Formula I comprises the (S) enantiomer. In some embodiments, when R3and R3’are not the same, it represents a stereocenter wherein the compound of Formula I comprises the (R) enantiomer. In some embodiments, a racemic mixture can be resolved to provide a pure enantiomer or a mixture enhanced with either the (R) or (S) enantiomer. In some embodiments, R6 and R7 are each independently selected hydrogen, halo, methyl, ethyl, n-propyl, isopropyl, n-butyl and isobutyl. In some embodiments, R6 is selected from hydrogen and halo. In some embodiments, R6 is selected from hydrogen and fluorine. In some embodiments, R6 is fluorine. In some embodiments, R6 is selected from C1-C8 alkoxy and halo. In some embodiments, R6 is selected from methoxy, chloro and fluoro. In some embodiments, R6 is fluorine. In some embodiments, R6 is methoxy. In some embodiments, R7 is selected from hydrogen and optionally substituted C1-C4alkyl. In some embodiments, R7is selected from hydrogen, methyl and ethyl. In some embodiments, R7is optionally substituted C1-C4alkyl. In some embodiments, when R6is fluoro, then R7is selected from hydrogen and optionally substituted C1-C4 alkyl. In some embodiments, R4is hydrogen and R5is selected from optionally substituted C1- C8alkyl, optionally substituted C2-C8alkenyl, halo, hydroxyl, -C1-C8alkoxy, -OC(O)R8, - OC(O)OR8, -OP(O)(OR9)2, and -OSO2R8. In some embodiments, R5 is selected from unsubstituted C1-C8 alkyl, hydroxyl, -C1-C8 alkoxy, -OC(O)R8, -OC(O)OR8, -OP(O)(OR9)2, and - OSO2R8. In some embodiments, R5 is selected from unsubstituted C2-C8 alkyl, hydroxyl, -C1- C8 alkoxy, -OC(O)R8, -OC(O)OR8, -OP(O)(OR9)2, and -OSO2R8. In some embodiments, R5 is hydroxy. In some embodiments, R5 is -OC(O)R8. In some embodiments, R8 is unsubstituted C1- C4alkyl. In some embodiments, R8is methyl. In some embodiments, R5 is hydrogen and R4 is selected from optionally substituted C1- 12 01312-0021-00PCT C8alkyl, optionally substituted C2-C8alkenyl, halo, hydroxyl, -C1-C8alkoxy, -OC(O)R8, - OC(O)OR8, -OP(O)(OR9)2, and -OSO2R8. In some embodiments, R4is selected from unsubstituted C1-C8alkyl, hydroxyl, -C1-C8alkoxy, -OC(O)R8, -OC(O)OR8, -OP(O)(OR9)2, and - OSO2R8. In some embodiments, R5is selected from unsubstituted C1-C8alkyl, -C2-C8alkoxy, - OC(O)R8, -OC(O)OR8, -OP(O)(OR9)2, and -OSO2R8. In some embodiments, R5is -OC(O)R8. In some embodiments, R8is unsubstituted C1-C4alkyl. In some embodiments, R8is methyl. In certain embodiments, one or more hydrogen atoms on compounds of Formula I may be replaced with one or more deuterium atoms. For example, in certain embodiments R6may comprise a deuterium atom as a replacement for a hydrogen, or when R7is a -CH3, each hydrogen atom may be replaced to form a -CD3 residue. Similarly, another non-limiting example includes when X and / or Y is a -CH3, each hydrogen atom may be replaced to form a - CD3 residue. In some embodiments, R4 is not halo. In some embodiments, R5 is not halo. In some embodiments, one of R4 and R5 is hydrogen and the other of R4 and R5 is selected from hydroxyl, -OC(O)R8, -OC(O)OR8, and -C1-C8 alkoxy; R6 is selected from hydrogen and fluorine; and R7 is selected from hydrogen, methyl and ethyl. In some embodiments for compounds of Formula I, when X and Y are both methyl, W1 is S, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is CR6 and Z7 is CR7, and R2, R3, R5, R6, and R7 are all hydrogen, then R4 is not hydroxyl or methoxy. In some embodiments for compounds of Formula I, when X and Y are both methyl, W1 is S, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is CR6 and Z7 is CR7, and R2, R3, R4, R6, and R7 are all hydrogen, then R5is not hydroxy or methoxy. In some embodiments for compounds of Formula I, when X and Y are both ethyl, W1 is S, W2is -CH2-, Z4is CR4, Z5is CR5, Z6is CR6and Z7is CR7, and R2, R3, R4, R6, and R7are all hydrogen, then R5is not methoxy. In some embodiments for compounds of Formula I, when X and Y are both methyl, W1is S, W2is -CH2-, Z4is CR4, Z5is CR5, Z6is CR6and Z7is CR7, then at least one of R2, R3, R4, R5, R6, or R7is not hydrogen. In some embodiments for compounds of Formula I, when X and Y are both propyl, W1is S, W2is -CH2-, Z4is CR4, Z5is CR5, Z6is CR6and Z7is CR7, then at least one of R2, R3, R4, R5, R6, or R7 is not hydrogen. In some embodiments for compounds of Formula I, when X methyl and Y is hydrogen, W1 is S, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is CR6 and Z7 is CR7, then at least one of R2, R3, 13 01312-0021-00PCT R4, R5, R6, or R7 is not hydrogen. In some embodiments for compounds of Formula I, when X ethyl and Y is hydrogen, W1is S, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is CR6 and Z7 is CR7, then at least one of R2, R3, R4, R5, R6, or R7 is not hydrogen. In some embodiments for compounds of Formula I, when X and Y are both methyl, W1 is Se, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is CR6 and Z7 is CR7, and R2, R3, R5, R6, and R7 are all hydrogen, then R4 is not hydroxyl or methoxy. In some embodiments for compounds of Formula I, when X and Y are both methyl, W1 is O, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is CR6 and Z7 is CR7, and R2, R3, R4, R6, and R7 are all hydrogen, then R5 is not hydroxy, methoxy, or bromo. In some embodiments for compounds of Formula I, when X and Y are both methyl, W1 is O, W2is -CH2-, Z4is CR4, Z5is CR5, Z6is CR6and Z7is CR7, and R2, R3, R4, R5, and R6are all hydrogen, then R7is not methoxy. In some embodiments for compounds of Formula I, when X is methyl or ethyl and Y is hydrogen, W1is O, W2is -CH2-, Z4is CR4, Z5is CR5, Z6is CR6and Z7is CR7, and R2, R3, R4, R6, and R7are all hydrogen, then R5is not methoxy. In some embodiments for compounds of Formula I, when X methyl and Y is hydrogen, W1is O, W2is -CH2-, Z4is CR4, Z5is CR5, Z6is CR6and Z7is CR7, then at least one of R2, R3, R4, R5, R6, or R7 is not hydrogen. In some embodiments for compounds of Formula I, when X is methyl and Y is hydrogen, W1 is O, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is CR6 and Z7 is CR7, and R2, R3, R4, R5, and R7 are all hydrogen, then R6 is not methoxy. In some embodiments for compounds of Formula I, when X is methyl and Y is hydrogen, W1 is O, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is CR6 and Z7 is CR7, and R2, R3, R4, R5, and R6 are all hydrogen, then R7 is not methoxy. In some embodiments for compounds of Formula I, at least one of R2, R3, R5, R6 or R7 is not hydrogen when X and Y are both methyl, W1 is NH, W2 is -CH2-, Z4 is N, Z5 is CR5, Z6 is CR6 and Z7 is CR7. In some embodiments for compounds of Formula I, R5 is not methyl or methoxy when X and Y are both methyl, W1is NH, W2is -CH2-, Z4is N, Z5is CR5, Z6is CR6and Z7is CR7, and R2, R3, R6and R7are all hydrogen. 14 01312-0021-00PCT In some embodiments for compounds of Formula I, at least one of R2, R3, R4, R6 or R7 is not hydrogen when X and Y are both methyl, W1 is NH, W2 is -CH2-, Z4 is CR4, Z5 is N, Z6 is CR6 and Z7 is CR7. In some embodiments for compounds of Formula I, R2 is not ethyl or iodo when X and Y are both methyl, W1 is NH, W2 is -CH2-, Z4 is CR4, Z5 is N, Z6 is CR6 and Z7 is CR7, and R3, R4, R6 and R7 are all hydrogen. In some embodiments for compounds of Formula I, at least one of R2, R3, R4, R5 or R7 is not hydrogen when X and Y are both ethyl, W1 is NH, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is N and Z7is CR7. In some embodiments for compounds of Formula I, R6 is not chloro when X and Y are both methyl, W1is NH, W2is -CH2-, Z4is CR4, Z5is CR5, Z6is CR6and Z7is N, and R2, R3, R4, and R5are all hydrogen. In some embodiments for compounds of Formula I, R6is not chloro when X is hydrogen and Y is methyl, W1is NH, W2is -CH2-, Z4is CR4, Z5is CR5, Z6is CR6and Z7is N, and R2, R3, R4, and R5are all hydrogen. In some embodiments for compounds of Formula I, at least one of R2, R3, R4, R5or R6is not hydrogen when X and Y are both methyl, W1 is NH, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is CR6 and Z7 is N. In some embodiments, R2 is not ethyl or iodo when X and Y are both methyl, W1 is NH, W2 is -CH2-, Z4 is CR4, Z5 is CR5, Z6 is CR6 and Z7 is N, and R3, R4, R5 and R6 are all hydrogen. Exemplary compounds of Formula I include: 15

[0014]              01312-0021-00PCT and salts, solvates, hydrates, and prodrugs of any of the foregoing compounds. In some embodiments, the compounds of Formula I comprise salts. In some embodiments, the compounds of Formula I comprise pharmaceutically-acceptable salts. Exemplary salts include, but are not limited to, HCl, HI, HBr, HF, ascorbate, hydrofumarate, fumarate, oxalate, maleate, and the like. In certain embodiments, the compound of Formula I is in its free-base form. In some embodiments, the compound of Formula I comprises a salt, such as a [1:1] salt (e.g., HCl, hydrofumarate) or a [2:1] salt (e.g., oxalate, fumarate). For the [1:1] salts, one ammonium cation of one compound of Formula I is balanced by a single anion (Cl-, I-, etc.). For the [2:1] salts, two ammonium cations of two molecules of Formula I are balanced by a dianionic species, such as a dianion derived from di-acids such as oxalic acid and fumaric acid. Other exemplary salts include zwitterionic forms of compounds of Formula I, such as when R4 is -OP(O)O2(R9)2 and each R9 is hydrogen, wherein deprotonation of an -OH on R4 may result in intramolecular coordination of the resulting -O- with the quaternary ethylammonium residue (e.g., -(CH2)2N+H(CH3)2). Other exemplary compounds of Formula I include those below in Table 1, which is also represented by Formula Ia: Table 1 ef. X Y R2 R3 R4 R5 R6 R7 1 -CH3 -CH3 H H -OCH3 H H H 33 14 -(CH2)2CH3-(CH2)3CH3H H -OCH3H H H 15 -(CH2)2CH3 -CH2-HC=CH2 H H -OCH3 H H H 16 CH(CH) CH(CH) H H OCH H H H 69 -CH2CH3-CH2CH3H H H -OCH3H H 70 -CH2CH3 -(CH2)2CH3 H H H -OCH3 H H 124 -CH2-HC=CH2-CH2-HC=CH2H H H -OC(O)CH3H H 25 -CH3 -CH3 H H -OCH3 H H -CH3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 333 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 33 01312-0021-00PCT 179 -(CH2)2CH3-(CH2)3CH3H H -OC(O)CH3H H -CH380 -(CH2)2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 81 -CH(CH3)2-CH(CH3)2H H -OC(O)CH3H H -CH3182 -CH(CH3)2 -(CH2)3CH3 H H -OC(O)CH3 H H -CH3 183 -CH(CH3)2 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 184 -(CH2)3CH3-(CH2)3CH3H H -OC(O)CH3H H -CH3185 -(CH2)3CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 186 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 187 -CH3-CH3H H H -OCH3H -CH3188 -CH3 -CH2CH3 H H H -OCH3 H -CH3 189 -CH3-(CH2)2CH3H H H -OCH3H -CH3190 -CH3 -CH(CH3)2 H H H -OCH3 H -CH3 191 -CH3 -(CH2)3CH3 H H H -OCH3 H -CH3 192 -CH3-CH2-HC=CH2H H H -OCH3H -CH3193 -CH2CH3 -CH2CH3 H H H -OCH3 H -CH3 194 -CH2CH3 -(CH2)2CH3 H H H -OCH3 H -CH3 195 -CH2CH3-CH(CH3)2H H H -OCH3H -CH3196 -CH2CH3 -(CH2)3CH3 H H H -OCH3 H -CH3 197 -CH2CH3-CH2-HC=CH2H H H -OCH3H -CH3198 -(CH2)2CH3-(CH2)2CH3H H H -OCH3H -CH3199 -(CH2)2CH3 -CH(CH3)2 H H H -OCH3 H -CH3 200 -(CH2)2CH3-(CH2)3CH3H H H -OCH3H -CH3201 -(CH2)2CH3 -CH2-HC=CH2 H H H -OCH3 H -CH3 202 -CH(CH3)2 -CH(CH3)2 H H H -OCH3 H -CH3 203 -CH(CH3)2-(CH2)3CH3H H H -OCH3H -CH3204 -CH(CH3)2 -CH2-HC=CH2 H H H -OCH3 H -CH3 205 -(CH2)3CH3 -(CH2)3CH3 H H H -OCH3 H -CH3 206 -(CH2)3CH3-CH2-HC=CH2H H H -OCH3H -CH3207 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OCH3 H -CH3 208 -CH3-CH2CH3H H H -OH H -CH3209 -CH3 -(CH2)2CH3 H H H -OH H -CH3 210 -CH3 -CH(CH3)2 H H H -OH H -CH3 211 -CH3-(CH2)3CH3H H H -OH H -CH3212 -CH3 -CH2-HC=CH2 H H H -OH H -CH3 213 -CH2CH3 -CH2CH3 H H H -OH H -CH3 214 -CH2CH3-(CH2)2CH3H H H -OH H -CH3215 -CH2CH3 -CH(CH3)2 H H H -OH H -CH3 216 -CH2CH3-(CH2)3CH3H H H -OH H -CH3217 -CH2CH3 -CH2-HC=CH2 H H H -OH H -CH3 218 -(CH2)2CH3 -(CH2)2CH3 H H H -OH H -CH3 219 -(CH2)2CH3-CH(CH3)2H H H -OH H -CH3220 -(CH2)2CH3 -(CH2)3CH3 H H H -OH H -CH3 221 -(CH2)2CH3 -CH2-HC=CH2 H H H -OH H -CH3 222 -CH(CH3)2-CH(CH3)2H H H -OH H -CH3223 -CH(CH3)2 -(CH2)3CH3 H H H -OH H -CH3 224 -CH(CH3)2-CH2-HC=CH2H H H -OH H -CH3225 -(CH2)3CH3 -(CH2)3CH3 H H H -OH H -CH3 226 -(CH2)3CH3 -CH2-HC=CH2 H H H -OH H -CH3 227 -CH2-HC=CH2-CH2-HC=CH2H H H -OH H -CH3228 -CH3 -CH3 H H H -OC(O)CH3 H -CH3 229 -CH3 -CH2CH3 H H H -OC(O)CH3 H -CH3 230 -CH3-(CH2)2CH3H H H -OC(O)CH3H -CH3231 -CH3 -CH(CH3)2 H H H -OC(O)CH3 H -CH3 232 -CH3-(CH2)3CH3H H H -OC(O)CH3H -CH3233 -CH3-CH2-HC=CH2H H H -OC(O)CH3H -CH337 01312-0021-00PCT 234 -CH2CH3-CH2CH3H H H -OC(O)CH3H -CH335 -CH2CH3 -(CH2)2CH3 H H H -OC(O)CH3 H -CH3 36 -CH2CH3-CH(CH3)2H H H -OC(O)CH3H -CH3237 -CH2CH3 -(CH2)3CH3 H H H -OC(O)CH3 H -CH3 238 -CH2CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H -CH3 239 -(CH2)2CH3-(CH2)2CH3H H H -OC(O)CH3H -CH3240 -(CH2)2CH3 -CH(CH3)2 H H H -OC(O)CH3 H -CH3 241 -(CH2)2CH3 -(CH2)3CH3 H H H -OC(O)CH3 H -CH3 242 -(CH2)2CH3-CH2-HC=CH2H H H -OC(O)CH3H -CH3243 -CH(CH3)2 -CH(CH3)2 H H H -OC(O)CH3 H -CH3 244 -CH(CH3)2-(CH2)3CH3H H H -OC(O)CH3H -CH3245 -CH(CH3)2 -CH2-HC=CH2 H H H -OC(O)CH3 H -CH3 246 -(CH2)3CH3 -(CH2)3CH3 H H H -OC(O)CH3 H -CH3 247 -(CH2)3CH3-CH2-HC=CH2H H H -OC(O)CH3H -CH3248 -CH2-HC=CH2 -CH2-HC=CH2 H H H OC(O)CH3 H -CH3 249 -CH3 -CH3 -CH3 H H H H H 250 -CH3-CH3-CH3H -OH H H H 251 -CH3 -CH3 -CH3 H -OC(O)CH3 H H H 252 -CH3-CH3-CH3H -OCH3H H H 253 -CH3-CH2CH3-CH3H H H H H 254 -CH3 -CH2(CH3)2 -CH3 H H H H H 255 -CH3-CH3-CH3H F H H H 256 -CH3 -CH3 H -CH3 H H H H 257 -CH3 -CH3 H -CH3 -OH H H H 258 -CH3-CH3H -CH3-OC(O)CH3H H H 259 -CH3 -CH3 H -CH3 -OCH3 H H H 260 -CH3 -CH2CH3 H -CH3 H H H H 261 -CH3-CH2(CH3)2H -CH3H H H H 262 -CH3 -CH3 H -CH3 F H H H 263 -CH3-CH3H H H H F H 264 -CH3 -CH3 H H -OH H F H 265 -CH3 -CH3 H H -OC(O)CH3 H F H 266 -CH3-CH3H H -OCH3H F H 267 -CH3 -CH2CH3 H H H H F H 268 -CH3 -CH2(CH3)2 H H H H F H 269 -CH3-CH3H H F H F H 270 -CH3 -CH3 H H H H H -CH3 271 -CH3-CH3H H -OH H H -CH3272 -CH3 -CH3 H H -OC(O)CH3 H H -CH3 273 -CH3 -CH3 H H -OCH3 H H -CH3 274 -CH3-CH2CH3H H H H H -CH3275 -CH3 -CH2(CH3)2 H H H H H -CH3 276 -CH3 -CH3 H H F H H -CH3 277 -CH3-CH3-CH3H H -OH H H 278 -CH3 -CH3 -CH3 H H -OC(O)CH3 H H 279 -CH3-CH3-CH3H H -OCH3H H 280 -CH3 -CH2CH3 -CH3 H H H H H 281 -CH3 -CH2(CH3)2 -CH3 H H H H H 282 -CH3-CH3-CH3H H F H H 283 -CH3 -CH3 H -CH3 H H H H 284 -CH3 -CH3 H -CH3 H -OH H H 285 -CH3-CH3H -CH3H -OC(O)CH3H H 286 -CH3 -CH3 H -CH3 H -OCH3 H H 287 -CH3-CH2CH3H -CH3H H H H 288 -CH3-CH2(CH3)2H -CH3H H H H 38 01312-0021-00PCT 289 -CH3-CH3H -CH3H F H H 90 -CH3 -CH3 H H H H F H 91 -CH3-CH3H H H -OH F H 292 -CH3 -CH3 H H H -OC(O)CH3 F H 293 -CH3 -CH3 H H H -OCH3 F H 294 -CH3-CH2CH3H H H H F H 295 -CH3 -CH2(CH3)2 H H H H F H 296 -CH3 -CH3 H H H F F H 297 -CH3-CH3H H H H H -CH3298 -CH3 -CH3 H H H -OH H -CH3 299 -CH3-CH3H H H -OC(O)CH3H -CH3300 -CH3 -CH3 H H H -OCH3 H -CH3 301 -CH3 -CH2CH3 H H H H H -CH3 302 -CH3-CH2(CH3)2H H H H H -CH3303 -CH3 -CH3 H H H H F -CH3 304 H -CH3 H H H H H H 305 H -CH2CH3H H H H H H 306 H -(CH2)2CH3 H H H H H H 307 H -CH(CH3)2H H H H H H 308 H -(CH2)3CH3H H H H H H 309 H -CH2-HC=CH2 H H H H H H 310 H -CH3H -CH3H H H H 310a H -CH2CH3 H -CH3 H H H H 311 H -(CH2)2CH3 H -CH3 H H H H 312 H -CH(CH3)2H -CH3H H H H 313 H -(CH2)3CH3 H -CH3 H H H H 314 H -CH2-HC=CH2 H -CH3 H H H H 315 H -CH3H H -OH H H H 316 H -CH2CH3 H H -OH H H H 317 H -(CH2)2CH3H H -OH H H H 318 H -CH(CH3)2 H H -OH H H H 319 H -(CH2)3CH3 H H -OH H H H 320 H -CH2-HC=CH2H H -OH H H H 321 H -CH3 H H -OC(O)CH3 H H H 322 H -CH2CH3 H H -OC(O)CH3 H H H 324 H -(CH2)2CH3H H -OC(O)CH3H H H 325 H -CH(CH3)2 H H -OC(O)CH3 H H H 326 H -(CH2)3CH3H H -OC(O)CH3H H H 327 H -CH2-HC=CH2 H H -OC(O)CH3 H H H 328 H -CH3 H H H -OCH3 H H 329 H -CH2CH3H H H -OCH3H H 330 H -(CH2)2CH3 H H H -OCH3 H H 331 H -CH(CH3)2 H H H -OCH3 H H 332 H -(CH2)3CH3H H H -OCH3H H 333 H -CH2-HC=CH2 H H H -OCH3 H H 334 H -CH3H H H H F H 335 H -CH2CH3 H H H H F H 336 H -(CH2)2CH3 H H H H F H 337 H -CH(CH3)2H H H H F H 338 H -(CH2)3CH3 H H H H F H 339 H -CH2-HC=CH2 H H H H F H 340 H -CH3H -CH3-OH H H H 341 H -CH2CH3 H -CH3 -OH H H H 342 H -(CH2)2CH3H -CH3-OH H H H 343 H -CH(CH3)2H -CH3-OH H H H 39 01312-0021-00PCT 344 H -(CH2)3CH3H -CH3-OH H H H 45 H -CH2-HC=CH2 H -CH3 -OH H H H 46 H -CH3H -CH3-OC(O)CH3H H H 347 H -CH2CH3 H -CH3 -OC(O)CH3 H H H 348 H -(CH2)2CH3 H -CH3 -OC(O)CH3 H H H 349 H -CH(CH3)2H -CH3-OC(O)CH3H H H 350 H -(CH2)3CH3 H -CH3 -OC(O)CH3 H H H 351 H -CH2-HC=CH2 H -CH3 -OC(O)CH3 H H H 352 H -CH3H -CH3H -OCH3H H 353 H -CH2CH3 H -CH3 H -OCH3 H H 354 H -(CH2)2CH3H -CH3H -OCH3H H 355 H -CH(CH3)2 H -CH3 H -OCH3 H H 356 H -(CH2)3CH3 H -CH3 H -OCH3 H H 357 H -CH2-HC=CH2H -CH3H -OCH3H H 358 H -CH3 H -CH3 H H F H 359 H -CH2CH3 H -CH3 H H F H 360 H -(CH2)2CH3H -CH3H H F H 361 H -CH(CH3)2 H -CH3 H H F H 362 H -(CH2)3CH3H -CH3H H F H 363 H -CH2-HC=CH2H -CH3H H F H 364 H cyclopropyl H H H H H H 365 H cyclopropyl H -CH3H H H H 366 H cyclopropyl H H -OH H H H 367 H cyclopropyl H H -OC(O)CH3 H H H 368 H cyclopropyl H H H -OCH3H H 369 H cyclopropyl H H H H F H 370 H cyclopropyl H H H H H H 371 H cyclopropyl H -CH3-OH H F H 372 H cyclopropyl H -CH3 -OH H H H 373 H cyclopropyl H -CH3-OC(O)CH3H H H 374 H cyclopropyl H -CH3 H -OCH3 H H 375 H cyclopropyl H -CH3 H H F H 376 -CH3cyclopropyl H H H H H H 377 -CH3 cyclopropyl H -CH3 H H H H 378 -CH3 cyclopropyl H H -OH H H H 379 -CH3cyclopropyl H H -OC(O)CH3H H H 380 -CH3 cyclopropyl H H H -OCH3 H H 381 -CH3cyclopropyl H H H H F H 382 -CH3 cyclopropyl H H H H H H 383 -CH3 cyclopropyl H -CH3 -OH H F H 384 -CH3cyclopropyl H -CH3-OH H H H 385 -CH3 cyclopropyl H -CH3 -OC(O)CH3 H H H 386 -CH3 cyclopropyl H -CH3 H -OCH3 H H 387 -CH3cyclopropyl H -CH3H H F H 388 -CH2CH3 cyclopropyl H H H H H H 389 -CH2CH3cyclopropyl H -CH3H H H H 390 -CH2CH3 cyclopropyl H H -OH H H H 391 -CH2CH3 cyclopropyl H H -OC(O)CH3 H H H 392 -CH2CH3cyclopropyl H H H -OCH3H H 393 -CH2CH3 cyclopropyl H H H H F H 394 -CH2CH3 cyclopropyl H H H H H H 395 -CH2CH3cyclopropyl H -CH3-OH H F H 396 -CH2CH3 cyclopropyl H -CH3 -OH H H H 397 -CH2CH3cyclopropyl H -CH3-OC(O)CH3H H H 398 -CH2CH3cyclopropyl H -CH3H -OCH3H H 40 01312-0021-00PCT 399 -CH2CH3cyclopropyl H -CH3H H F H 00 -(CH2)2CH3 cyclopropyl H H H H H H 01 -(CH2)2CH3cyclopropyl H -CH3H H H H 402 -(CH2)2CH3 cyclopropyl H H -OH H H H 403 -(CH2)2CH3 cyclopropyl H H -OC(O)CH3 H H H 404 -(CH2)2CH3cyclopropyl H H H -OCH3H H 405 -(CH2)2CH3 cyclopropyl H H H H F H 406 -(CH2)2CH3 cyclopropyl H H H H H H 407 -(CH2)2CH3cyclopropyl H -CH3-OH H F H 408 -(CH2)2CH3 cyclopropyl H -CH3 -OH H H H 409 -(CH2)2CH3cyclopropyl H -CH3-OC(O)CH3H H H 410 -(CH2)2CH3 cyclopropyl H -CH3 H -OCH3 H H 411 -(CH2)2CH3 cyclopropyl H -CH3 H H F H 412 -CH2(CH3)2cyclopropyl H H H H H H 413 -CH2(CH3)2 cyclopropyl H -CH3 H H H H 414 -CH2(CH3)2 cyclopropyl H H -OH H H H 415 -CH2(CH3)2cyclopropyl H H -OC(O)CH3H H H 416 -CH2(CH3)2 cyclopropyl H H H -OCH3 H H 417 -CH2(CH3)2cyclopropyl H H H H F H 418 -CH2(CH3)2cyclopropyl H H H H H H 419 -CH2(CH3)2 cyclopropyl H -CH3 -OH H F H 420 -CH2(CH3)2cyclopropyl H -CH3-OH H H H 421 -CH2(CH3)2 cyclopropyl H -CH3 -OC(O)CH3 H H H 422 -CH2(CH3)2 cyclopropyl H -CH3 H -OCH3 H H 423 -CH2(CH3)2cyclopropyl H -CH3H H F H 424 cyclopropyl cyclopropyl H -CH3 H H H H 425 cyclopropyl cyclopropyl H H -OH H H H 426 cyclopropyl cyclopropyl H H -OC(O)CH3H H H 427 cyclopropyl cyclopropyl H H H -OCH3 H H 428 cyclopropyl cyclopropyl H H H H F H 429 cyclopropyl cyclopropyl H H H H H H 430 cyclopropyl cyclopropyl H -CH3 -OH H F H 431 cyclopropyl cyclopropyl H -CH3-OH H H H 432 cyclopropyl cyclopropyl H -CH3 -OC(O)CH3 H H H 433 cyclopropyl cyclopropyl H -CH3 H -OCH3 H H 434 cyclopropyl cyclopropyl H -CH3H H F H 435 H -CH3 H H -OH H H -CH3 436 H -CH2CH3H H -OH H H -CH3437 H -(CH2)2CH3 H H -OH H H -CH3 438 H -CH(CH3)2 H H -OH H H -CH3 439 H -(CH2)3CH3H H -OH H H -CH3440 H -CH2-HC=CH2 H H -OH H H -CH3 441 H -CH3 H H -OC(O)CH3 H H -CH3 442 H -CH2CH3H H -OC(O)CH3H H -CH3443 H -(CH2)2CH3 H H -OC(O)CH3 H H -CH3 444 H -CH(CH3)2H H -OC(O)CH3H H -CH3445 H -(CH2)3CH3 H H -OC(O)CH3 H H -CH3 446 H -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 447 H -CH3H H H -OCH3H -CH3448 H -CH2CH3 H H H -OCH3 H -CH3 449 H -(CH2)2CH3 H H H -OCH3 H -CH3 450 H -CH(CH3)2H H H -OCH3H -CH3451 H -(CH2)3CH3 H H H -OCH3 H -CH3 452 H -CH2-HC=CH2H H H -OCH3H -CH3453 H -CH3H H -OH H F H 41 01312-0021-00PCT 454 H -CH2CH3H H -OH H F H 55 H -(CH2)2CH3 H H -OH H F H 56 H -CH(CH3)2H H -OH H F H 457 H -(CH2)3CH3 H H -OH H F H 458 H -CH2-HC=CH2 H H -OH H F H 459 H -CH3H H -OC(O)CH3H F H 460 H -CH2CH3 H H -OC(O)CH3 H F H 461 H -(CH2)2CH3 H H -OC(O)CH3 H F H 462 H -CH(CH3)2H H -OC(O)CH3H F H 463 H -(CH2)3CH3 H H -OC(O)CH3 H F H 464 H -CH2-HC=CH2H H -OC(O)CH3H F H 465 H -CH3 H H H -OCH3 F H 466 H -CH2CH3 H H H -OCH3 F H 467 H -(CH2)2CH3H H H -OCH3F H 468 H -CH(CH3)2 H H H -OCH3 F H 469 H -(CH2)3CH3 H H H -OCH3 F H 470 H -CH2-HC=CH2H H H -OCH3F H 471 H -CD3 H H H H H H 472 H -CD3H H -OH H H H 473 H -CD3H H -OC(O)CH3H H H 474 H -CD3 H H H -OCH3 H H 475 H -CD3H H H H F H 476 H -CD3 H H -OH H F H 477 H -CD3 H H -OC(O)CH3 H F H 478 H -CD3H H H -OCH3F H 479 H -CD3 H H H H H -CH3 480 H -CD3 H H -OH H H -CH3 481 H -CD3H H -OC(O)CH3H H -CH3482 H -CD3 H H H -OCH3 H -CH3 483 H -CD3H H H H F -CH3484 H -CD3 H H -OH H F -CH3 485 H -CD3 H H -OC(O)CH3 H F -CH3 486 H -CD3H H H -OCH3F -CH3487 H -CD2CD3 H H H H H H 488 H -CD2CD3 H H -OH H H H 489 H -CD2CD3H H -OC(O)CH3H H H 490 H -CD2CD3 H H H -OCH3 H H 491 H -CD2CD3H H H H F H 492 H -CD2CD3 H H -OH H F H 493 H -CD2CD3 H H -OC(O)CH3 H F H 494 H -CD2CD3H H H -OCH3F H 495 H -CD2CD3 H H H H H -CH3 496 H -CD2CD3 H H -OH H H -CH3 497 H -CD2CD3H H -OC(O)CH3H H -CH3498 H -CD2CD3 H H H -OCH3 H -CH3 499 H -CD2CD3H H H H F -CH3500 H -CD2CD3 H H -OH H F -CH3 501 H -CD2CD3 H H -OC(O)CH3 H F -CH3 502 H -CD2CD3H H H -OCH3F -CH3503 H -CH3 H H -OH H F -CH3 504 H -CH2CH3 H H -OH H F -CH3 505 H -(CH2)2CH3H H -OH H F -CH3506 H -CH(CH3)2 H H -OH H F -CH3 507 H -(CH2)3CH3H H -OH H F -CH3508 H -CH2-HC=CH2H H -OH H F -CH342 01312-0021-00PCT 509 H -CH3H H -OC(O)CH3H F -CH310 H -CH2CH3 H H -OC(O)CH3 H F -CH3 11 H -(CH2)2CH3H H -OC(O)CH3H F -CH3512 H -CH(CH3)2 H H -OC(O)CH3 H F -CH3 513 H -(CH2)3CH3 H H -OC(O)CH3 H F -CH3 514 H -CH2-HC=CH2H H -OC(O)CH3H F -CH3515 H -CH3 H H H -OCH3 F -CH3 516 H -CH2CH3 H H H -OCH3 F -CH3 517 H -(CH2)2CH3H H H -OCH3F -CH3518 H -CH(CH3)2 H H H -OCH3 F -CH3 519 H -(CH2)3CH3H H H -OCH3F -CH3520 H -CH2-HC=CH2 H H H -OCH3 F -CH3 521 H -CH3 H D H H H H 522 H -CH2CH3H D H H H H 523 H -(CH2)2CH3 H D H H H H 524 H -CH(CH3)2 H D H H H H 525 H -(CH2)3CH3H D H H H H 526 H -CH2-HC=CH2 H D H H H H 527 H -CH3H D -OH H H H 528 H -CH2CH3H D -OH H H H 529 H -(CH2)2CH3 H D -OH H H H 530 H -CH(CH3)2H D -OH H H H 531 H -(CH2)3CH3 H D -OH H H H 532 H -CH2-HC=CH2 H D -OH H H H 533 H -CH3H D -OC(O)CH3H H H 534 H -CH2CH3 H D -OC(O)CH3 H H H 535 H -(CH2)2CH3 H D -OC(O)CH3 H H H 536 H -CH(CH3)2H D -OC(O)CH3H H H 537 H -(CH2)3CH3 H D -OC(O)CH3 H H H 538 H -CH2-HC=CH2H D -OC(O)CH3H H H 539 H -CH3 H D H -OCH3 H H 540 H -CH2CH3 H D H -OCH3 H H 541 H -(CH2)2CH3H D H -OCH3H H 542 H -CH(CH3)2 H D H -OCH3 H H 543 H -(CH2)3CH3 H D H -OCH3 H H 544 H -CH2-HC=CH2H D H -OCH3H H 545 H -CH3 H D H H F H 546 H -CH2CH3H D H H F H 547 H -(CH2)2CH3 H D H H F H 548 H -CH(CH3)2 H D H H F H 549 H -(CH2)3CH3H D H H F H 550 H -CH2-HC=CH2 H D H H F H 551 H -CH3 H D H H F CH3 552 H -CH2CH3H D H H F CH3553 H -(CH2)2CH3 H D H H F CH3 554 H -CH(CH3)2H D H H F CH3555 H -(CH2)3CH3 H D H H F CH3 556 H -CH2-HC=CH2 H D H H F CH3 Other exemplary compounds of Formula I include those below in Table 2, which is also represented by Formula Ib: 43 01312-0021-00PCT Formula Ib Table 2 ef. X Y R2 R3 R4 R5 R6 R7 1 -CH3-CH3H H -OCH3H H H 2 -CH3 -CH2CH3 H H -OCH3 H H H 3 -CH3 -(CH2)2CH3 H H -OCH3 H H H 4 -CH3-CH(CH3)2H H -OCH3H H H 5 -CH3 -(CH2)3CH3 H H -OCH3 H H H 6 -CH3-CH2-HC=CH2H H -OCH3H H H 7 -CH2CH3-CH2CH3H H -OCH3H H H 8 -CH2CH3 -(CH2)2CH3 H H -OCH3 H H H 9 -CH2CH3-CH(CH3)2H H -OCH3H H H 10 -CH2CH3 -(CH2)3CH3 H H -OCH3 H H H 11 -CH2CH3 -CH2-HC=CH2 H H -OCH3 H H H 12 -(CH2)2CH3-(CH2)2CH3H H -OCH3H H H 13 -(CH2)2CH3 -CH(CH3)2 H H -OCH3 H H H 14 -(CH2)2CH3 -(CH2)3CH3 H H -OCH3 H H H 15 -(CH2)2CH3-CH2-HC=CH2H H -OCH3H H H 16 -CH(CH3)2 -CH(CH3)2 H H -OCH3 H H H 17 -CH(CH3)2-(CH2)3CH3H H -OCH3H H H 18 -CH(CH3)2-CH2-HC=CH2H H -OCH3H H H 19 -(CH2)3CH3 -(CH2)3CH3 H H -OCH3 H H H 20 -(CH2)3CH3-CH2-HC=CH2H H -OCH3H H H 21 -CH2-HC=CH2 -CH2-HC=CH2 H H -OCH3 H H H 22 -CH3 -CH2CH3 H H -OH H H H 23 -CH3-(CH2)2CH3H H -OH H H H 24 -CH3 -CH(CH3)2 H H -OH H H H 25 -CH3 -(CH2)3CH3 H H -OH H H H 26 -CH3-CH2-HC=CH2H H -OH H H H 27 -CH2CH3 -CH2CH3 H H -OH H H H 28 -CH2CH3-(CH2)2CH3H H -OH H H H 29 -CH2CH3 -CH(CH3)2 H H -OH H H H 30 -CH2CH3 -(CH2)3CH3 H H -OH H H H 31 -CH2CH3-CH2-HC=CH2H H -OH H H H 32 -(CH2)2CH3 -(CH2)2CH3 H H -OH H H H 33 -(CH2)2CH3 -CH(CH3)2 H H -OH H H H 34 -(CH2)2CH3-(CH2)3CH3H H -OH H H H 35 -(CH2)2CH3 -CH2-HC=CH2 H H -OH H H H 36 -CH(CH3)2-CH(CH3)2H H -OH H H H 37 -CH(CH3)2-(CH2)3CH3H H -OH H H H 38 -CH(CH3)2 -CH2-HC=CH2 H H -OH H H H 39 -(CH2)3CH3-(CH2)3CH3H H -OH H H H 44 01312-0021-00PCT 40 -(CH2)3CH3-CH2-HC=CH2H H -OH H H H 41 -CH2-HC=CH2 -CH2-HC=CH2 H H -OH H H H 42 -CH3-CH3H H -OC(O)CH3H H H 43 -CH3 -CH2CH3 H H -OC(O)CH3 H H H 44 -CH3 -(CH2)2CH3 H H -OC(O)CH3 H H H 45 -CH3-CH(CH3)2H H -OC(O)CH3H H H 46 -CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 47 -CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 48 -CH2CH3-CH2CH3H H -OC(O)CH3H H H 49 -CH2CH3 -(CH2)2CH3 H H -OC(O)CH3 H H H 50 -CH2CH3-CH(CH3)2H H -OC(O)CH3H H H 51 -CH2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 52 -CH2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 53 -(CH2)2CH3-(CH2)2CH3H H -OC(O)CH3H H H 54 -(CH2)2CH3 -CH(CH3)2 H H -OC(O)CH3 H H H 55 -(CH2)2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 56 -(CH2)2CH3-CH2-HC=CH2H H -OC(O)CH3H H H 57 -CH(CH3)2 -CH(CH3)2 H H -OC(O)CH3 H H H 58 -CH(CH3)2-(CH2)3CH3H H -OC(O)CH3H H H 59 -CH(CH3)2-CH2-HC=CH2H H -OC(O)CH3H H H 60 -(CH2)3CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 61 -(CH2)3CH3-CH2-HC=CH2H H -OC(O)CH3H H H 62 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H H H 63 -CH3 -CH3 H H H -OCH2CH3 H H 64 -CH3-CH2CH3H H H -OCH3H H 65 -CH3 -(CH2)2CH3 H H H -OCH3 H H 66 -CH3 -CH(CH3)2 H H H -OCH3 H H 67 -CH3-(CH2)3CH3H H H -OCH3H H 68 -CH3 -CH2-HC=CH2 H H H -OCH3 H H 69 -CH2CH3-CH2CH3H H H -OCH3H H 70 -CH2CH3 -(CH2)2CH3 H H H -OCH3 H H 71 -CH2CH3 -CH(CH3)2 H H H -OCH3 H H 72 -CH2CH3-(CH2)3CH3H H H -OCH3H H 73 -CH2CH3 -CH2-HC=CH2 H H H -OCH3 H H 74 -(CH2)2CH3 -(CH2)2CH3 H H H -OCH3 H H 75 -(CH2)2CH3-CH(CH3)2H H H -OCH3H H 76 -(CH2)2CH3 -(CH2)3CH3 H H H -OCH3 H H 77 -(CH2)2CH3-CH2-HC=CH2H H H -OCH3H H 78 -CH(CH3)2 -CH(CH3)2 H H H -OCH3 H H 79 -CH(CH3)2 -(CH2)3CH3 H H H -OCH3 H H 80 -CH(CH3)2-CH2-HC=CH2H H H -OCH3H H 81 -(CH2)3CH3 -(CH2)3CH3 H H H -OCH3 H H 82 -(CH2)3CH3 -CH2-HC=CH2 H H H -OCH3 H H 83 -CH2-HC=CH2-CH2-HC=CH2H H H -OCH3H H 84 -CH3 -CH2CH3 H H H -OH H H 85 -CH3-(CH2)2CH3H H H -OH H H 86 -CH3 -CH(CH3)2 H H H -OH H H 87 -CH3 -(CH2)3CH3 H H H -OH H H 88 -CH3-CH2-HC=CH2H H H -OH H H 89 -CH2CH3 -CH2CH3 H H H -OH H H 90 -CH2CH3 -(CH2)2CH3 H H H -OH H H 91 -CH2CH3-CH(CH3)2H H H -OH H H 92 -CH2CH3 -(CH2)3CH3 H H H -OH H H 93 -CH2CH3-CH2-HC=CH2H H H -OH H H 94 -(CH2)2CH3-(CH2)2CH3H H H -OH H H 45 01312-0021-00PCT 95 -(CH2)2CH3-CH(CH3)2H H H -OH H H 96 -(CH2)2CH3 -(CH2)3CH3 H H H -OH H H 97 -(CH2)2CH3-CH2-HC=CH2H H H -OH H H 98 -CH(CH3)2 -CH(CH3)2 H H H -OH H H 99 -CH(CH3)2 -(CH2)3CH3 H H H -OH H H 100 -CH(CH3)2-CH2-HC=CH2H H H -OH H H 101 -(CH2)3CH3 -(CH2)3CH3 H H H -OH H H 102 -(CH2)3CH3 -CH2-HC=CH2 H H H -OH H H 103 -CH2-HC=CH2-CH2-HC=CH2H H H -OH H H 104 -CH3 -CH3 H H H -OC(O)CH3 H H 105 -CH3-CH2CH3H H H -OC(O)CH3H H 106 -CH3 -(CH2)2CH3 H H H -OC(O)CH3 H H 107 -CH3 -CH(CH3)2 H H H -OC(O)CH3 H H 108 -CH3-(CH2)3CH3H H H -OC(O)CH3H H 109 -CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H H 110 -CH2CH3 -CH2CH3 H H H -OC(O)CH3 H H 111 -CH2CH3-(CH2)2CH3H H H -OC(O)CH3H H 112 -CH2CH3 -CH(CH3)2 H H H -OC(O)CH3 H H 113 -CH2CH3-(CH2)3CH3H H H -OC(O)CH3H H 114 -CH2CH3-CH2-HC=CH2H H H -OC(O)CH3H H 115 -(CH2)2CH3 -(CH2)2CH3 H H H -OC(O)CH3 H H 116 -(CH2)2CH3-CH(CH3)2H H H -OC(O)CH3H H 117 -(CH2)2CH3 -(CH2)3CH3 H H H -OC(O)CH3 H H 118 -(CH2)2CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H H 119 -CH(CH3)2-CH(CH3)2H H H -OC(O)CH3H H 120 -CH(CH3)2 -(CH2)3CH3 H H H -OC(O)CH3 H H 121 -CH(CH3)2 -CH2-HC=CH2 H H H -OC(O)CH3 H H 122 -(CH2)3CH3-(CH2)3CH3H H H -OC(O)CH3H H 123 -(CH2)3CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H H 124 -CH2-HC=CH2-CH2-HC=CH2H H H -OC(O)CH3H H 125 -CH3 -CH3 H H -OCH3 H H -CH3 126 -CH3 -CH2CH3 H H -OCH3 H H -CH3 127 -CH3-(CH2)2CH3H H -OCH3H H -CH3128 -CH3 -CH(CH3)2 H H -OCH3 H H -CH3 129 -CH3 -(CH2)3CH3 H H -OCH3 H H -CH3 130 -CH3-CH2-HC=CH2H H -OCH3H H -CH3131 -CH2CH3 -CH2CH3 H H -OCH3 H H -CH3 132 -CH2CH3-(CH2)2CH3H H -OCH3H H -CH3133 -CH2CH3 -CH(CH3)2 H H -OCH3 H H -CH3 134 -CH2CH3 -(CH2)3CH3 H H -OCH3 H H -CH3 135 -CH2CH3-CH2-HC=CH2H H -OCH3H H -CH3135 -(CH2)2CH3 -(CH2)2CH3 H H -OCH3 H H -CH3 137 -(CH2)2CH3 -CH(CH3)2 H H -OCH3 H H -CH3 138 -(CH2)2CH3-(CH2)3CH3H H -OCH3H H -CH3139 -(CH2)2CH3 -CH2-HC=CH2 H H -OCH3 H H -CH3 140 -CH(CH3)2-CH(CH3)2H H -OCH3H H -CH3141 -CH(CH3)2 -(CH2)3CH3 H H -OCH3 H H -CH3 142 -CH(CH3)2 -CH2-HC=CH2 H H -OCH3 H H -CH3 143 -(CH2)3CH3-(CH2)3CH3H H -OCH3H H -CH3144 -(CH2)3CH3 -CH2-HC=CH2 H H -OCH3 H H -CH3 145 -CH2-HC=CH2 -CH2-HC=CH2 H H -OCH3 H H -CH3 146 -CH3-CH2CH3H H -OH H H -CH3147 -CH3 -(CH2)2CH3 H H -OH H H -CH3 148 -CH3-CH(CH3)2H H -OH H H -CH3149 -CH3-(CH2)3CH3H H -OH H H -CH346 01312-0021-00PCT 150 -CH3-CH2-HC=CH2H H -OH H H -CH351 -CH2CH3 -CH2CH3 H H -OH H H -CH3 52 -CH2CH3-(CH2)2CH3H H -OH H H -CH3153 -CH2CH3 -CH(CH3)2 H H -OH H H -CH3 154 -CH2CH3 -(CH2)3CH3 H H -OH H H -CH3 155 -CH2CH3-CH2-HC=CH2H H -OH H H -CH3156 -(CH2)2CH3 -(CH2)2CH3 H H -OH H H -CH3 157 -(CH2)2CH3 -CH(CH3)2 H H -OH H H -CH3 158 -(CH2)2CH3-(CH2)3CH3H H -OH H H -CH3159 -(CH2)2CH3 -CH2-HC=CH2 H H -OH H H -CH3 160 -CH(CH3)2-CH(CH3)2H H -OH H H -CH3161 -CH(CH3)2 -(CH2)3CH3 H H -OH H H -CH3 162 -CH(CH3)2 -CH2-HC=CH2 H H -OH H H -CH3 163 -(CH2)3CH3-(CH2)3CH3H H -OH H H -CH3164 -(CH2)3CH3 -CH2-HC=CH2 H H -OH H H -CH3 165 -CH2-HC=CH2 -CH2-HC=CH2 H H -OH H H -CH3 166 -CH3-CH3H H -OC(O)CH3H H -CH3167 -CH3 -CH2CH3 H H -OC(O)CH3 H H -CH3 168 -CH3-(CH2)2CH3H H -OC(O)CH3H H -CH3169 -CH3-CH(CH3)2H H -OC(O)CH3H H -CH3170 -CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH3 171 -CH3-CH2-HC=CH2H H -OC(O)CH3H H -CH3172 -CH2CH3 -CH2CH3 H H -OC(O)CH3 H H -CH3 173 -CH2CH3 -(CH2)2CH3 H H -OC(O)CH3 H H -CH3 174 -CH2CH3-CH(CH3)2H H -OC(O)CH3H H -CH3175 -CH2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH3 176 -CH2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 177 -(CH2)2CH3-(CH2)2CH3H H -OC(O)CH3H H -CH3178 -(CH2)2CH3 -CH(CH3)2 H H -OC(O)CH3 H H -CH3 179 -(CH2)2CH3-(CH2)3CH3H H -OC(O)CH3H H -CH3180 -(CH2)2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 181 -CH(CH3)2 -CH(CH3)2 H H -OC(O)CH3 H H -CH3 182 -CH(CH3)2-(CH2)3CH3H H -OC(O)CH3H H -CH3183 -CH(CH3)2 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 184 -(CH2)3CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH3 185 -(CH2)3CH3-CH2-HC=CH2H H -OC(O)CH3H H -CH3186 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 187 -CH3-CH3H H H -OCH3H -CH3188 -CH3 -CH2CH3 H H H -OCH3 H -CH3 189 -CH3 -(CH2)2CH3 H H H -OCH3 H -CH3 190 -CH3-CH(CH3)2H H H -OCH3H -CH3191 -CH3 -(CH2)3CH3 H H H -OCH3 H -CH3 192 -CH3 -CH2-HC=CH2 H H H -OCH3 H -CH3 193 -CH2CH3-CH2CH3H H H -OCH3H -CH3194 -CH2CH3 -(CH2)2CH3 H H H -OCH3 H -CH3 195 -CH2CH3-CH(CH3)2H H H -OCH3H -CH3196 -CH2CH3 -(CH2)3CH3 H H H -OCH3 H -CH3 197 -CH2CH3 -CH2-HC=CH2 H H H -OCH3 H -CH3 198 -(CH2)2CH3-(CH2)2CH3H H H -OCH3H -CH3199 -(CH2)2CH3 -CH(CH3)2 H H H -OCH3 H -CH3 200 -(CH2)2CH3 -(CH2)3CH3 H H H -OCH3 H -CH3 201 -(CH2)2CH3-CH2-HC=CH2H H H -OCH3H -CH3202 -CH(CH3)2 -CH(CH3)2 H H H -OCH3 H -CH3 203 -CH(CH3)2-(CH2)3CH3H H H -OCH3H -CH3204 -CH(CH3)2-CH2-HC=CH2H H H -OCH3H -CH347 01312-0021-00PCT 205 -(CH2)3CH3-(CH2)3CH3H H H -OCH3H -CH306 -(CH2)3CH3 -CH2-HC=CH2 H H H -OCH3 H -CH3 07 -CH2-HC=CH2-CH2-HC=CH2H H H -OCH3H -CH3208 -CH3 -CH2CH3 H H H -OH H -CH3 209 -CH3 -(CH2)2CH3 H H H -OH H -CH3 210 -CH3-CH(CH3)2H H H -OH H -CH3211 -CH3 -(CH2)3CH3 H H H -OH H -CH3 212 -CH3 -CH2-HC=CH2 H H H -OH H -CH3 213 -CH2CH3-CH2CH3H H H -OH H -CH3214 -CH2CH3 -(CH2)2CH3 H H H -OH H -CH3 215 -CH2CH3-CH(CH3)2H H H -OH H -CH3216 -CH2CH3 -(CH2)3CH3 H H H -OH H -CH3 217 -CH2CH3 -CH2-HC=CH2 H H H -OH H -CH3 218 -(CH2)2CH3-(CH2)2CH3H H H -OH H -CH3219 -(CH2)2CH3 -CH(CH3)2 H H H -OH H -CH3 220 -(CH2)2CH3 -(CH2)3CH3 H H H -OH H -CH3 221 -(CH2)2CH3-CH2-HC=CH2H H H -OH H -CH3222 -CH(CH3)2 -CH(CH3)2 H H H -OH H -CH3 223 -CH(CH3)2-(CH2)3CH3H H H -OH H -CH3224 -CH(CH3)2-CH2-HC=CH2H H H -OH H -CH3225 -(CH2)3CH3 -(CH2)3CH3 H H H -OH H -CH3 226 -(CH2)3CH3-CH2-HC=CH2H H H -OH H -CH3227 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OH H -CH3 228 -CH3 -CH3 H H H -OC(O)CH3 H -CH3 229 -CH3-CH2CH3H H H -OC(O)CH3H -CH3230 -CH3 -(CH2)2CH3 H H H -OC(O)CH3 H -CH3 231 -CH3 -CH(CH3)2 H H H -OC(O)CH3 H -CH3 232 -CH3-(CH2)3CH3H H H -OC(O)CH3H -CH3233 -CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H -CH3 234 -CH2CH3-CH2CH3H H H -OC(O)CH3H -CH3235 -CH2CH3 -(CH2)2CH3 H H H -OC(O)CH3 H -CH3 236 -CH2CH3 -CH(CH3)2 H H H -OC(O)CH3 H -CH3 237 -CH2CH3-(CH2)3CH3H H H -OC(O)CH3H -CH3238 -CH2CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H -CH3 239 -(CH2)2CH3 -(CH2)2CH3 H H H -OC(O)CH3 H -CH3 240 -(CH2)2CH3-CH(CH3)2H H H -OC(O)CH3H -CH3241 -(CH2)2CH3 -(CH2)3CH3 H H H -OC(O)CH3 H -CH3 242 -(CH2)2CH3-CH2-HC=CH2H H H -OC(O)CH3H -CH3243 -CH(CH3)2 -CH(CH3)2 H H H -OC(O)CH3 H -CH3 244 -CH(CH3)2 -(CH2)3CH3 H H H -OC(O)CH3 H -CH3 245 -CH(CH3)2-CH2-HC=CH2H H H -OC(O)CH3H -CH3246 -(CH2)3CH3 -(CH2)3CH3 H H H -OC(O)CH3 H -CH3 247 -(CH2)3CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H -CH3 248 -CH2-HC=CH2-CH2-HC=CH2H H H OC(O)CH3H -CH3249 -CH3 -CH3 -CH3 H H H H H 250 -CH3-CH3-CH3H -OH H H H 251 -CH3 -CH3 -CH3 H -OC(O)CH3 H H H 252 -CH3 -CH3 -CH3 H -OCH3 H H H 253 -CH3-CH2CH3-CH3H H H H H 254 -CH3 -CH2(CH3)2 -CH3 H H H H H 255 -CH3 -CH3 -CH3 H F H H H 256 -CH3-CH3H -CH3H H H H 257 -CH3 -CH3 H -CH3 -OH H H H 258 -CH3-CH3H -CH3-OC(O)CH3H H H 259 -CH3-CH3H -CH3-OCH3H H H 48 01312-0021-00PCT 260 -CH3-CH2CH3H -CH3H H H H 61 -CH3 -CH2(CH3)2 H -CH3 H H H H 62 -CH3-CH3H -CH3F H H H 263 -CH3 -CH3 H H H H F H 264 -CH3 -CH3 H H -OH H F H 265 -CH3-CH3H H -OC(O)CH3H F H 266 -CH3 -CH3 H H -OCH3 H F H 267 -CH3 -CH2CH3 H H H H F H 268 -CH3-CH2(CH3)2H H H H F H 269 -CH3 -CH3 H H F H F H 270 -CH3-CH3H H H H H -CH3271 -CH3 -CH3 H H -OH H H -CH3 272 -CH3 -CH3 H H -OC(O)CH3 H H -CH3 273 -CH3-CH3H H -OCH3H H -CH3274 -CH3 -CH2CH3 H H H H H -CH3 275 -CH3 -CH2(CH3)2 H H H H H -CH3 276 -CH3-CH3H H F H H -CH3277 -CH3 -CH3 -CH3 H H -OH H H 278 -CH3-CH3-CH3H H -OC(O)CH3H H 279 -CH3-CH3-CH3H H -OCH3H H 280 -CH3 -CH2CH3 -CH3 H H H H H 281 -CH3-CH2(CH3)2-CH3H H H H H 282 -CH3 -CH3 -CH3 H H F H H 283 -CH3 -CH3 H -CH3 H H H H 284 -CH3-CH3H -CH3H -OH H H 285 -CH3 -CH3 H -CH3 H -OC(O)CH3 H H 286 -CH3 -CH3 H -CH3 H -OCH3 H H 287 -CH3-CH2CH3H -CH3H H H H 288 -CH3 -CH2(CH3)2 H -CH3 H H H H 289 -CH3-CH3H -CH3H F H H 290 -CH3 -CH3 H H H H F H 291 -CH3 -CH3 H H H -OH F H 292 -CH3-CH3H H H -OC(O)CH3F H 293 -CH3 -CH3 H H H -OCH3 F H 294 -CH3 -CH2CH3 H H H H F H 295 -CH3-CH2(CH3)2H H H H F H 296 -CH3 -CH3 H H H F F H 297 -CH3-CH3H H H H H -CH3298 -CH3 -CH3 H H H -OH H -CH3 299 -CH3 -CH3 H H H -OC(O)CH3 H -CH3 300 -CH3-CH3H H H -OCH3H -CH3301 -CH3 -CH2CH3 H H H H H -CH3 302 -CH3 -CH2(CH3)2 H H H H H -CH3 303 -CH3-CH3H H H H F -CH3304 H -CH3 H H H H H H 305 H -CH2CH3H H H H H H 306 H -(CH2)2CH3 H H H H H H 307 H -CH(CH3)2 H H H H H H 308 H -(CH2)3CH3H H H H H H 309 H -CH2-HC=CH2 H H H H H H 310 H -CH3 H -CH3 H H H H 310a H -CH2CH3H -CH3H H H H 311 H -(CH2)2CH3 H -CH3 H H H H 312 H -CH(CH3)2H -CH3H H H H 313 H -(CH2)3CH3H -CH3H H H H 49 01312-0021-00PCT 314 H -CH2-HC=CH2H -CH3H H H H 15 H -CH3 H H -OH H H H 16 H -CH2CH3H H -OH H H H 317 H -(CH2)2CH3 H H -OH H H H 318 H -CH(CH3)2 H H -OH H H H 319 H -(CH2)3CH3H H -OH H H H 320 H -CH2-HC=CH2 H H -OH H H H 321 H -CH3 H H -OC(O)CH3 H H H 322 H -CH2CH3H H -OC(O)CH3H H H 324 H -(CH2)2CH3 H H -OC(O)CH3 H H H 325 H -CH(CH3)2H H -OC(O)CH3H H H 326 H -(CH2)3CH3 H H -OC(O)CH3 H H H 327 H -CH2-HC=CH2 H H -OC(O)CH3 H H H 328 H -CH3H H H -OCH3H H 329 H -CH2CH3 H H H -OCH3 H H 330 H -(CH2)2CH3 H H H -OCH3 H H 331 H -CH(CH3)2H H H -OCH3H H 332 H -(CH2)3CH3 H H H -OCH3 H H 333 H -CH2-HC=CH2H H H -OCH3H H 334 H -CH3H H H H F H 335 H -CH2CH3 H H H H F H 336 H -(CH2)2CH3H H H H F H 337 H -CH(CH3)2 H H H H F H 338 H -(CH2)3CH3 H H H H F H 339 H -CH2-HC=CH2H H H H F H 340 H -CH3 H -CH3 -OH H H H 341 H -CH2CH3 H -CH3 -OH H H H 342 H -(CH2)2CH3H -CH3-OH H H H 343 H -CH(CH3)2 H -CH3 -OH H H H 344 H -(CH2)3CH3H -CH3-OH H H H 345 H -CH2-HC=CH2 H -CH3 -OH H H H 346 H -CH3 H -CH3 -OC(O)CH3 H H H 347 H -CH2CH3H -CH3-OC(O)CH3H H H 348 H -(CH2)2CH3 H -CH3 -OC(O)CH3 H H H 349 H -CH(CH3)2 H -CH3 -OC(O)CH3 H H H 350 H -(CH2)3CH3H -CH3-OC(O)CH3H H H 351 H -CH2-HC=CH2 H -CH3 -OC(O)CH3 H H H 352 H -CH3H -CH3H -OCH3H H 353 H -CH2CH3 H -CH3 H -OCH3 H H 354 H -(CH2)2CH3 H -CH3 H -OCH3 H H 355 H -CH(CH3)2H -CH3H -OCH3H H 356 H -(CH2)3CH3 H -CH3 H -OCH3 H H 357 H -CH2-HC=CH2 H -CH3 H -OCH3 H H 358 H -CH3H -CH3H H F H 359 H -CH2CH3 H -CH3 H H F H 360 H -(CH2)2CH3H -CH3H H F H 361 H -CH(CH3)2 H -CH3 H H F H 362 H -(CH2)3CH3 H -CH3 H H F H 363 H -CH2-HC=CH2H -CH3H H F H 364 H cyclopropyl H H H H H H 365 H cyclopropyl H -CH3 H H H H 366 H cyclopropyl H H -OH H H H 367 H cyclopropyl H H -OC(O)CH3 H H H 368 H cyclopropyl H H H -OCH3H H 369 H cyclopropyl H H H H F H 50 01312-0021-00PCT 370 H cyclopropyl H H H H H H 71 H cyclopropyl H -CH3 -OH H F H 72 H cyclopropyl H -CH3-OH H H H 373 H cyclopropyl H -CH3 -OC(O)CH3 H H H 374 H cyclopropyl H -CH3 H -OCH3 H H 375 H cyclopropyl H -CH3H H F H 376 -CH3 cyclopropyl H H H H H H 377 -CH3 cyclopropyl H -CH3 H H H H 378 -CH3cyclopropyl H H -OH H H H 379 -CH3 cyclopropyl H H -OC(O)CH3 H H H 380 -CH3cyclopropyl H H H -OCH3H H 381 -CH3 cyclopropyl H H H H F H 382 -CH3 cyclopropyl H H H H H H 383 -CH3cyclopropyl H -CH3-OH H F H 384 -CH3 cyclopropyl H -CH3 -OH H H H 385 -CH3 cyclopropyl H -CH3 -OC(O)CH3 H H H 386 -CH3cyclopropyl H -CH3H -OCH3H H 387 -CH3 cyclopropyl H -CH3 H H F H 388 -CH2CH3cyclopropyl H H H H H H 389 -CH2CH3cyclopropyl H -CH3H H H H 390 -CH2CH3 cyclopropyl H H -OH H H H 391 -CH2CH3cyclopropyl H H -OC(O)CH3H H H 392 -CH2CH3 cyclopropyl H H H -OCH3 H H 393 -CH2CH3 cyclopropyl H H H H F H 394 -CH2CH3cyclopropyl H H H H H H 395 -CH2CH3 cyclopropyl H -CH3 -OH H F H 396 -CH2CH3 cyclopropyl H -CH3 -OH H H H 397 -CH2CH3cyclopropyl H -CH3-OC(O)CH3H H H 398 -CH2CH3 cyclopropyl H -CH3 H -OCH3 H H 399 -CH2CH3cyclopropyl H -CH3H H F H 400 -(CH2)2CH3 cyclopropyl H H H H H H 401 -(CH2)2CH3 cyclopropyl H -CH3 H H H H 402 -(CH2)2CH3cyclopropyl H H -OH H H H 403 -(CH2)2CH3 cyclopropyl H H -OC(O)CH3 H H H 404 -(CH2)2CH3 cyclopropyl H H H -OCH3 H H 405 -(CH2)2CH3cyclopropyl H H H H F H 406 -(CH2)2CH3 cyclopropyl H H H H H H 407 -(CH2)2CH3cyclopropyl H -CH3-OH H F H 408 -(CH2)2CH3 cyclopropyl H -CH3 -OH H H H 409 -(CH2)2CH3 cyclopropyl H -CH3 -OC(O)CH3 H H H 410 -(CH2)2CH3cyclopropyl H -CH3H -OCH3H H 411 -(CH2)2CH3 cyclopropyl H -CH3 H H F H 412 -CH2(CH3)2 cyclopropyl H H H H H H 413 -CH2(CH3)2cyclopropyl H -CH3H H H H 414 -CH2(CH3)2 cyclopropyl H H -OH H H H 415 -CH2(CH3)2cyclopropyl H H -OC(O)CH3H H H 416 -CH2(CH3)2 cyclopropyl H H H -OCH3 H H 417 -CH2(CH3)2 cyclopropyl H H H H F H 418 -CH2(CH3)2cyclopropyl H H H H H H 419 -CH2(CH3)2 cyclopropyl H -CH3 -OH H F H 420 -CH2(CH3)2 cyclopropyl H -CH3 -OH H H H 421 -CH2(CH3)2cyclopropyl H -CH3-OC(O)CH3H H H 422 -CH2(CH3)2 cyclopropyl H -CH3 H -OCH3 H H 423 -CH2(CH3)2cyclopropyl H -CH3H H F H 424 cyclopropyl cyclopropyl H -CH3H H H H 51 01312-0021-00PCT 425 cyclopropyl cyclopropyl H H -OH H H H 26 cyclopropyl cyclopropyl H H -OC(O)CH3 H H H 27 cyclopropyl cyclopropyl H H H -OCH3H H 428 cyclopropyl cyclopropyl H H H H F H 429 cyclopropyl cyclopropyl H H H H H H 430 cyclopropyl cyclopropyl H -CH3-OH H F H 431 cyclopropyl cyclopropyl H -CH3 -OH H H H 432 cyclopropyl cyclopropyl H -CH3 -OC(O)CH3 H H H 433 cyclopropyl cyclopropyl H -CH3H -OCH3H H 434 cyclopropyl cyclopropyl H -CH3 H H F H 435 H -CH3H H -OH H H -CH3436 H -CH2CH3 H H -OH H H -CH3 437 H -(CH2)2CH3 H H -OH H H -CH3 438 H -CH(CH3)2H H -OH H H -CH3439 H -(CH2)3CH3 H H -OH H H -CH3 440 H -CH2-HC=CH2 H H -OH H H -CH3 441 H -CH3H H -OC(O)CH3H H -CH3442 H -CH2CH3 H H -OC(O)CH3 H H -CH3 443 H -(CH2)2CH3H H -OC(O)CH3H H -CH3444 H -CH(CH3)2H H -OC(O)CH3H H -CH3445 H -(CH2)3CH3 H H -OC(O)CH3 H H -CH3 446 H -CH2-HC=CH2H H -OC(O)CH3H H -CH3447 H -CH3 H H H -OCH3 H -CH3 448 H -CH2CH3 H H H -OCH3 H -CH3 449 H -(CH2)2CH3H H H -OCH3H -CH3450 H -CH(CH3)2 H H H -OCH3 H -CH3 451 H -(CH2)3CH3 H H H -OCH3 H -CH3 452 H -CH2-HC=CH2H H H -OCH3H -CH3453 H -CH3 H H -OH H F H 454 H -CH2CH3H H -OH H F H 455 H -(CH2)2CH3 H H -OH H F H 456 H -CH(CH3)2 H H -OH H F H 457 H -(CH2)3CH3H H -OH H F H 458 H -CH2-HC=CH2 H H -OH H F H 459 H -CH3 H H -OC(O)CH3 H F H 460 H -CH2CH3H H -OC(O)CH3H F H 461 H -(CH2)2CH3 H H -OC(O)CH3 H F H 462 H -CH(CH3)2H H -OC(O)CH3H F H 463 H -(CH2)3CH3 H H -OC(O)CH3 H F H 464 H -CH2-HC=CH2 H H -OC(O)CH3 H F H 465 H -CH3H H H -OCH3F H 466 H -CH2CH3 H H H -OCH3 F H 467 H -(CH2)2CH3 H H H -OCH3 F H 468 H -CH(CH3)2H H H -OCH3F H 469 H -(CH2)3CH3 H H H -OCH3 F H 470 H -CH2-HC=CH2H H H -OCH3F H 471 H -CD3 H H H H H H 472 H -CD3 H H -OH H H H 473 H -CD3H H -OC(O)CH3H H H 474 H -CD3 H H H -OCH3 H H 475 H -CD3 H H H H F H 476 H -CD3H H -OH H F H 477 H -CD3 H H -OC(O)CH3 H F H 478 H -CD3H H H -OCH3F H 479 H -CD3H H H H H -CH352 01312-0021-00PCT 480 H -CD3H H -OH H H -CH381 H -CD3 H H -OC(O)CH3 H H -CH3 82 H -CD3H H H -OCH3H -CH3483 H -CD3 H H H H F -CH3 484 H -CD3 H H -OH H F -CH3 485 H -CD3H H -OC(O)CH3H F -CH3486 H -CD3 H H H -OCH3 F -CH3 487 H -CD2CD3 H H H H H H 488 H -CD2CD3H H -OH H H H 489 H -CD2CD3 H H -OC(O)CH3 H H H 490 H -CD2CD3H H H -OCH3H H 491 H -CD2CD3 H H H H F H 492 H -CD2CD3 H H -OH H F H 493 H -CD2CD3H H -OC(O)CH3H F H 494 H -CD2CD3 H H H -OCH3 F H 495 H -CD2CD3 H H H H H -CH3 496 H -CD2CD3H H -OH H H -CH3497 H -CD2CD3 H H -OC(O)CH3 H H -CH3 498 H -CD2CD3H H H -OCH3H -CH3499 H -CD2CD3H H H H F -CH3500 H -CD2CD3 H H -OH H F -CH3 501 H -CD2CD3H H -OC(O)CH3H F -CH3502 H -CD2CD3 H H H -OCH3 F -CH3 503 H -CH3 H H -OH H F -CH3 504 H -CH2CH3H H -OH H F -CH3505 H -(CH2)2CH3 H H -OH H F -CH3 506 H -CH(CH3)2 H H -OH H F -CH3 507 H -(CH2)3CH3H H -OH H F -CH3508 H -CH2-HC=CH2 H H -OH H F -CH3 509 H -CH3H H -OC(O)CH3H F -CH3510 H -CH2CH3 H H -OC(O)CH3 H F -CH3 511 H -(CH2)2CH3 H H -OC(O)CH3 H F -CH3 512 H -CH(CH3)2H H -OC(O)CH3H F -CH3513 H -(CH2)3CH3 H H -OC(O)CH3 H F -CH3 514 H -CH2-HC=CH2 H H -OC(O)CH3 H F -CH3 515 H -CH3H H H -OCH3F -CH3516 H -CH2CH3 H H H -OCH3 F -CH3 517 H -(CH2)2CH3H H H -OCH3F -CH3518 H -CH(CH3)2 H H H -OCH3 F -CH3 519 H -(CH2)3CH3 H H H -OCH3 F -CH3 520 H -CH2-HC=CH2H H H -OCH3F -CH3521 H -CH3 H D H H H H 522 H -CH2CH3 H D H H H H 523 H -(CH2)2CH3H D H H H H 524 H -CH(CH3)2 H D H H H H 525 H -(CH2)3CH3H D H H H H 526 H -CH2-HC=CH2 H D H H H H 527 H -CH3 H D -OH H H H 528 H -CH2CH3H D -OH H H H 529 H -(CH2)2CH3 H D -OH H H H 530 H -CH(CH3)2 H D -OH H H H 531 H -(CH2)3CH3H D -OH H H H 532 H -CH2-HC=CH2 H D -OH H H H 533 H -CH3H D -OC(O)CH3H H H 534 H -CH2CH3H D -OC(O)CH3H H H 53 01312-0021-00PCT 535 H -(CH2)2CH3H D -OC(O)CH3H H H 36 H -CH(CH3)2 H D -OC(O)CH3 H H H 37 H -(CH2)3CH3H D -OC(O)CH3H H H 538 H -CH2-HC=CH2 H D -OC(O)CH3 H H H 539 H -CH3 H D H -OCH3 H H 540 H -CH2CH3H D H -OCH3H H 541 H -(CH2)2CH3 H D H -OCH3 H H 542 H -CH(CH3)2 H D H -OCH3 H H 543 H -(CH2)3CH3H D H -OCH3H H 544 H -CH2-HC=CH2 H D H -OCH3 H H 545 H -CH3H D H H F H 546 H -CH2CH3 H D H H F H 547 H -(CH2)2CH3 H D H H F H 548 H -CH(CH3)2H D H H F H 549 H -(CH2)3CH3 H D H H F H 550 H -CH2-HC=CH2 H D H H F H 551 H -CH3H D H H F CH3552 H -CH2CH3 H D H H F CH3 553 H -(CH2)2CH3H D H H F CH3554 H -CH(CH3)2H D H H F CH3555 H -(CH2)3CH3 H D H H F CH3 556 H -CH2-HC=CH2H D H H F CH3Other exemplary compounds of Formula I include those below in Table 3, which is also represented by Formula Ic: Formula Ic Table 3 ef. X Y R2R3R4R5R6R71 -CH3 -CH3 H H -OCH3 H H H 2 -CH3-CH2CH3H H -OCH3H H H 3 -CH3-(CH2)2CH3H H -OCH3H H H 4 -CH3 -CH(CH3)2 H H -OCH3 H H H 5 -CH3-(CH2)3CH3H H -OCH3H H H 6 -CH3 -CH2-HC=CH2 H H -OCH3 H H H 7 -CH2CH3 -CH2CH3 H H -OCH3 H H H 8 -CH2CH3-(CH2)2CH3H H -OCH3H H H 9 -CH2CH3 -CH(CH3)2 H H -OCH3 H H H 10 -CH2CH3 -(CH2)3CH3 H H -OCH3 H H H 11 -CH2CH3-CH2-HC=CH2H H -OCH3H H H 54 01312-0021-00PCT 12 -(CH2)2CH3-(CH2)2CH3H H -OCH3H H H 13 -(CH2)2CH3 -CH(CH3)2 H H -OCH3 H H H 14 -(CH2)2CH3-(CH2)3CH3H H -OCH3H H H 15 -(CH2)2CH3 -CH2-HC=CH2 H H -OCH3 H H H 16 -CH(CH3)2 -CH(CH3)2 H H -OCH3 H H H 17 -CH(CH3)2-(CH2)3CH3H H -OCH3H H H 18 -CH(CH3)2 -CH2-HC=CH2 H H -OCH3 H H H 19 -(CH2)3CH3 -(CH2)3CH3 H H -OCH3 H H H 20 -(CH2)3CH3-CH2-HC=CH2H H -OCH3H H H 21 -CH2-HC=CH2 -CH2-HC=CH2 H H -OCH3 H H H 22 -CH3-CH2CH3H H -OH H H H 23 -CH3 -(CH2)2CH3 H H -OH H H H 24 -CH3 -CH(CH3)2 H H -OH H H H 25 -CH3-(CH2)3CH3H H -OH H H H 26 -CH3 -CH2-HC=CH2 H H -OH H H H 27 -CH2CH3 -CH2CH3 H H -OH H H H 28 -CH2CH3-(CH2)2CH3H H -OH H H H 29 -CH2CH3 -CH(CH3)2 H H -OH H H H 30 -CH2CH3-(CH2)3CH3H H -OH H H H 31 -CH2CH3-CH2-HC=CH2H H -OH H H H 32 -(CH2)2CH3 -(CH2)2CH3 H H -OH H H H 33 -(CH2)2CH3-CH(CH3)2H H -OH H H H 34 -(CH2)2CH3 -(CH2)3CH3 H H -OH H H H 35 -(CH2)2CH3 -CH2-HC=CH2 H H -OH H H H 36 -CH(CH3)2-CH(CH3)2H H -OH H H H 37 -CH(CH3)2 -(CH2)3CH3 H H -OH H H H 38 -CH(CH3)2 -CH2-HC=CH2 H H -OH H H H 39 -(CH2)3CH3-(CH2)3CH3H H -OH H H H 40 -(CH2)3CH3 -CH2-HC=CH2 H H -OH H H H 41 -CH2-HC=CH2-CH2-HC=CH2H H -OH H H H 42 -CH3 -CH3 H H -OC(O)CH3 H H H 43 -CH3 -CH2CH3 H H -OC(O)CH3 H H H 44 -CH3-(CH2)2CH3H H -OC(O)CH3H H H 45 -CH3 -CH(CH3)2 H H -OC(O)CH3 H H H 46 -CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 47 -CH3-CH2-HC=CH2H H -OC(O)CH3H H H 48 -CH2CH3 -CH2CH3 H H -OC(O)CH3 H H H 49 -CH2CH3-(CH2)2CH3H H -OC(O)CH3H H H 50 -CH2CH3 -CH(CH3)2 H H -OC(O)CH3 H H H 51 -CH2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 52 -CH2CH3-CH2-HC=CH2H H -OC(O)CH3H H H 53 -(CH2)2CH3 -(CH2)2CH3 H H -OC(O)CH3 H H H 54 -(CH2)2CH3 -CH(CH3)2 H H -OC(O)CH3 H H H 55 -(CH2)2CH3-(CH2)3CH3H H -OC(O)CH3H H H 56 -(CH2)2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 57 -CH(CH3)2-CH(CH3)2H H -OC(O)CH3H H H 58 -CH(CH3)2 -(CH2)3CH3 H H -OC(O)CH3 H H H 59 -CH(CH3)2 -CH2-HC=CH2 H H -OC(O)CH3 H H H 60 -(CH2)3CH3-(CH2)3CH3H H -OC(O)CH3H H H 61 -(CH2)3CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 62 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H H H 63 -CH3-CH3H H H -OCH2CH3H H 64 -CH3 -CH2CH3 H H H -OCH3 H H 65 -CH3-(CH2)2CH3H H H -OCH3H H 66 -CH3-CH(CH3)2H H H -OCH3H H 55 01312-0021-00PCT 67 -CH3-(CH2)3CH3H H H -OCH3H H 68 -CH3 -CH2-HC=CH2 H H H -OCH3 H H 69 -CH2CH3-CH2CH3H H H -OCH3H H 70 -CH2CH3 -(CH2)2CH3 H H H -OCH3 H H 71 -CH2CH3 -CH(CH3)2 H H H -OCH3 H H 72 -CH2CH3-(CH2)3CH3H H H -OCH3H H 73 -CH2CH3 -CH2-HC=CH2 H H H -OCH3 H H 74 -(CH2)2CH3 -(CH2)2CH3 H H H -OCH3 H H 75 -(CH2)2CH3-CH(CH3)2H H H -OCH3H H 76 -(CH2)2CH3 -(CH2)3CH3 H H H -OCH3 H H 77 -(CH2)2CH3-CH2-HC=CH2H H H -OCH3H H 78 -CH(CH3)2 -CH(CH3)2 H H H -OCH3 H H 79 -CH(CH3)2 -(CH2)3CH3 H H H -OCH3 H H 80 -CH(CH3)2-CH2-HC=CH2H H H -OCH3H H 81 -(CH2)3CH3 -(CH2)3CH3 H H H -OCH3 H H 82 -(CH2)3CH3 -CH2-HC=CH2 H H H -OCH3 H H 83 -CH2-HC=CH2-CH2-HC=CH2H H H -OCH3H H 84 -CH3 -CH2CH3 H H H -OH H H 85 -CH3-(CH2)2CH3H H H -OH H H 86 -CH3-CH(CH3)2H H H -OH H H 87 -CH3 -(CH2)3CH3 H H H -OH H H 88 -CH3-CH2-HC=CH2H H H -OH H H 89 -CH2CH3 -CH2CH3 H H H -OH H H 90 -CH2CH3 -(CH2)2CH3 H H H -OH H H 91 -CH2CH3-CH(CH3)2H H H -OH H H 92 -CH2CH3 -(CH2)3CH3 H H H -OH H H 93 -CH2CH3 -CH2-HC=CH2 H H H -OH H H 94 -(CH2)2CH3-(CH2)2CH3H H H -OH H H 95 -(CH2)2CH3 -CH(CH3)2 H H H -OH H H 96 -(CH2)2CH3-(CH2)3CH3H H H -OH H H 97 -(CH2)2CH3 -CH2-HC=CH2 H H H -OH H H 98 -CH(CH3)2 -CH(CH3)2 H H H -OH H H 99 -CH(CH3)2-(CH2)3CH3H H H -OH H H 100 -CH(CH3)2 -CH2-HC=CH2 H H H -OH H H 101 -(CH2)3CH3 -(CH2)3CH3 H H H -OH H H 102 -(CH2)3CH3-CH2-HC=CH2H H H -OH H H 103 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OH H H 104 -CH3-CH3H H H -OC(O)CH3H H 105 -CH3 -CH2CH3 H H H -OC(O)CH3 H H 106 -CH3 -(CH2)2CH3 H H H -OC(O)CH3 H H 107 -CH3-CH(CH3)2H H H -OC(O)CH3H H 108 -CH3 -(CH2)3CH3 H H H -OC(O)CH3 H H 109 -CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H H 110 -CH2CH3-CH2CH3H H H -OC(O)CH3H H 111 -CH2CH3 -(CH2)2CH3 H H H -OC(O)CH3 H H 112 -CH2CH3-CH(CH3)2H H H -OC(O)CH3H H 113 -CH2CH3 -(CH2)3CH3 H H H -OC(O)CH3 H H 114 -CH2CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H H 115 -(CH2)2CH3-(CH2)2CH3H H H -OC(O)CH3H H 116 -(CH2)2CH3 -CH(CH3)2 H H H -OC(O)CH3 H H 117 -(CH2)2CH3 -(CH2)3CH3 H H H -OC(O)CH3 H H 118 -(CH2)2CH3-CH2-HC=CH2H H H -OC(O)CH3H H 119 -CH(CH3)2 -CH(CH3)2 H H H -OC(O)CH3 H H 120 -CH(CH3)2-(CH2)3CH3H H H -OC(O)CH3H H 121 -CH(CH3)2-CH2-HC=CH2H H H -OC(O)CH3H H 56 01312-0021-00PCT 122 -(CH2)3CH3-(CH2)3CH3H H H -OC(O)CH3H H 23 -(CH2)3CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H H 24 -CH2-HC=CH2-CH2-HC=CH2H H H -OC(O)CH3H H 125 -CH3 -CH3 H H -OCH3 H H -CH3 126 -CH3 -CH2CH3 H H -OCH3 H H -CH3 127 -CH3-(CH2)2CH3H H -OCH3H H -CH3128 -CH3 -CH(CH3)2 H H -OCH3 H H -CH3 129 -CH3 -(CH2)3CH3 H H -OCH3 H H -CH3 130 -CH3-CH2-HC=CH2H H -OCH3H H -CH3131 -CH2CH3 -CH2CH3 H H -OCH3 H H -CH3 132 -CH2CH3-(CH2)2CH3H H -OCH3H H -CH3133 -CH2CH3 -CH(CH3)2 H H -OCH3 H H -CH3 134 -CH2CH3 -(CH2)3CH3 H H -OCH3 H H -CH3 135 -CH2CH3-CH2-HC=CH2H H -OCH3H H -CH3135 -(CH2)2CH3 -(CH2)2CH3 H H -OCH3 H H -CH3 137 -(CH2)2CH3 -CH(CH3)2 H H -OCH3 H H -CH3 138 -(CH2)2CH3-(CH2)3CH3H H -OCH3H H -CH3139 -(CH2)2CH3 -CH2-HC=CH2 H H -OCH3 H H -CH3 140 -CH(CH3)2-CH(CH3)2H H -OCH3H H -CH3141 -CH(CH3)2-(CH2)3CH3H H -OCH3H H -CH3142 -CH(CH3)2 -CH2-HC=CH2 H H -OCH3 H H -CH3 143 -(CH2)3CH3-(CH2)3CH3H H -OCH3H H -CH3144 -(CH2)3CH3 -CH2-HC=CH2 H H -OCH3 H H -CH3 145 -CH2-HC=CH2 -CH2-HC=CH2 H H -OCH3 H H -CH3 146 -CH3-CH2CH3H H -OH H H -CH3147 -CH3 -(CH2)2CH3 H H -OH H H -CH3 148 -CH3 -CH(CH3)2 H H -OH H H -CH3 149 -CH3-(CH2)3CH3H H -OH H H -CH3150 -CH3 -CH2-HC=CH2 H H -OH H H -CH3 151 -CH2CH3-CH2CH3H H -OH H H -CH3152 -CH2CH3 -(CH2)2CH3 H H -OH H H -CH3 153 -CH2CH3 -CH(CH3)2 H H -OH H H -CH3 154 -CH2CH3-(CH2)3CH3H H -OH H H -CH3155 -CH2CH3 -CH2-HC=CH2 H H -OH H H -CH3 156 -(CH2)2CH3 -(CH2)2CH3 H H -OH H H -CH3 157 -(CH2)2CH3-CH(CH3)2H H -OH H H -CH3158 -(CH2)2CH3 -(CH2)3CH3 H H -OH H H -CH3 159 -(CH2)2CH3-CH2-HC=CH2H H -OH H H -CH3160 -CH(CH3)2 -CH(CH3)2 H H -OH H H -CH3 161 -CH(CH3)2 -(CH2)3CH3 H H -OH H H -CH3 162 -CH(CH3)2-CH2-HC=CH2H H -OH H H -CH3163 -(CH2)3CH3 -(CH2)3CH3 H H -OH H H -CH3 164 -(CH2)3CH3 -CH2-HC=CH2 H H -OH H H -CH3 165 -CH2-HC=CH2-CH2-HC=CH2H H -OH H H -CH3166 -CH3 -CH3 H H -OC(O)CH3 H H -CH3 167 -CH3-CH2CH3H H -OC(O)CH3H H -CH3168 -CH3 -(CH2)2CH3 H H -OC(O)CH3 H H -CH3 169 -CH3 -CH(CH3)2 H H -OC(O)CH3 H H -CH3 170 -CH3-(CH2)3CH3H H -OC(O)CH3H H -CH3171 -CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 172 -CH2CH3 -CH2CH3 H H -OC(O)CH3 H H -CH3 173 -CH2CH3-(CH2)2CH3H H -OC(O)CH3H H -CH3174 -CH2CH3 -CH(CH3)2 H H -OC(O)CH3 H H -CH3 175 -CH2CH3-(CH2)3CH3H H -OC(O)CH3H H -CH3176 -CH2CH3-CH2-HC=CH2H H -OC(O)CH3H H -CH357 01312-0021-00PCT 177 -(CH2)2CH3-(CH2)2CH3H H -OC(O)CH3H H -CH378 -(CH2)2CH3 -CH(CH3)2 H H -OC(O)CH3 H H -CH3 79 -(CH2)2CH3-(CH2)3CH3H H -OC(O)CH3H H -CH3180 -(CH2)2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 181 -CH(CH3)2 -CH(CH3)2 H H -OC(O)CH3 H H -CH3 182 -CH(CH3)2-(CH2)3CH3H H -OC(O)CH3H H -CH3183 -CH(CH3)2 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 184 -(CH2)3CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH3 185 -(CH2)3CH3-CH2-HC=CH2H H -OC(O)CH3H H -CH3186 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 187 -CH3-CH3H H H -OCH3H -CH3188 -CH3 -CH2CH3 H H H -OCH3 H -CH3 189 -CH3 -(CH2)2CH3 H H H -OCH3 H -CH3 190 -CH3-CH(CH3)2H H H -OCH3H -CH3191 -CH3 -(CH2)3CH3 H H H -OCH3 H -CH3 192 -CH3 -CH2-HC=CH2 H H H -OCH3 H -CH3 193 -CH2CH3-CH2CH3H H H -OCH3H -CH3194 -CH2CH3 -(CH2)2CH3 H H H -OCH3 H -CH3 195 -CH2CH3-CH(CH3)2H H H -OCH3H -CH3196 -CH2CH3-(CH2)3CH3H H H -OCH3H -CH3197 -CH2CH3 -CH2-HC=CH2 H H H -OCH3 H -CH3 198 -(CH2)2CH3-(CH2)2CH3H H H -OCH3H -CH3199 -(CH2)2CH3 -CH(CH3)2 H H H -OCH3 H -CH3 200 -(CH2)2CH3 -(CH2)3CH3 H H H -OCH3 H -CH3 201 -(CH2)2CH3-CH2-HC=CH2H H H -OCH3H -CH3202 -CH(CH3)2 -CH(CH3)2 H H H -OCH3 H -CH3 203 -CH(CH3)2 -(CH2)3CH3 H H H -OCH3 H -CH3 204 -CH(CH3)2-CH2-HC=CH2H H H -OCH3H -CH3205 -(CH2)3CH3 -(CH2)3CH3 H H H -OCH3 H -CH3 206 -(CH2)3CH3-CH2-HC=CH2H H H -OCH3H -CH3207 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OCH3 H -CH3 208 -CH3 -CH2CH3 H H H -OH H -CH3 209 -CH3-(CH2)2CH3H H H -OH H -CH3210 -CH3 -CH(CH3)2 H H H -OH H -CH3 211 -CH3 -(CH2)3CH3 H H H -OH H -CH3 212 -CH3-CH2-HC=CH2H H H -OH H -CH3213 -CH2CH3 -CH2CH3 H H H -OH H -CH3 214 -CH2CH3-(CH2)2CH3H H H -OH H -CH3215 -CH2CH3 -CH(CH3)2 H H H -OH H -CH3 216 -CH2CH3 -(CH2)3CH3 H H H -OH H -CH3 217 -CH2CH3-CH2-HC=CH2H H H -OH H -CH3218 -(CH2)2CH3 -(CH2)2CH3 H H H -OH H -CH3 219 -(CH2)2CH3 -CH(CH3)2 H H H -OH H -CH3 220 -(CH2)2CH3-(CH2)3CH3H H H -OH H -CH3221 -(CH2)2CH3 -CH2-HC=CH2 H H H -OH H -CH3 222 -CH(CH3)2-CH(CH3)2H H H -OH H -CH3223 -CH(CH3)2 -(CH2)3CH3 H H H -OH H -CH3 224 -CH(CH3)2 -CH2-HC=CH2 H H H -OH H -CH3 225 -(CH2)3CH3-(CH2)3CH3H H H -OH H -CH3226 -(CH2)3CH3 -CH2-HC=CH2 H H H -OH H -CH3 227 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OH H -CH3 228 -CH3-CH3H H H -OC(O)CH3H -CH3229 -CH3 -CH2CH3 H H H -OC(O)CH3 H -CH3 230 -CH3-(CH2)2CH3H H H -OC(O)CH3H -CH3231 -CH3-CH(CH3)2H H H -OC(O)CH3H -CH358 01312-0021-00PCT 232 -CH3-(CH2)3CH3H H H -OC(O)CH3H -CH333 -CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H -CH3 34 -CH2CH3-CH2CH3H H H -OC(O)CH3H -CH3235 -CH2CH3 -(CH2)2CH3 H H H -OC(O)CH3 H -CH3 236 -CH2CH3 -CH(CH3)2 H H H -OC(O)CH3 H -CH3 237 -CH2CH3-(CH2)3CH3H H H -OC(O)CH3H -CH3238 -CH2CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H -CH3 239 -(CH2)2CH3 -(CH2)2CH3 H H H -OC(O)CH3 H -CH3 240 -(CH2)2CH3-CH(CH3)2H H H -OC(O)CH3H -CH3241 -(CH2)2CH3 -(CH2)3CH3 H H H -OC(O)CH3 H -CH3 242 -(CH2)2CH3-CH2-HC=CH2H H H -OC(O)CH3H -CH3243 -CH(CH3)2 -CH(CH3)2 H H H -OC(O)CH3 H -CH3 244 -CH(CH3)2 -(CH2)3CH3 H H H -OC(O)CH3 H -CH3 245 -CH(CH3)2-CH2-HC=CH2H H H -OC(O)CH3H -CH3246 -(CH2)3CH3 -(CH2)3CH3 H H H -OC(O)CH3 H -CH3 247 -(CH2)3CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H -CH3 248 -CH2-HC=CH2-CH2-HC=CH2H H H OC(O)CH3H -CH3249 -CH3 -CH3 -CH3 H H H H H 250 -CH3-CH3-CH3H -OH H H H 251 -CH3-CH3-CH3H -OC(O)CH3H H H 252 -CH3 -CH3 -CH3 H -OCH3 H H H 253 -CH3-CH2CH3-CH3H H H H H 254 -CH3 -CH2(CH3)2 -CH3 H H H H H 255 -CH3 -CH3 -CH3 H F H H H 256 -CH3-CH3H -CH3H H H H 257 -CH3 -CH3 H -CH3 -OH H H H 258 -CH3 -CH3 H -CH3 -OC(O)CH3 H H H 259 -CH3-CH3H -CH3-OCH3H H H 260 -CH3 -CH2CH3 H -CH3 H H H H 261 -CH3-CH2(CH3)2H -CH3H H H H 262 -CH3 -CH3 H -CH3 F H H H 263 -CH3 -CH3 H H H H F H 264 -CH3-CH3H H -OH H F H 265 -CH3 -CH3 H H -OC(O)CH3 H F H 266 -CH3 -CH3 H H -OCH3 H F H 267 -CH3-CH2CH3H H H H F H 268 -CH3 -CH2(CH3)2 H H H H F H 269 -CH3-CH3H H F H F H 270 -CH3 -CH3 H H H H H -CH3 271 -CH3 -CH3 H H -OH H H -CH3 272 -CH3-CH3H H -OC(O)CH3H H -CH3273 -CH3 -CH3 H H -OCH3 H H -CH3 274 -CH3 -CH2CH3 H H H H H -CH3 275 -CH3-CH2(CH3)2H H H H H -CH3276 -CH3 -CH3 H H F H H -CH3 277 -CH3-CH3-CH3H H -OH H H 278 -CH3 -CH3 -CH3 H H -OC(O)CH3 H H 279 -CH3 -CH3 -CH3 H H -OCH3 H H 280 -CH3-CH2CH3-CH3H H H H H 281 -CH3 -CH2(CH3)2 -CH3 H H H H H 282 -CH3 -CH3 -CH3 H H F H H 283 -CH3-CH3H -CH3H H H H 284 -CH3 -CH3 H -CH3 H -OH H H 285 -CH3-CH3H -CH3H -OC(O)CH3H H 286 -CH3-CH3H -CH3H -OCH3H H 59 01312-0021-00PCT 287 -CH3-CH2CH3H -CH3H H H H 88 -CH3 -CH2(CH3)2 H -CH3 H H H H 89 -CH3-CH3H -CH3H F H H 290 -CH3 -CH3 H H H H F H 291 -CH3 -CH3 H H H -OH F H 292 -CH3-CH3H H H -OC(O)CH3F H 293 -CH3 -CH3 H H H -OCH3 F H 294 -CH3 -CH2CH3 H H H H F H 295 -CH3-CH2(CH3)2H H H H F H 296 -CH3 -CH3 H H H F F H 297 -CH3-CH3H H H H H -CH3298 -CH3 -CH3 H H H -OH H -CH3 299 -CH3 -CH3 H H H -OC(O)CH3 H -CH3 300 -CH3-CH3H H H -OCH3H -CH3301 -CH3 -CH2CH3 H H H H H -CH3 302 -CH3 -CH2(CH3)2 H H H H H -CH3 303 -CH3-CH3H H H H F -CH3304 H -CH3 H H H H H H 305 H -CH2CH3H H H H H H 306 H -(CH2)2CH3H H H H H H 307 H -CH(CH3)2 H H H H H H 308 H -(CH2)3CH3H H H H H H 309 H -CH2-HC=CH2 H H H H H H 310 H -CH3 H -CH3 H H H H 310a H -CH2CH3H -CH3H H H H 311 H -(CH2)2CH3 H -CH3 H H H H 312 H -CH(CH3)2 H -CH3 H H H H 313 H -(CH2)3CH3H -CH3H H H H 314 H -CH2-HC=CH2 H -CH3 H H H H 315 H -CH3H H -OH H H H 316 H -CH2CH3 H H -OH H H H 317 H -(CH2)2CH3 H H -OH H H H 318 H -CH(CH3)2H H -OH H H H 319 H -(CH2)3CH3 H H -OH H H H 320 H -CH2-HC=CH2 H H -OH H H H 321 H -CH3H H -OC(O)CH3H H H 322 H -CH2CH3 H H -OC(O)CH3 H H H 324 H -(CH2)2CH3H H -OC(O)CH3H H H 325 H -CH(CH3)2 H H -OC(O)CH3 H H H 326 H -(CH2)3CH3 H H -OC(O)CH3 H H H 327 H -CH2-HC=CH2H H -OC(O)CH3H H H 328 H -CH3 H H H -OCH3 H H 329 H -CH2CH3 H H H -OCH3 H H 330 H -(CH2)2CH3H H H -OCH3H H 331 H -CH(CH3)2 H H H -OCH3 H H 332 H -(CH2)3CH3H H H -OCH3H H 333 H -CH2-HC=CH2 H H H -OCH3 H H 334 H -CH3 H H H H F H 335 H -CH2CH3H H H H F H 336 H -(CH2)2CH3 H H H H F H 337 H -CH(CH3)2 H H H H F H 338 H -(CH2)3CH3H H H H F H 339 H -CH2-HC=CH2 H H H H F H 340 H -CH3H -CH3-OH H H H 341 H -CH2CH3H -CH3-OH H H H 60 01312-0021-00PCT 342 H -(CH2)2CH3H -CH3-OH H H H 43 H -CH(CH3)2 H -CH3 -OH H H H 44 H -(CH2)3CH3H -CH3-OH H H H 345 H -CH2-HC=CH2 H -CH3 -OH H H H 346 H -CH3 H -CH3 -OC(O)CH3 H H H 347 H -CH2CH3H -CH3-OC(O)CH3H H H 348 H -(CH2)2CH3 H -CH3 -OC(O)CH3 H H H 349 H -CH(CH3)2 H -CH3 -OC(O)CH3 H H H 350 H -(CH2)3CH3H -CH3-OC(O)CH3H H H 351 H -CH2-HC=CH2 H -CH3 -OC(O)CH3 H H H 352 H -CH3H -CH3H -OCH3H H 353 H -CH2CH3 H -CH3 H -OCH3 H H 354 H -(CH2)2CH3 H -CH3 H -OCH3 H H 355 H -CH(CH3)2H -CH3H -OCH3H H 356 H -(CH2)3CH3 H -CH3 H -OCH3 H H 357 H -CH2-HC=CH2 H -CH3 H -OCH3 H H 358 H -CH3H -CH3H H F H 359 H -CH2CH3 H -CH3 H H F H 360 H -(CH2)2CH3H -CH3H H F H 361 H -CH(CH3)2H -CH3H H F H 362 H -(CH2)3CH3 H -CH3 H H F H 363 H -CH2-HC=CH2H -CH3H H F H 364 H cyclopropyl H H H H H H 365 H cyclopropyl H -CH3 H H H H 366 H cyclopropyl H H -OH H H H 367 H cyclopropyl H H -OC(O)CH3 H H H 368 H cyclopropyl H H H -OCH3 H H 369 H cyclopropyl H H H H F H 370 H cyclopropyl H H H H H H 371 H cyclopropyl H -CH3-OH H F H 372 H cyclopropyl H -CH3 -OH H H H 373 H cyclopropyl H -CH3 -OC(O)CH3 H H H 374 H cyclopropyl H -CH3H -OCH3H H 375 H cyclopropyl H -CH3 H H F H 376 -CH3 cyclopropyl H H H H H H 377 -CH3cyclopropyl H -CH3H H H H 378 -CH3 cyclopropyl H H -OH H H H 379 -CH3cyclopropyl H H -OC(O)CH3H H H 380 -CH3 cyclopropyl H H H -OCH3 H H 381 -CH3 cyclopropyl H H H H F H 382 -CH3cyclopropyl H H H H H H 383 -CH3 cyclopropyl H -CH3 -OH H F H 384 -CH3 cyclopropyl H -CH3 -OH H H H 385 -CH3cyclopropyl H -CH3-OC(O)CH3H H H 386 -CH3 cyclopropyl H -CH3 H -OCH3 H H 387 -CH3cyclopropyl H -CH3H H F H 388 -CH2CH3 cyclopropyl H H H H H H 389 -CH2CH3 cyclopropyl H -CH3 H H H H 390 -CH2CH3cyclopropyl H H -OH H H H 391 -CH2CH3 cyclopropyl H H -OC(O)CH3 H H H 392 -CH2CH3 cyclopropyl H H H -OCH3 H H 393 -CH2CH3cyclopropyl H H H H F H 394 -CH2CH3 cyclopropyl H H H H H H 395 -CH2CH3cyclopropyl H -CH3-OH H F H 396 -CH2CH3cyclopropyl H -CH3-OH H H H 61 01312-0021-00PCT 397 -CH2CH3cyclopropyl H -CH3-OC(O)CH3H H H 98 -CH2CH3 cyclopropyl H -CH3 H -OCH3 H H 99 -CH2CH3cyclopropyl H -CH3H H F H 400 -(CH2)2CH3 cyclopropyl H H H H H H 401 -(CH2)2CH3 cyclopropyl H -CH3 H H H H 402 -(CH2)2CH3cyclopropyl H H -OH H H H 403 -(CH2)2CH3 cyclopropyl H H -OC(O)CH3 H H H 404 -(CH2)2CH3 cyclopropyl H H H -OCH3 H H 405 -(CH2)2CH3cyclopropyl H H H H F H 406 -(CH2)2CH3 cyclopropyl H H H H H H 407 -(CH2)2CH3cyclopropyl H -CH3-OH H F H 408 -(CH2)2CH3 cyclopropyl H -CH3 -OH H H H 409 -(CH2)2CH3 cyclopropyl H -CH3 -OC(O)CH3 H H H 410 -(CH2)2CH3cyclopropyl H -CH3H -OCH3H H 411 -(CH2)2CH3 cyclopropyl H -CH3 H H F H 412 -CH2(CH3)2 cyclopropyl H H H H H H 413 -CH2(CH3)2cyclopropyl H -CH3H H H H 414 -CH2(CH3)2 cyclopropyl H H -OH H H H 415 -CH2(CH3)2cyclopropyl H H -OC(O)CH3H H H 416 -CH2(CH3)2cyclopropyl H H H -OCH3H H 417 -CH2(CH3)2 cyclopropyl H H H H F H 418 -CH2(CH3)2cyclopropyl H H H H H H 419 -CH2(CH3)2 cyclopropyl H -CH3 -OH H F H 420 -CH2(CH3)2 cyclopropyl H -CH3 -OH H H H 421 -CH2(CH3)2cyclopropyl H -CH3-OC(O)CH3H H H 422 -CH2(CH3)2 cyclopropyl H -CH3 H -OCH3 H H 423 -CH2(CH3)2 cyclopropyl H -CH3 H H F H 424 cyclopropyl cyclopropyl H -CH3H H H H 425 cyclopropyl cyclopropyl H H -OH H H H 426 cyclopropyl cyclopropyl H H -OC(O)CH3H H H 427 cyclopropyl cyclopropyl H H H -OCH3 H H 428 cyclopropyl cyclopropyl H H H H F H 429 cyclopropyl cyclopropyl H H H H H H 430 cyclopropyl cyclopropyl H -CH3 -OH H F H 431 cyclopropyl cyclopropyl H -CH3 -OH H H H 432 cyclopropyl cyclopropyl H -CH3-OC(O)CH3H H H 433 cyclopropyl cyclopropyl H -CH3 H -OCH3 H H 434 cyclopropyl cyclopropyl H -CH3H H F H 435 H -CH3 H H -OH H H -CH3 436 H -CH2CH3 H H -OH H H -CH3 437 H -(CH2)2CH3H H -OH H H -CH3438 H -CH(CH3)2 H H -OH H H -CH3 439 H -(CH2)3CH3 H H -OH H H -CH3 440 H -CH2-HC=CH2H H -OH H H -CH3441 H -CH3 H H -OC(O)CH3 H H -CH3 442 H -CH2CH3H H -OC(O)CH3H H -CH3443 H -(CH2)2CH3 H H -OC(O)CH3 H H -CH3 444 H -CH(CH3)2 H H -OC(O)CH3 H H -CH3 445 H -(CH2)3CH3H H -OC(O)CH3H H -CH3446 H -CH2-HC=CH2 H H -OC(O)CH3 H H -CH3 447 H -CH3 H H H -OCH3 H -CH3 448 H -CH2CH3H H H -OCH3H -CH3449 H -(CH2)2CH3 H H H -OCH3 H -CH3 450 H -CH(CH3)2H H H -OCH3H -CH3451 H -(CH2)3CH3H H H -OCH3H -CH362 01312-0021-00PCT 452 H -CH2-HC=CH2H H H -OCH3H -CH353 H -CH3 H H -OH H F H 54 H -CH2CH3H H -OH H F H 455 H -(CH2)2CH3 H H -OH H F H 456 H -CH(CH3)2 H H -OH H F H 457 H -(CH2)3CH3H H -OH H F H 458 H -CH2-HC=CH2 H H -OH H F H 459 H -CH3 H H -OC(O)CH3 H F H 460 H -CH2CH3H H -OC(O)CH3H F H 461 H -(CH2)2CH3 H H -OC(O)CH3 H F H 462 H -CH(CH3)2H H -OC(O)CH3H F H 463 H -(CH2)3CH3 H H -OC(O)CH3 H F H 464 H -CH2-HC=CH2 H H -OC(O)CH3 H F H 465 H -CH3H H H -OCH3F H 466 H -CH2CH3 H H H -OCH3 F H 467 H -(CH2)2CH3 H H H -OCH3 F H 468 H -CH(CH3)2H H H -OCH3F H 469 H -(CH2)3CH3 H H H -OCH3 F H 470 H -CH2-HC=CH2H H H -OCH3F H 471 H -CD3H H H H H H 472 H -CD3 H H -OH H H H 473 H -CD3H H -OC(O)CH3H H H 474 H -CD3 H H H -OCH3 H H 475 H -CD3 H H H H F H 476 H -CD3H H -OH H F H 477 H -CD3 H H -OC(O)CH3 H F H 478 H -CD3 H H H -OCH3 F H 479 H -CD3H H H H H -CH3480 H -CD3 H H -OH H H -CH3 481 H -CD3H H -OC(O)CH3H H -CH3482 H -CD3 H H H -OCH3 H -CH3 483 H -CD3 H H H H F -CH3 484 H -CD3H H -OH H F -CH3485 H -CD3 H H -OC(O)CH3 H F -CH3 486 H -CD3 H H H -OCH3 F -CH3 487 H -CD2CD3H H H H H H 488 H -CD2CD3 H H -OH H H H 489 H -CD2CD3H H -OC(O)CH3H H H 490 H -CD2CD3 H H H -OCH3 H H 491 H -CD2CD3 H H H H F H 492 H -CD2CD3H H -OH H F H 493 H -CD2CD3 H H -OC(O)CH3 H F H 494 H -CD2CD3 H H H -OCH3 F H 495 H -CD2CD3H H H H H -CH3496 H -CD2CD3 H H -OH H H -CH3 497 H -CD2CD3H H -OC(O)CH3H H -CH3498 H -CD2CD3 H H H -OCH3 H -CH3 499 H -CD2CD3 H H H H F -CH3 500 H -CD2CD3H H -OH H F -CH3501 H -CD2CD3 H H -OC(O)CH3 H F -CH3 502 H -CD2CD3 H H H -OCH3 F -CH3 503 H -CH3H H -OH H F -CH3504 H -CH2CH3 H H -OH H F -CH3 505 H -(CH2)2CH3H H -OH H F -CH3506 H -CH(CH3)2H H -OH H F -CH363 01312-0021-00PCT 507 H -(CH2)3CH3H H -OH H F -CH308 H -CH2-HC=CH2 H H -OH H F -CH3 09 H -CH3H H -OC(O)CH3H F -CH3510 H -CH2CH3 H H -OC(O)CH3 H F -CH3 511 H -(CH2)2CH3 H H -OC(O)CH3 H F -CH3 512 H -CH(CH3)2H H -OC(O)CH3H F -CH3513 H -(CH2)3CH3 H H -OC(O)CH3 H F -CH3 514 H -CH2-HC=CH2 H H -OC(O)CH3 H F -CH3 515 H -CH3H H H -OCH3F -CH3516 H -CH2CH3 H H H -OCH3 F -CH3 517 H -(CH2)2CH3H H H -OCH3F -CH3518 H -CH(CH3)2 H H H -OCH3 F -CH3 519 H -(CH2)3CH3 H H H -OCH3 F -CH3 520 H -CH2-HC=CH2H H H -OCH3F -CH3521 H -CH3 H D H H H H 522 H -CH2CH3 H D H H H H 523 H -(CH2)2CH3H D H H H H 524 H -CH(CH3)2 H D H H H H 525 H -(CH2)3CH3H D H H H H 526 H -CH2-HC=CH2H D H H H H 527 H -CH3 H D -OH H H H 528 H -CH2CH3H D -OH H H H 529 H -(CH2)2CH3 H D -OH H H H 530 H -CH(CH3)2 H D -OH H H H 531 H -(CH2)3CH3H D -OH H H H 532 H -CH2-HC=CH2 H D -OH H H H 533 H -CH3 H D -OC(O)CH3 H H H 534 H -CH2CH3H D -OC(O)CH3H H H 535 H -(CH2)2CH3 H D -OC(O)CH3 H H H 536 H -CH(CH3)2H D -OC(O)CH3H H H 537 H -(CH2)3CH3 H D -OC(O)CH3 H H H 538 H -CH2-HC=CH2 H D -OC(O)CH3 H H H 539 H -CH3H D H -OCH3H H 540 H -CH2CH3 H D H -OCH3 H H 541 H -(CH2)2CH3 H D H -OCH3 H H 542 H -CH(CH3)2H D H -OCH3H H 543 H -(CH2)3CH3 H D H -OCH3 H H 544 H -CH2-HC=CH2H D H -OCH3H H 545 H -CH3 H D H H F H 546 H -CH2CH3 H D H H F H 547 H -(CH2)2CH3H D H H F H 548 H -CH(CH3)2 H D H H F H 549 H -(CH2)3CH3 H D H H F H 550 H -CH2-HC=CH2H D H H F H 551 H -CH3 H D H H F CH3 552 H -CH2CH3H D H H F CH3553 H -(CH2)2CH3 H D H H F CH3 554 H -CH(CH3)2 H D H H F CH3 555 H -(CH2)3CH3H D H H F CH3556 H -CH2-HC=CH2 H D H H F CH3 Other exemplary compounds of Formula I include those below in Table 4, which is also represented by Formula Id: 64 01312-0021-00PCT Formula Id Table 4 ef. X Y R2 R3 R5 R6 R7 R1 1 -CH3-CH3H H -OCH3H H H 2 -CH3 -CH2CH3 H H -OCH3 H H H 3 -CH3 -(CH2)2CH3 H H -OCH3 H H H 4 -CH3-CH(CH3)2H H -OCH3H H H 5 -CH3 -(CH2)3CH3 H H -OCH3 H H H 6 -CH3-CH2-HC=CH2H H -OCH3H H H 7 -CH2CH3 -CH2CH3 H H -OCH3 H H H 8 -CH2CH3 -(CH2)2CH3 H H -OCH3 H H H 9 -CH2CH3-CH(CH3)2H H -OCH3H H H 10 -CH2CH3 -(CH2)3CH3 H H -OCH3 H H H 11 -CH2CH3 -CH2-HC=CH2 H H -OCH3 H H H 12 -(CH2)2CH3-(CH2)2CH3H H -OCH3H H H 13 -(CH2)2CH3 -CH(CH3)2 H H -OCH3 H H H 14 -(CH2)2CH3-(CH2)3CH3H H -OCH3H H H 15 -(CH2)2CH3-CH2-HC=CH2H H -OCH3H H H 16 -CH(CH3)2 -CH(CH3)2 H H -OCH3 H H H 17 -CH(CH3)2-(CH2)3CH3H H -OCH3H H H 18 -CH(CH3)2 -CH2-HC=CH2 H H -OCH3 H H H 19 -(CH2)3CH3 -(CH2)3CH3 H H -OCH3 H H H 20 -(CH2)3CH3-CH2-HC=CH2H H -OCH3H H H 21 -CH2-HC=CH2 -CH2-HC=CH2 H H -OCH3 H H H 22 -CH3 -CH2CH3 H H -OH H H H 23 -CH3-(CH2)2CH3H H -OH H H H 24 -CH3 -CH(CH3)2 H H -OH H H H 25 -CH3-(CH2)3CH3H H -OH H H H 26 -CH3 -CH2-HC=CH2 H H -OH H H H 27 -CH2CH3 -CH2CH3 H H -OH H H H 28 -CH2CH3-(CH2)2CH3H H -OH H H H 29 -CH2CH3 -CH(CH3)2 H H -OH H H H 30 -CH2CH3 -(CH2)3CH3 H H -OH H H H 31 -CH2CH3-CH2-HC=CH2H H -OH H H H 32 -(CH2)2CH3 -(CH2)2CH3 H H -OH H H H 33 -(CH2)2CH3-CH(CH3)2H H -OH H H H 34 -(CH2)2CH3-(CH2)3CH3H H -OH H H H 65 01312-0021-00PCT 35 -(CH2)2CH3-CH2-HC=CH2H H -OH H H H 36 -CH(CH3)2 -CH(CH3)2 H H -OH H H H 37 -CH(CH3)2-(CH2)3CH3H H -OH H H H 38 -CH(CH3)2 -CH2-HC=CH2 H H -OH H H H 39 -(CH2)3CH3 -(CH2)3CH3 H H -OH H H H 40 -(CH2)3CH3-CH2-HC=CH2H H -OH H H H 41 -CH2-HC=CH2 -CH2-HC=CH2 H H -OH H H H 42 -CH3 -CH3 H H -OC(O)CH3 H H H 43 -CH3-CH2CH3H H -OC(O)CH3H H H 44 -CH3 -(CH2)2CH3 H H -OC(O)CH3 H H H 45 -CH3-CH(CH3)2H H -OC(O)CH3H H H 46 -CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 47 -CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 48 -CH2CH3-CH2CH3H H -OC(O)CH3H H H 49 -CH2CH3 -(CH2)2CH3 H H -OC(O)CH3 H H H 50 -CH2CH3 -CH(CH3)2 H H -OC(O)CH3 H H H 51 -CH2CH3-(CH2)3CH3H H -OC(O)CH3H H H 52 -CH2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 53 -(CH2)2CH3-(CH2)2CH3H H -OC(O)CH3H H H 54 -(CH2)2CH3-CH(CH3)2H H -OC(O)CH3H H H 55 -(CH2)2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 56 -(CH2)2CH3-CH2-HC=CH2H H -OC(O)CH3H H H 57 -CH(CH3)2 -CH(CH3)2 H H -OC(O)CH3 H H H 58 -CH(CH3)2 -(CH2)3CH3 H H -OC(O)CH3 H H H 59 -CH(CH3)2-CH2-HC=CH2H H -OC(O)CH3H H H 60 -(CH2)3CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 61 -(CH2)3CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 62 -CH2-HC=CH2-CH2-HC=CH2H H -OC(O)CH3H H H 63 -CH3 -CH3 H H -OCH3 H H -CH2CH3 64 -CH3-CH2CH3H H -OCH3H H -CH2CH365 -CH3 -(CH2)2CH3 H H -OCH3 H H -CH2CH3 66 -CH3 -CH(CH3)2 H H -OCH3 H H -CH2CH3 67 -CH3-(CH2)3CH3H H -OCH3H H -CH2CH368 -CH3 -CH2-HC=CH2 H H -OCH3 H H -CH2CH3 69 -CH2CH3 -CH2CH3 H H -OCH3 H H -CH2CH3 70 -CH2CH3-(CH2)2CH3H H -OCH3H H -CH2CH371 -CH2CH3 -CH(CH3)2 H H -OCH3 H H -CH2CH3 72 -CH2CH3-(CH2)3CH3H H -OCH3H H -CH2CH373 -CH2CH3 -CH2-HC=CH2 H H -OCH3 H H -CH2CH3 74 -(CH2)2CH3 -(CH2)2CH3 H H -OCH3 H H -CH2CH3 75 -(CH2)2CH3-CH(CH3)2H H -OCH3H H -CH2CH376 -(CH2)2CH3 -(CH2)3CH3 H H -OCH3 H H -CH2CH3 77 -(CH2)2CH3 -CH2-HC=CH2 H H -OCH3 H H -CH2CH3 78 -CH(CH3)2-CH(CH3)2H H -OCH3H H -CH2CH379 -CH(CH3)2 -(CH2)3CH3 H H -OCH3 H H -CH2CH3 80 -CH(CH3)2-CH2-HC=CH2H H -OCH3H H -CH2CH381 -(CH2)3CH3 -(CH2)3CH3 H H -OCH3 H H -CH2CH3 82 -(CH2)3CH3 -CH2-HC=CH2 H H -OCH3 H H -CH2CH3 83 -CH2-HC=CH2-CH2-HC=CH2H H -OCH3H H -CH2CH384 -CH3 -CH2CH3 H H H F H H 85 -CH3 -(CH2)2CH3 H H H F H H 86 -CH3-CH(CH3)2H H H F H H 87 -CH3 -(CH2)3CH3 H H H F H H 88 -CH3-CH2-HC=CH2H H H F H H 89 -CH2CH3-CH2CH3H H H F H H 66 01312-0021-00PCT 90 -CH2CH3-(CH2)2CH3H H H F H H 91 -CH2CH3 -CH(CH3)2 H H H F H H 92 -CH2CH3-(CH2)3CH3H H H F H H 93 -CH2CH3 -CH2-HC=CH2 H H H F H H 94 -(CH2)2CH3 -(CH2)2CH3 H H H F H H 95 -(CH2)2CH3-CH(CH3)2H H H F H H 96 -(CH2)2CH3 -(CH2)3CH3 H H H F H H 97 -(CH2)2CH3 -CH2-HC=CH2 H H H F H H 98 -CH(CH3)2-CH(CH3)2H H H F H H 99 -CH(CH3)2 -(CH2)3CH3 H H H F H H 100 -CH(CH3)2-CH2-HC=CH2H H H F H H 101 -(CH2)3CH3 -(CH2)3CH3 H H H F H H 102 -(CH2)3CH3 -CH2-HC=CH2 H H H F H H 103 -CH2-HC=CH2-CH2-HC=CH2H H H F H H 104 -CH3 -CH3 H H H H -CH3 H 105 -CH3 -CH2CH3 H H H H -CH3 H 106 -CH3-(CH2)2CH3H H H H -CH3H 107 -CH3 -CH(CH3)2 H H H H -CH3 H 108 -CH3-(CH2)3CH3H H H H -CH3H 109 -CH3-CH2-HC=CH2H H H H -CH3H 110 -CH2CH3 -CH2CH3 H H H H -CH3 H 111 -CH2CH3-(CH2)2CH3H H H H -CH3H 112 -CH2CH3 -CH(CH3)2 H H H H -CH3 H 113 -CH2CH3 -(CH2)3CH3 H H H H -CH3 H 114 -CH2CH3-CH2-HC=CH2H H H H -CH3H 115 -(CH2)2CH3 -(CH2)2CH3 H H H H -CH3 H 116 -(CH2)2CH3 -CH(CH3)2 H H H H -CH3 H 117 -(CH2)2CH3-(CH2)3CH3H H H H -CH3H 118 -(CH2)2CH3 -CH2-HC=CH2 H H H H -CH3 H 119 -CH(CH3)2-CH(CH3)2H H H H -CH3H 120 -CH(CH3)2 -(CH2)3CH3 H H H H -CH3 H 121 -CH(CH3)2 -CH2-HC=CH2 H H H H -CH3 H 122 -(CH2)3CH3-(CH2)3CH3H H H H -CH3H 123 -(CH2)3CH3 -CH2-HC=CH2 H H H H -CH3 H 124 -CH2-HC=CH2 -CH2-HC=CH2 H H H H -CH3 H 125 -CH3-CH3H H -OCH3H -CH3H 126 -CH3 -CH2CH3 H H -OCH3 H -CH3 H 127 -CH3-(CH2)2CH3H H -OCH3H -CH3H 128 -CH3 -CH(CH3)2 H H -OCH3 H -CH3 H 129 -CH3 -(CH2)3CH3 H H -OCH3 H -CH3 H 130 -CH3-CH2-HC=CH2H H -OCH3H -CH3H 131 -CH2CH3 -CH2CH3 H H -OCH3 H -CH3 H 132 -CH2CH3 -(CH2)2CH3 H H -OCH3 H -CH3 H 133 -CH2CH3-CH(CH3)2H H -OCH3H -CH3H 134 -CH2CH3 -(CH2)3CH3 H H -OCH3 H -CH3 H 135 -CH2CH3-CH2-HC=CH2H H -OCH3H -CH3H 135 -(CH2)2CH3 -(CH2)2CH3 H H -OCH3 H -CH3 H 137 -(CH2)2CH3 -CH(CH3)2 H H -OCH3 H -CH3 H 138 -(CH2)2CH3-(CH2)3CH3H H -OCH3H -CH3H 139 -(CH2)2CH3 -CH2-HC=CH2 H H -OCH3 H -CH3 H 140 -CH(CH3)2 -CH(CH3)2 H H -OCH3 H -CH3 H 141 -CH(CH3)2-(CH2)3CH3H H -OCH3H -CH3H 142 -CH(CH3)2 -CH2-HC=CH2 H H -OCH3 H -CH3 H 143 -(CH2)3CH3-(CH2)3CH3H H -OCH3H -CH3H 144 -(CH2)3CH3-CH2-HC=CH2H H -OCH3H -CH3H 67 01312-0021-00PCT 145 -CH2-HC=CH2-CH2-HC=CH2H H -OCH3H -CH3H 46 -CH3 -CH2CH3 H H -OCH3 F H H 47 -CH3-(CH2)2CH3H H -OCH3F H H 148 -CH3 -CH(CH3)2 H H -OCH3 F H H 149 -CH3 -(CH2)3CH3 H H -OCH3 F H H 150 -CH3-CH2-HC=CH2H H -OCH3F H H 151 -CH2CH3 -CH2CH3 H H -OCH3 F H H 152 -CH2CH3 -(CH2)2CH3 H H -OCH3 F H H 153 -CH2CH3-CH(CH3)2H H -OCH3F H H 154 -CH2CH3 -(CH2)3CH3 H H -OCH3 F H H 155 -CH2CH3-CH2-HC=CH2H H -OCH3F H H 156 -(CH2)2CH3 -(CH2)2CH3 H H -OCH3 F H H 157 -(CH2)2CH3 -CH(CH3)2 H H -OCH3 F H H 158 -(CH2)2CH3-(CH2)3CH3H H -OCH3F H H 159 -(CH2)2CH3 -CH2-HC=CH2 H H -OCH3 F H H 160 -CH(CH3)2 -CH(CH3)2 H H -OCH3 F H H 161 -CH(CH3)2-(CH2)3CH3H H -OCH3F H H 162 -CH(CH3)2 -CH2-HC=CH2 H H -OCH3 F H H 163 -(CH2)3CH3-(CH2)3CH3H H -OCH3F H H 164 -(CH2)3CH3-CH2-HC=CH2H H -OCH3F H H 165 -CH2-HC=CH2 -CH2-HC=CH2 H H -OCH3 F H H 166 H -CH3H H H H H -CH2CH3167 H -CH2CH3 H H H H H -CH2CH3 168 H -(CH2)2CH3 H H H H H -CH2CH3 169 H -CH(CH3)2H H H H H -CH2CH3170 H -(CH2)3CH3 H H H H H -CH2CH3 171 H -CH2-HC=CH2 H H H H H -CH2CH3 171a H -CH3H H -OCH3H H H 172 H -CH2CH3 H H -OCH3 H H H 173 H -(CH2)2CH3H H -OCH3H H H 174 H -CH(CH3)2 H H -OCH3 H H H 175 H -(CH2)3CH3 H H -OCH3 H H H 176 H -CH2-HC=CH2H H -OCH3H H H 177 H -CH3 H H -OCH3 H H -CH2CH3 178 H -CH2CH3 H H -OCH3 H H -CH2CH3 179 H -(CH2)2CH3H H -OCH3H H -CH2CH3180 H -CH(CH3)2 H H -OCH3 H H -CH2CH3 181 H -(CH2)3CH3H H -OCH3H H -CH2CH3182 H -CH2-HC=CH2 H H -OCH3 H H -CH2CH3 183 H -CH3 H H -OCH3 H -CH3 H 184 H -CH2CH3H H -OCH3H -CH3H 185 H -(CH2)2CH3 H H -OCH3 H -CH3 H 186 H -CH(CH3)2 H H -OCH3 H -CH3 H 187 H -(CH2)3CH3H H -OCH3H -CH3H 188 H -CH2-HC=CH2 H H -OCH3 H -CH3 H 189 H -CH3H H H F -CH3H 190 H -CH2CH3 H H H F -CH3 H 191 H -(CH2)2CH3 H H H F -CH3 H 192 H -CH(CH3)2H H H F -CH3H 193 H -(CH2)3CH3 H H H F -CH3 H 194 H -CH2-HC=CH2 H H H F -CH3 H 195 H -CH3H H -OCH3F H H 196 H -CH2CH3 H H -OCH3 F H H 197 H -(CH2)2CH3H H -OCH3F H H 198 H -CH(CH3)2H H -OCH3F H H 68 01312-0021-00PCT 199 H -(CH2)3CH3H H -OCH3F H H 00 H -CH2-HC=CH2 H H -OCH3 F H H 01 H -CH3H H H H -CH3H 202 H -CH2CH3 H H H H -CH3 H 203 H -(CH2)2CH3 H H H H -CH3 H 204 H -CH(CH3)2H H H H -CH3H 205 H -(CH2)3CH3 H H H H -CH3 H 206 H -CH2-HC=CH2 H H H H -CH3 H 207 H -CH3H H H F H H 208 H -CH2CH3 H H H F H H 209 H -(CH2)2CH3H H H F H H 210 H -CH(CH3)2 H H H F H H 211 H -(CH2)3CH3 H H H F H H 212 H -CH2-HC=CH2H H H F H H 212a cyclopropyl -CH3 H H H H H H 213 cyclopropyl -CH2CH3 H H H H H H 214 cyclopropyl -(CH2)2CH3H H H H H H 215 cyclopropyl -CH(CH3)2 H H H H H H 216 cyclopropyl -(CH2)3CH3H H H H H H 217 cyclopropyl -CH2-HC=CH2H H H H H H 218 cyclopropyl -CH3 H H -OCH3 H H H 219 cyclopropyl -CH2CH3H H -OCH3H H H 220 cyclopropyl -(CH2)2CH3 H H -OCH3 H H H 221 cyclopropyl -CH(CH3)2 H H -OCH3 H H H 222 cyclopropyl -(CH2)3CH3H H -OCH3H H H 223 cyclopropyl -CH2-HC=CH2 H H -OCH3 H H H 224 cyclopropyl -CH3 H H -OH H H H 225 cyclopropyl -CH2CH3H H -OH H H H 226 cyclopropyl -(CH2)2CH3 H H -OH H H H 227 cyclopropyl -CH(CH3)2H H -OH H H H 228 cyclopropyl -(CH2)3CH3 H H -OH H H H 229 cyclopropyl -CH2-HC=CH2 H H -OH H H H 230 cyclopropyl -CH3H H -OC(O)CH3H H H 231 cyclopropyl -CH2CH3 H H -OC(O)CH3 H H H 232 cyclopropyl -(CH2)2CH3 H H -OC(O)CH3 H H H 233 cyclopropyl -CH(CH3)2H H -OC(O)CH3H H H 234 cyclopropyl -(CH2)3CH3 H H -OC(O)CH3 H H H 235 cyclopropyl -CH2-HC=CH2H H -OC(O)CH3H H H 236 cyclopropyl -CH3 H H H H H -CH2CH3 237 cyclopropyl -CH2CH3 H H H H H -CH2CH3 238 cyclopropyl -(CH2)2CH3H H H H H -CH2CH3239 cyclopropyl -CH(CH3)2 H H H H H -CH2CH3 240 cyclopropyl -(CH2)3CH3 H H H H H -CH2CH3 241 cyclopropyl -CH2-HC=CH2H H H H H -CH2CH3242 cyclopropyl -CH3 H H -OCH3 H H -CH2CH3 243 cyclopropyl -CH2CH3H H -OCH3H H -CH2CH3244 cyclopropyl -(CH2)2CH3 H H -OCH3 H H -CH2CH3 245 cyclopropyl -CH(CH3)2 H H -OCH3 H H -CH2CH3 246 cyclopropyl -(CH2)3CH3H H -OCH3H H -CH2CH3247 cyclopropyl -CH2-HC=CH2 H H -OCH3 H H -CH2CH3 248 H -CH3 H H H H H H 249 H -CH2CH3H H H H H H 250 H -(CH2)2CH3 H H H H H H 251 H -CH(CH3)2H H H H H H 252 H -(CH2)3CH3H H H H H H 69 01312-0021-00PCT 253 H -CH2-HC=CH2H H H H H H 54 H cyclopropyl H H H H H H 55 H -CH3H -CH3H H H H 256 H -CH2CH3 H -CH3 H H H H 257 H -(CH2)2CH3 H -CH3 H H H H 258 H -CH(CH3)2H -CH3H H H H 259 H -(CH2)3CH3 H -CH3 H H H H 260 H -CH2-HC=CH2 H -CH3 H H H H 261 H cyclopropyl H -CH3H H H H 262 H -CH3 H -CH3 -OCH3 H H H 263 H -CH2CH3H -CH3-OCH3H H H 264 H -(CH2)2CH3 H -CH3 -OCH3 H H H 265 H -CH(CH3)2 H -CH3 -OCH3 H H H 266 H -(CH2)3CH3H -CH3-OCH3H H H 267 H -CH2-HC=CH2 H -CH3 -OCH3 H H H 268 H cyclopropyl H -CH3 -OCH3 H H H 269 H -CH3H -CH3H H H -CH2CH3270 H -CH2CH3 H -CH3 H H H -CH2CH3 271 H -(CH2)2CH3H -CH3H H H -CH2CH3272 H -CH(CH3)2H -CH3H H H -CH2CH3273 H -(CH2)3CH3 H -CH3 H H H -CH2CH3 274 H -CH2-HC=CH2H -CH3H H H -CH2CH3275 H cyclopropyl H -CH3 H H H -CH2CH3 276 H -CH3 H -CH3 -OCH3 H H -CH2CH3 277 H -CH2CH3H -CH3-OCH3H H -CH2CH3278 H -(CH2)2CH3 H -CH3 -OCH3 H H -CH2CH3 279 H -CH(CH3)2 H -CH3 -OCH3 H H -CH2CH3 280 H -(CH2)3CH3H -CH3-OCH3H H -CH2CH3281 H -CH2-HC=CH2 H -CH3 -OCH3 H H -CH2CH3 282 H cyclopropyl H -CH3-OCH3H H -CH2CH3283 H -CH3 H -CH3 H H -CH3 H 284 H -CH2CH3 H -CH3 H H -CH3 H 285 H -(CH2)2CH3H -CH3H H -CH3H 286 H -CH(CH3)2 H -CH3 H H -CH3 H 287 H -(CH2)3CH3 H -CH3 H H -CH3 H 288 H -CH2-HC=CH2H -CH3H H -CH3H 289 H cyclopropyl H -CH3 H H -CH3 H 290 H -CH3H -CH3H F H H 291 H -CH2CH3 H -CH3 H F H H 292 H -(CH2)2CH3 H -CH3 H F H H 293 H -CH(CH3)2H -CH3H F H H 294 H -(CH2)3CH3 H -CH3 H F H H 295 H -CH2-HC=CH2 H -CH3 H F H H 296 H cyclopropyl H -CH3H F H H 297 H -CH3 H -CH3 -OCH3 H -CH3 H 298 H -CH2CH3H -CH3-OCH3H -CH3H 299 H -(CH2)2CH3 H -CH3 -OCH3 H -CH3 H 300 H -CH(CH3)2 H -CH3 -OCH3 H -CH3 H 301 H -(CH2)3CH3H -CH3-OCH3H -CH3H 302 H -CH2-HC=CH2 H -CH3 -OCH3 H -CH3 H 303 H cyclopropyl H -CH3 -OCH3 H -CH3 H 304 H -CH3H -CH3-OCH3F H H 305 H -CH2CH3 H -CH3 -OCH3 F H H 306 H -(CH2)2CH3H -CH3-OCH3F H H 307 H -CH(CH3)2H -CH3-OCH3F H H 70 01312-0021-00PCT 308 H -(CH2)3CH3H -CH3-OCH3F H H 09 H -CH2-HC=CH2 H -CH3 -OCH3 F H H 10 H cyclopropyl H -CH3-OCH3F H H 311 H H H -CH3 H H H H 312 H H H -CH3 -OCH3 H H H 313 H H H -CH3H F H H 314 H H H -CH3 H H -CH3 H 315 H H H -CH3 H H H -CH2CH3 316 H H H -CH3-OCH3H H -CH2CH3317 H H H -CH3 -OCH3 H -CH3 H 318 H H H -CH3-OCH3F -CH3H 319 H H H -CH3 -OH F H H 320 H H H -CH3 -OCH3 H H -CH3 321 -CH3-CH3H H H H H H 322 -CH3 -CH2CH3 H H H H H H 323 -CH3 -(CH2)2CH3 H H H H H H 324 -CH3-CH(CH3)2H H H H H H 325 -CH3 -(CH2)3CH3 H H H H H H 326 -CH3-CH2-HC=CH2H H H H H H 327 -CH2CH3-CH2CH3H H H H H H 328 -CH2CH3 -(CH2)2CH3 H H H H H H 329 -CH2CH3-CH(CH3)2H H H H H H 330 -CH2CH3 -(CH2)3CH3 H H H H H H 331 -CH2CH3 -CH2-HC=CH2 H H H H H H 332 -(CH2)2CH3-(CH2)2CH3H H H H H H 333 -(CH2)2CH3 -CH(CH3)2 H H H H H H 334 -(CH2)2CH3 -(CH2)3CH3 H H H H H H 335 -(CH2)2CH3-CH2-HC=CH2H H H H H H 336 -CH(CH3)2 -CH(CH3)2 H H H H H H 337 -CH(CH3)2-(CH2)3CH3H H H H H H 338 -CH(CH3)2 -CH2-HC=CH2 H H H H H H 339 -(CH2)3CH3 -(CH2)3CH3 H H H H H H 340 -(CH2)3CH3-CH2-HC=CH2H H H H H H 341 -CH2-HC=CH2 -CH2-HC=CH2 H H H H H H 342 H -CD3 H H H H H H 343 H -CD3H H -OH H H H 344 H -CD3 H H -OC(O)CH3 H H H 345 H -CD3H H -OCH3H H H 346 H -CD3 H H H F H H 347 H -CD3 H H -OH F H H 348 H -CD3H H -OC(O)CH3F H H 349 H -CD3 H H -OCH3 F H H 350 H -CD3 H H H H -CH3 H 351 H -CD3H H -OH H -CH3H 352 H -CD3 H H -OC(O)CH3 H -CH3 H 353 H -CD3H H -OCH3H -CH3H 354 H -CD3 H H H H H -CH2CH3 355 H -CD3 H H -OH H H -CH2CH3 356 H -CD3H H -OC(O)CH3H H -CH2CH3357 H -CD3 H H -OCH3 H H -CH2CH3 358 H -CD2CD3 H H H H H H 359 H -CD2CD3H H -OH H H H 360 H -CD2CD3 H H -OC(O)CH3 H H H 361 H -CD2CD3H H -OCH3H H H 362 H -CD2CD3H H H F H H 71 01312-0021-00PCT 363 H -CD2CD3H H -OH F H H 64 H -CD2CD3 H H -OC(O)CH3 F H H 65 H -CD2CD3H H -OCH3F H H 366 H -CD2CD3 H H H H -CH3 H 367 H -CD2CD3 H H -OH H -CH3 H 368 H -CD2CD3H H -OC(O)CH3H -CH3H 369 H -CD2CD3 H H -OCH3 H -CH3 H 370 H -CD2CD3 H H H H H -CH2CH3 371 H -CD2CD3H H -OH H H -CH2CH3372 H -CD2CD3 H H -OC(O)CH3 H H -CH2CH3 373 H -CD2CD3H H -OCH3H H -CH2CH3374 H -CH3 H D H H H H 375 H -CH2CH3 H D H H H H 376 H -(CH2)2CH3H D H H H H 377 H -CH(CH3)2 H D H H H H 378 H -(CH2)3CH3 H D H H H H 379 H -CH2-HC=CH2H D H H H H 380 H -CH3 H D -OCH3 H H H 381 H -CH2CH3H D -OCH3H H H 382 H -(CH2)2CH3H D -OCH3H H H 383 H -CH(CH3)2 H D -OCH3 H H H 384 H -(CH2)3CH3H D -OCH3H H H 385 H -CH2-HC=CH2 H D -OCH3 H H H 386 H -CH3 H D -OCH3 F H H 387 H -CH2CH3H D -OCH3F H H 388 H -(CH2)2CH3 H D -OCH3 F H H 389 H -CH(CH3)2 H D -OCH3 F H H 390 H -(CH2)3CH3H D -OCH3F H H 391 H -CH2-HC=CH2 H D -OCH3 F H H 392 H -CH3H D -OCH3H -CH3H 393 H -CH2CH3 H D -OCH3 H -CH3 H 394 H -(CH2)2CH3 H D -OCH3 H -CH3 H 395 H -CH(CH3)2H D -OCH3H -CH3H 396 H -(CH2)3CH3 H D -OCH3 H -CH3 H 397 H -CH2-HC=CH2 H D -OCH3 H -CH3 H 398 H -CH3H D H F -CH3H 399 H -CH2CH3 H D H F -CH3 H 400 H -(CH2)2CH3H D H F -CH3H 401 H -CH(CH3)2 H D H F -CH3 H 402 H -(CH2)3CH3 H D H F -CH3 H 403 H -CH2-HC=CH2H D H F -CH3H 404 H -CH3 H D H F H H 405 H -CH2CH3 H D H F H H 406 H -(CH2)2CH3H D H F H H 407 H -CH(CH3)2 H D H F H H 408 H -(CH2)3CH3H D H F H H 409 H -CH2-HC=CH2 H D H F H H 410 H -CH3 H D H H -CH3 H 411 H -CH2CH3H D H H -CH3H 412 H -(CH2)2CH3 H D H H -CH3 H 413 H -CH(CH3)2 H D H H -CH3 H 414 H -(CH2)3CH3H D H H -CH3H 415 H -CH2-HC=CH2 H D H H -CH3 H 72 01312-0021-00PCT Other exemplary compounds of Formula I include those below in Table 5, which is also represented by Formula Ie: Formula Ie Table 5 ef. X Y R2 R3 R4 R6 R7 R1 1 -CH3-CH3H H -OCH3H H H 2 -CH3 -CH2CH3 H H -OCH3 H H H 3 -CH3 -(CH2)2CH3 H H -OCH3 H H H 4 -CH3-CH(CH3)2H H -OCH3H H H 5 -CH3 -(CH2)3CH3 H H -OCH3 H H H 6 -CH3-CH2-HC=CH2H H -OCH3H H H 7 -CH2CH3 -CH2CH3 H H -OCH3 H H H 8 -CH2CH3 -(CH2)2CH3 H H -OCH3 H H H 9 -CH2CH3-CH(CH3)2H H -OCH3H H H 10 -CH2CH3 -(CH2)3CH3 H H -OCH3 H H H 11 -CH2CH3 -CH2-HC=CH2 H H -OCH3 H H H 12 -(CH2)2CH3-(CH2)2CH3H H -OCH3H H H 13 -(CH2)2CH3 -CH(CH3)2 H H -OCH3 H H H 14 -(CH2)2CH3-(CH2)3CH3H H -OCH3H H H 15 -(CH2)2CH3 -CH2-HC=CH2 H H -OCH3 H H H 16 -CH(CH3)2 -CH(CH3)2 H H -OCH3 H H H 17 -CH(CH3)2-(CH2)3CH3H H -OCH3H H H 18 -CH(CH3)2 -CH2-HC=CH2 H H -OCH3 H H H 19 -(CH2)3CH3 -(CH2)3CH3 H H -OCH3 H H H 20 -(CH2)3CH3-CH2-HC=CH2H H -OCH3H H H 21 -CH2-HC=CH2 -CH2-HC=CH2 H H -OCH3 H H H 22 -CH3-CH2CH3H H -OH H H H 23 -CH3-(CH2)2CH3H H -OH H H H 24 -CH3 -CH(CH3)2 H H -OH H H H 25 -CH3-(CH2)3CH3H H -OH H H H 26 -CH3 -CH2-HC=CH2 H H -OH H H H 27 -CH2CH3 -CH2CH3 H H -OH H H H 28 -CH2CH3-(CH2)2CH3H H -OH H H H 29 -CH2CH3 -CH(CH3)2 H H -OH H H H 30 -CH2CH3 -(CH2)3CH3 H H -OH H H H 31 -CH2CH3-CH2-HC=CH2H H -OH H H H 32 -(CH2)2CH3 -(CH2)2CH3 H H -OH H H H 33 -(CH2)2CH3-CH(CH3)2H H -OH H H H 34 -(CH2)2CH3 -(CH2)3CH3 H H -OH H H H 35 -(CH2)2CH3 -CH2-HC=CH2 H H -OH H H H 73 01312-0021-00PCT 36 -CH(CH3)2-CH(CH3)2H H -OH H H H 37 -CH(CH3)2 -(CH2)3CH3 H H -OH H H H 38 -CH(CH3)2-CH2-HC=CH2H H -OH H H H 39 -(CH2)3CH3 -(CH2)3CH3 H H -OH H H H 40 -(CH2)3CH3 -CH2-HC=CH2 H H -OH H H H 41 -CH2-HC=CH2-CH2-HC=CH2H H -OH H H H 42 -CH3 -CH3 H H -OC(O)CH3 H H H 43 -CH3 -CH2CH3 H H -OC(O)CH3 H H H 44 -CH3-(CH2)2CH3H H -OC(O)CH3H H H 45 -CH3 -CH(CH3)2 H H -OC(O)CH3 H H H 46 -CH3-(CH2)3CH3H H -OC(O)CH3H H H 47 -CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 48 -CH2CH3 -CH2CH3 H H -OC(O)CH3 H H H 49 -CH2CH3-(CH2)2CH3H H -OC(O)CH3H H H 50 -CH2CH3 -CH(CH3)2 H H -OC(O)CH3 H H H 51 -CH2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 52 -CH2CH3-CH2-HC=CH2H H -OC(O)CH3H H H 53 -(CH2)2CH3 -(CH2)2CH3 H H -OC(O)CH3 H H H 54 -(CH2)2CH3-CH(CH3)2H H -OC(O)CH3H H H 55 -(CH2)2CH3-(CH2)3CH3H H -OC(O)CH3H H H 56 -(CH2)2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 57 -CH(CH3)2-CH(CH3)2H H -OC(O)CH3H H H 58 -CH(CH3)2 -(CH2)3CH3 H H -OC(O)CH3 H H H 59 -CH(CH3)2 -CH2-HC=CH2 H H -OC(O)CH3 H H H 60 -(CH2)3CH3-(CH2)3CH3H H -OC(O)CH3H H H 61 -(CH2)3CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 62 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H H H 63 -CH3-CH3H H -OH H H -CH2CH364 -CH3 -CH2CH3 H H -OH H H -CH2CH3 65 -CH3-(CH2)2CH3H H -OH H H -CH2CH366 -CH3 -CH(CH3)2 H H -OH H H -CH2CH3 67 -CH3 -(CH2)3CH3 H H -OH H H -CH2CH3 68 -CH3-CH2-HC=CH2H H -OH H H -CH2CH369 -CH2CH3 -CH2CH3 H H -OH H H -CH2CH3 70 -CH2CH3 -(CH2)2CH3 H H -OH H H -CH2CH3 71 -CH2CH3-CH(CH3)2H H -OH H H -CH2CH372 -CH2CH3 -(CH2)3CH3 H H -OH H H -CH2CH3 73 -CH2CH3-CH2-HC=CH2H H -OH H H -CH2CH374 -(CH2)2CH3 -(CH2)2CH3 H H -OH H H -CH2CH3 75 -(CH2)2CH3 -CH(CH3)2 H H -OH H H -CH2CH3 76 -(CH2)2CH3-(CH2)3CH3H H -OH H H -CH2CH377 -(CH2)2CH3 -CH2-HC=CH2 H H -OH H H -CH2CH3 78 -CH(CH3)2 -CH(CH3)2 H H -OH H H -CH2CH3 79 -CH(CH3)2-(CH2)3CH3H H -OH H H -CH2CH380 -CH(CH3)2 -CH2-HC=CH2 H H -OH H H -CH2CH3 81 -(CH2)3CH3-(CH2)3CH3H H -OH H H -CH2CH382 -(CH2)3CH3 -CH2-HC=CH2 H H -OH H H -CH2CH3 83 -CH2-HC=CH2 -CH2-HC=CH2 H H -OH H H -CH2CH3 84 -CH3-CH2CH3H H H F H H 85 -CH3 -(CH2)2CH3 H H H F H H 86 -CH3 -CH(CH3)2 H H H F H H 87 -CH3-(CH2)3CH3H H H F H H 88 -CH3 -CH2-HC=CH2 H H H F H H 89 -CH2CH3-CH2CH3H H H F H H 90 -CH2CH3-(CH2)2CH3H H H F H H 74 01312-0021-00PCT 91 -CH2CH3-CH(CH3)2H H H F H H 92 -CH2CH3 -(CH2)3CH3 H H H F H H 93 -CH2CH3-CH2-HC=CH2H H H F H H 94 -(CH2)2CH3 -(CH2)2CH3 H H H F H H 95 -(CH2)2CH3 -CH(CH3)2 H H H F H H 96 -(CH2)2CH3-(CH2)3CH3H H H F H H 97 -(CH2)2CH3 -CH2-HC=CH2 H H H F H H 98 -CH(CH3)2 -CH(CH3)2 H H H F H H 99 -CH(CH3)2-(CH2)3CH3H H H F H H 100 -CH(CH3)2 -CH2-HC=CH2 H H H F H H 101 -(CH2)3CH3-(CH2)3CH3H H H F H H 102 -(CH2)3CH3 -CH2-HC=CH2 H H H F H H 103 -CH2-HC=CH2 -CH2-HC=CH2 H H H F H H 104 -CH3-CH3H H H H -CH3H 105 -CH3 -CH2CH3 H H H H -CH3 H 106 -CH3 -(CH2)2CH3 H H H H -CH3 H 107 -CH3-CH(CH3)2H H H H -CH3H 108 -CH3 -(CH2)3CH3 H H H H -CH3 H 109 -CH3-CH2-HC=CH2H H H H -CH3H 110 -CH2CH3-CH2CH3H H H H -CH3H 111 -CH2CH3 -(CH2)2CH3 H H H H -CH3 H 112 -CH2CH3-CH(CH3)2H H H H -CH3H 113 -CH2CH3 -(CH2)3CH3 H H H H -CH3 H 114 -CH2CH3 -CH2-HC=CH2 H H H H -CH3 H 115 -(CH2)2CH3-(CH2)2CH3H H H H -CH3H 116 -(CH2)2CH3 -CH(CH3)2 H H H H -CH3 H 117 -(CH2)2CH3 -(CH2)3CH3 H H H H -CH3 H 118 -(CH2)2CH3-CH2-HC=CH2H H H H -CH3H 119 -CH(CH3)2 -CH(CH3)2 H H H H -CH3 H 120 -CH(CH3)2-(CH2)3CH3H H H H -CH3H 121 -CH(CH3)2 -CH2-HC=CH2 H H H H -CH3 H 122 -(CH2)3CH3 -(CH2)3CH3 H H H H -CH3 H 123 -(CH2)3CH3-CH2-HC=CH2H H H H -CH3H 124 -CH2-HC=CH2 -CH2-HC=CH2 H H H H -CH3 H 125 -CH3 -CH3 H H -OH H -CH3 H 126 -CH3-CH2CH3H H -OH H -CH3H 127 -CH3 -(CH2)2CH3 H H -OH H -CH3 H 128 -CH3-CH(CH3)2H H -OH H -CH3H 129 -CH3 -(CH2)3CH3 H H -OH H -CH3 H 130 -CH3 -CH2-HC=CH2 H H -OH H -CH3 H 131 -CH2CH3-CH2CH3H H -OH H -CH3H 132 -CH2CH3 -(CH2)2CH3 H H -OH H -CH3 H 133 -CH2CH3 -CH(CH3)2 H H -OH H -CH3 H 134 -CH2CH3-(CH2)3CH3H H -OH H -CH3H 135 -CH2CH3 -CH2-HC=CH2 H H -OH H -CH3 H 135 -(CH2)2CH3-(CH2)2CH3H H -OH H -CH3H 137 -(CH2)2CH3 -CH(CH3)2 H H -OH H -CH3 H 138 -(CH2)2CH3 -(CH2)3CH3 H H -OH H -CH3 H 139 -(CH2)2CH3-CH2-HC=CH2H H -OH H -CH3H 140 -CH(CH3)2 -CH(CH3)2 H H -OH H -CH3 H 141 -CH(CH3)2 -(CH2)3CH3 H H -OH H -CH3 H 142 -CH(CH3)2-CH2-HC=CH2H H -OH H -CH3H 143 -(CH2)3CH3 -(CH2)3CH3 H H -OH H -CH3 H 144 -(CH2)3CH3-CH2-HC=CH2H H -OH H -CH3H 145 -CH2-HC=CH2-CH2-HC=CH2H H -OH H -CH3H 75 01312-0021-00PCT 146 -CH3-CH2CH3H H -OH F H H 47 -CH3 -(CH2)2CH3 H H -OH F H H 48 -CH3-CH(CH3)2H H -OH F H H 149 -CH3 -(CH2)3CH3 H H -OH F H H 150 -CH3 -CH2-HC=CH2 H H -OH F H H 151 -CH2CH3-CH2CH3H H -OH F H H 152 -CH2CH3 -(CH2)2CH3 H H -OH F H H 153 -CH2CH3 -CH(CH3)2 H H -OH F H H 154 -CH2CH3-(CH2)3CH3H H -OH F H H 155 -CH2CH3 -CH2-HC=CH2 H H -OH F H H 156 -(CH2)2CH3-(CH2)2CH3H H -OH F H H 157 -(CH2)2CH3 -CH(CH3)2 H H -OH F H H 158 -(CH2)2CH3 -(CH2)3CH3 H H -OH F H H 159 -(CH2)2CH3-CH2-HC=CH2H H -OH F H H 160 -CH(CH3)2 -CH(CH3)2 H H -OH F H H 161 -CH(CH3)2 -(CH2)3CH3 H H -OH F H H 162 -CH(CH3)2-CH2-HC=CH2H H -OH F H H 163 -(CH2)3CH3 -(CH2)3CH3 H H -OH F H H 164 -(CH2)3CH3-CH2-HC=CH2H H -OH F H H 165 -CH2-HC=CH2-CH2-HC=CH2H H -OH F H H 166 H -CH3 H H H H H -CH2CH3 167 H -CH2CH3H H H H H -CH2CH3168 H -(CH2)2CH3 H H H H H -CH2CH3 169 H -CH(CH3)2 H H H H H -CH2CH3 170 H -(CH2)3CH3H H H H H -CH2CH3171 H -CH2-HC=CH2 H H H H H -CH2CH3 171a H -CH3 H H -OH H H H 172 H -CH2CH3H H -OH H H H 173 H -(CH2)2CH3 H H -OH H H H 174 H -CH(CH3)2H H -OH H H H 175 H -(CH2)3CH3 H H -OH H H H 176 H -CH2-HC=CH2 H H -OH H H H 177 H -CH3H H -OH H H -CH2CH3178 H -CH2CH3 H H -OH H H -CH2CH3 179 H -(CH2)2CH3 H H -OH H H -CH2CH3 180 H -CH(CH3)2H H -OH H H -CH2CH3181 H -(CH2)3CH3 H H -OH H H -CH2CH3 182 H -CH2-HC=CH2H H -OH H H -CH2CH3183 H -CH3 H H -OH H -CH3 H 184 H -CH2CH3 H H -OH H -CH3 H 185 H -(CH2)2CH3H H -OH H -CH3H 186 H -CH(CH3)2 H H -OH H -CH3 H 187 H -(CH2)3CH3 H H -OH H -CH3 H 188 H -CH2-HC=CH2H H -OH H -CH3H 189 H -CH3 H H H F -CH3 H 190 H -CH2CH3H H H F -CH3H 191 H -(CH2)2CH3 H H H F -CH3 H 192 H -CH(CH3)2 H H H F -CH3 H 193 H -(CH2)3CH3H H H F -CH3H 194 H -CH2-HC=CH2 H H H F -CH3 H 195 H -CH3 H H -OH F H H 196 H -CH2CH3H H -OH F H H 197 H -(CH2)2CH3 H H -OH F H H 198 H -CH(CH3)2H H -OH F H H 199 H -(CH2)3CH3H H -OH F H H 76 01312-0021-00PCT 200 H -CH2-HC=CH2H H -OH F H H 01 H -CH3 H H H H -CH3 H 02 H -CH2CH3H H H H -CH3H 203 H -(CH2)2CH3 H H H H -CH3 H 204 H -CH(CH3)2 H H H H -CH3 H 205 H -(CH2)3CH3H H H H -CH3H 206 H -CH2-HC=CH2 H H H H -CH3 H 207 H -CH3 H H H F H H 208 H -CH2CH3H H H F H H 209 H -(CH2)2CH3 H H H F H H 210 H -CH(CH3)2H H H F H H 211 H -(CH2)3CH3 H H H F H H 212 H -CH2-HC=CH2 H H H F H H 212a cyclopropyl -CH3H H H H H H 213 cyclopropyl -CH2CH3 H H H H H H 214 cyclopropyl -(CH2)2CH3 H H H H H H 215 cyclopropyl -CH(CH3)2H H H H H H 216 cyclopropyl -(CH2)3CH3 H H H H H H 217 cyclopropyl -CH2-HC=CH2H H H H H H 218 cyclopropyl -CH3H H -OCH3H H H 219 cyclopropyl -CH2CH3 H H -OCH3 H H H 220 cyclopropyl -(CH2)2CH3H H -OCH3H H H 221 cyclopropyl -CH(CH3)2 H H -OCH3 H H H 222 cyclopropyl -(CH2)3CH3 H H -OCH3 H H H 223 cyclopropyl -CH2-HC=CH2H H -OCH3H H H 224 cyclopropyl -CH3 H H -OH H H H 225 cyclopropyl -CH2CH3 H H -OH H H H 226 cyclopropyl -(CH2)2CH3H H -OH H H H 227 cyclopropyl -CH(CH3)2 H H -OH H H H 228 cyclopropyl -(CH2)3CH3H H -OH H H H 229 cyclopropyl -CH2-HC=CH2 H H -OH H H H 230 cyclopropyl -CH3 H H -OC(O)CH3 H H H 231 cyclopropyl -CH2CH3H H -OC(O)CH3H H H 232 cyclopropyl -(CH2)2CH3 H H -OC(O)CH3 H H H 233 cyclopropyl -CH(CH3)2 H H -OC(O)CH3 H H H 234 cyclopropyl -(CH2)3CH3H H -OC(O)CH3H H H 235 cyclopropyl -CH2-HC=CH2 H H -OC(O)CH3 H H H 236 cyclopropyl -CH3H H H H H -CH2CH3237 cyclopropyl -CH2CH3 H H H H H -CH2CH3 238 cyclopropyl -(CH2)2CH3 H H H H H -CH2CH3 239 cyclopropyl -CH(CH3)2H H H H H -CH2CH3240 cyclopropyl -(CH2)3CH3 H H H H H -CH2CH3 241 cyclopropyl -CH2-HC=CH2 H H H H H -CH2CH3 242 cyclopropyl -CH3H H -OH H H -CH2CH3243 cyclopropyl -CH2CH3 H H -OH H H -CH2CH3 244 cyclopropyl -(CH2)2CH3H H -OH H H -CH2CH3245 cyclopropyl -CH(CH3)2 H H -OH H H -CH2CH3 246 cyclopropyl -(CH2)3CH3 H H -OH H H -CH2CH3 247 cyclopropyl -CH2-HC=CH2H H -OH H H -CH2CH3248 H -CH3 H H H H H H 249 H -CH2CH3 H H H H H H 250 H -(CH2)2CH3H H H H H H 251 H -CH(CH3)2 H H H H H H 252 H -(CH2)3CH3H H H H H H 253 H -CH2-HC=CH2H H H H H H 77 01312-0021-00PCT 254 H cyclopropyl H H H H H H 55 H -CH3 H -CH3 H H H H 56 H -CH2CH3H -CH3H H H H 257 H -(CH2)2CH3 H -CH3 H H H H 258 H -CH(CH3)2 H -CH3 H H H H 259 H -(CH2)3CH3H -CH3H H H H 260 H -CH2-HC=CH2 H -CH3 H H H H 261 H cyclopropyl H -CH3 H H H H 262 H -CH3H -CH3-OH H H H 263 H -CH2CH3 H -CH3 -OH H H H 264 H -(CH2)2CH3H -CH3-OH H H H 265 H -CH(CH3)2 H -CH3 -OH H H H 266 H -(CH2)3CH3 H -CH3 -OH H H H 267 H -CH2-HC=CH2H -CH3-OH H H H 268 H cyclopropyl H -CH3 -OH H H H 269 H -CH3 H -CH3 H H H -CH2CH3 270 H -CH2CH3H -CH3H H H -CH2CH3271 H -(CH2)2CH3 H -CH3 H H H -CH2CH3 272 H -CH(CH3)2H -CH3H H H -CH2CH3273 H -(CH2)3CH3H -CH3H H H -CH2CH3274 H -CH2-HC=CH2 H -CH3 H H H -CH2CH3 275 H cyclopropyl H -CH3H H H -CH2CH3276 H -CH3 H -CH3 -OH H H -CH2CH3 277 H -CH2CH3 H -CH3 -OH H H -CH2CH3 278 H -(CH2)2CH3H -CH3-OH H H -CH2CH3279 H -CH(CH3)2 H -CH3 -OH H H -CH2CH3 280 H -(CH2)3CH3 H -CH3 -OH H H -CH2CH3 281 H -CH2-HC=CH2H -CH3-OH H H -CH2CH3282 H cyclopropyl H -CH3 -OH H H -CH2CH3 283 H -CH3H -CH3H H -CH3H 284 H -CH2CH3 H -CH3 H H -CH3 H 285 H -(CH2)2CH3 H -CH3 H H -CH3 H 286 H -CH(CH3)2H -CH3H H -CH3H 287 H -(CH2)3CH3 H -CH3 H H -CH3 H 288 H -CH2-HC=CH2 H -CH3 H H -CH3 H 289 H cyclopropyl H -CH3H H -CH3H 290 H -CH3 H -CH3 H F H H 291 H -CH2CH3H -CH3H F H H 292 H -(CH2)2CH3 H -CH3 H F H H 293 H -CH(CH3)2 H -CH3 H F H H 294 H -(CH2)3CH3H -CH3H F H H 295 H -CH2-HC=CH2 H -CH3 H F H H 296 H cyclopropyl H -CH3 H F H H 297 H -CH3H -CH3-OH H -CH3H 298 H -CH2CH3 H -CH3 -OH H -CH3 H 299 H -(CH2)2CH3H -CH3-OH H -CH3H 300 H -CH(CH3)2 H -CH3 -OH H -CH3 H 301 H -(CH2)3CH3 H -CH3 -OH H -CH3 H 302 H -CH2-HC=CH2H -CH3-OH H -CH3H 303 H cyclopropyl H -CH3 -OH H -CH3 H 304 H -CH3 H -CH3 -OH F H H 305 H -CH2CH3H -CH3-OH F H H 306 H -(CH2)2CH3 H -CH3 -OH F H H 307 H -CH(CH3)2H -CH3-OH F H H 308 H -(CH2)3CH3H -CH3-OH F H H 78 01312-0021-00PCT 309 H -CH2-HC=CH2H -CH3-OH F H H 10 H cyclopropyl H -CH3 -OH F H H 11 H H H -CH3H H H H 312 H H H -CH3 -OH H H H 313 H H H -CH3 H F H H 314 H H H -CH3H H -CH3H 315 H H H -CH3 H H H -CH2CH3 316 H H H -CH3 -OH H H -CH2CH3 317 H H H -CH3-OH H -CH3H 318 H H H -CH3 -OH F -CH3 H 319 H H H -CH3-OH F H H 320 H H H -CH3 -OH H H -CH3 321 -CH3 -CH3 H H H H H H 322 -CH3-CH2CH3H H H H H H 323 -CH3 -(CH2)2CH3 H H H H H H 324 -CH3 -CH(CH3)2 H H H H H H 325 -CH3-(CH2)3CH3H H H H H H 326 -CH3 -CH2-HC=CH2 H H H H H H 327 -CH2CH3-CH2CH3H H H H H H 328 -CH2CH3-(CH2)2CH3H H H H H H 329 -CH2CH3 -CH(CH3)2 H H H H H H 330 -CH2CH3-(CH2)3CH3H H H H H H 331 -CH2CH3 -CH2-HC=CH2 H H H H H H 332 -(CH2)2CH3 -(CH2)2CH3 H H H H H H 333 -(CH2)2CH3-CH(CH3)2H H H H H H 334 -(CH2)2CH3 -(CH2)3CH3 H H H H H H 335 -(CH2)2CH3 -CH2-HC=CH2 H H H H H H 336 -CH(CH3)2-CH(CH3)2H H H H H H 337 -CH(CH3)2 -(CH2)3CH3 H H H H H H 338 -CH(CH3)2-CH2-HC=CH2H H H H H H 339 -(CH2)3CH3 -(CH2)3CH3 H H H H H H 340 -(CH2)3CH3 -CH2-HC=CH2 H H H H H H 341 -CH2-HC=CH2-CH2-HC=CH2H H H H H H 342 H -CD3 H H H H H H 343 H -CD3 H H -OH H H H 344 H -CD3H H -OC(O)CH3H H H 345 H -CD3 H H -OCH3 H H H 346 H -CD3H H H F H H 347 H -CD3 H H -OH F H H 348 H -CD3 H H -OC(O)CH3 F H H 349 H -CD3H H -OCH3F H H 350 H -CD3 H H H H -CH3 H 351 H -CD3 H H -OH H -CH3 H 352 H -CD3H H -OC(O)CH3H -CH3H 353 H -CD3 H H -OCH3 H -CH3 H 354 H -CD3H H H H H -CH2CH3355 H -CD3 H H -OH H H -CH2CH3 356 H -CD3 H H -OC(O)CH3 H H -CH2CH3 357 H -CD3H H -OCH3H H -CH2CH3358 H -CD2CD3 H H H H H H 359 H -CD2CD3 H H -OH H H H 360 H -CD2CD3H H -OC(O)CH3H H H 361 H -CD2CD3 H H -OCH3 H H H 362 H -CD2CD3H H H F H H 363 H -CD2CD3H H -OH F H H 79 01312-0021-00PCT 364 H -CD2CD3H H -OC(O)CH3F H H 65 H -CD2CD3 H H -OCH3 F H H 66 H -CD2CD3H H H H -CH3H 367 H -CD2CD3 H H -OH H -CH3 H 368 H -CD2CD3 H H -OC(O)CH3 H -CH3 H 369 H -CD2CD3H H -OCH3H -CH3H 370 H -CD2CD3 H H H H H -CH2CH3 371 H -CD2CD3 H H -OH H H -CH2CH3 372 H -CD2CD3H H -OC(O)CH3H H -CH2CH3373 H -CD2CD3 H H -OCH3 H H -CH2CH3 374 H -CH3H D H H H H 375 H -CH2CH3 H D H H H H 376 H -(CH2)2CH3 H D H H H H 377 H -CH(CH3)2H D H H H H 378 H -(CH2)3CH3 H D H H H H 379 H -CH2-HC=CH2 H D H H H H 380 H -CH3H D -OH H H H 381 H -CH2CH3 H D -OH H H H 382 H -(CH2)2CH3H D -OH H H H 383 H -CH(CH3)2H D -OH H H H 384 H -(CH2)3CH3 H D -OH H H H 385 H -CH2-HC=CH2H D -OH H H H 386 H -CH3 H D -OH F H H 387 H -CH2CH3 H D -OH F H H 388 H -(CH2)2CH3H D -OH F H H 389 H -CH(CH3)2 H D -OH F H H 390 H -(CH2)3CH3 H D -OH F H H 391 H -CH2-HC=CH2H D -OH F H H 392 H -CH3 H D -OH H -CH3 H 393 H -CH2CH3H D -OH H -CH3H 394 H -(CH2)2CH3 H D -OH H -CH3 H 395 H -CH(CH3)2 H D -OH H -CH3 H 396 H -(CH2)3CH3H D -OH H -CH3H 397 H -CH2-HC=CH2 H D -OH H -CH3 H 398 H -CH3 H D H F -CH3 H 399 H -CH2CH3H D H F -CH3H 400 H -(CH2)2CH3 H D H F -CH3 H 401 H -CH(CH3)2H D H F -CH3H 402 H -(CH2)3CH3 H D H F -CH3 H 403 H -CH2-HC=CH2 H D H F -CH3 H 404 H -CH3H D H F H H 405 H -CH2CH3 H D H F H H 406 H -(CH2)2CH3 H D H F H H 407 H -CH(CH3)2H D H F H H 408 H -(CH2)3CH3 H D H F H H 409 H -CH2-HC=CH2H D H F H H 410 H -CH3 H D H H -CH3 H 411 H -CH2CH3 H D H H -CH3 H 412 H -(CH2)2CH3H D H H -CH3H 413 H -CH(CH3)2 H D H H -CH3 H 414 H -(CH2)3CH3 H D H H -CH3 H 415 H -CH2-HC=CH2H D H H -CH3H Other exemplary compounds of Formula I include those below in Table 6, which is also 80 01312-0021-00PCT represented by Formula If: Formula If Table 6 ef. X Y R2 R3 R4 R5 R7 R1 1 -CH3-CH3H H -OCH3H H H 2 -CH3 -CH2CH3 H H -OCH3 H H H 3 -CH3 -(CH2)2CH3 H H -OCH3 H H H 4 -CH3-CH(CH3)2H H -OCH3H H H 5 -CH3 -(CH2)3CH3 H H -OCH3 H H H 6 -CH3-CH2-HC=CH2H H -OCH3H H H 7 -CH2CH3-CH2CH3H H -OCH3H H H 8 -CH2CH3 -(CH2)2CH3 H H -OCH3 H H H 9 -CH2CH3-CH(CH3)2H H -OCH3H H H 10 -CH2CH3 -(CH2)3CH3 H H -OCH3 H H H 11 -CH2CH3 -CH2-HC=CH2 H H -OCH3 H H H 12 -(CH2)2CH3-(CH2)2CH3H H -OCH3H H H 13 -(CH2)2CH3 -CH(CH3)2 H H -OCH3 H H H 14 -(CH2)2CH3 -(CH2)3CH3 H H -OCH3 H H H 15 -(CH2)2CH3-CH2-HC=CH2H H -OCH3H H H 16 -CH(CH3)2 -CH(CH3)2 H H -OCH3 H H H 17 -CH(CH3)2-(CH2)3CH3H H -OCH3H H H 18 -CH(CH3)2 -CH2-HC=CH2 H H -OCH3 H H H 19 -(CH2)3CH3 -(CH2)3CH3 H H -OCH3 H H H 20 -(CH2)3CH3-CH2-HC=CH2H H -OCH3H H H 21 -CH2-HC=CH2 -CH2-HC=CH2 H H -OCH3 H H H 22 -CH3 -CH2CH3 H H -OH H H H 23 -CH3-(CH2)2CH3H H -OH H H H 24 -CH3 -CH(CH3)2 H H -OH H H H 25 -CH3-(CH2)3CH3H H -OH H H H 26 -CH3-CH2-HC=CH2H H -OH H H H 27 -CH2CH3 -CH2CH3 H H -OH H H H 28 -CH2CH3-(CH2)2CH3H H -OH H H H 29 -CH2CH3 -CH(CH3)2 H H -OH H H H 30 -CH2CH3 -(CH2)3CH3 H H -OH H H H 31 -CH2CH3-CH2-HC=CH2H H -OH H H H 32 -(CH2)2CH3 -(CH2)2CH3 H H -OH H H H 33 -(CH2)2CH3 -CH(CH3)2 H H -OH H H H 34 -(CH2)2CH3-(CH2)3CH3H H -OH H H H 35 -(CH2)2CH3 -CH2-HC=CH2 H H -OH H H H 36 -CH(CH3)2-CH(CH3)2H H -OH H H H 81 01312-0021-00PCT 37 -CH(CH3)2-(CH2)3CH3H H -OH H H H 38 -CH(CH3)2 -CH2-HC=CH2 H H -OH H H H 39 -(CH2)3CH3-(CH2)3CH3H H -OH H H H 40 -(CH2)3CH3 -CH2-HC=CH2 H H -OH H H H 41 -CH2-HC=CH2 -CH2-HC=CH2 H H -OH H H H 42 -CH3-CH3H H -OC(O)CH3H H H 43 -CH3 -CH2CH3 H H -OC(O)CH3 H H H 44 -CH3 -(CH2)2CH3 H H -OC(O)CH3 H H H 45 -CH3-CH(CH3)2H H -OC(O)CH3H H H 46 -CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 47 -CH3-CH2-HC=CH2H H -OC(O)CH3H H H 48 -CH2CH3 -CH2CH3 H H -OC(O)CH3 H H H 49 -CH2CH3 -(CH2)2CH3 H H -OC(O)CH3 H H H 50 -CH2CH3-CH(CH3)2H H -OC(O)CH3H H H 51 -CH2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 52 -CH2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 53 -(CH2)2CH3-(CH2)2CH3H H -OC(O)CH3H H H 54 -(CH2)2CH3 -CH(CH3)2 H H -OC(O)CH3 H H H 55 -(CH2)2CH3-(CH2)3CH3H H -OC(O)CH3H H H 56 -(CH2)2CH3-CH2-HC=CH2H H -OC(O)CH3H H H 57 -CH(CH3)2 -CH(CH3)2 H H -OC(O)CH3 H H H 58 -CH(CH3)2-(CH2)3CH3H H -OC(O)CH3H H H 59 -CH(CH3)2 -CH2-HC=CH2 H H -OC(O)CH3 H H H 60 -(CH2)3CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 61 -(CH2)3CH3-CH2-HC=CH2H H -OC(O)CH3H H H 62 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H H H 63 -CH3 -CH3 H H H -OCH3 H H 64 -CH3-CH2CH3H H H -OCH3H H 65 -CH3 -(CH2)2CH3 H H H -OCH3 H H 66 -CH3-CH(CH3)2H H H -OCH3H H 67 -CH3 -(CH2)3CH3 H H H -OCH3 H H 68 -CH3 -CH2-HC=CH2 H H H -OCH3 H H 69 -CH2CH3-CH2CH3H H H -OCH3H H 70 -CH2CH3 -(CH2)2CH3 H H H -OCH3 H H 71 -CH2CH3 -CH(CH3)2 H H H -OCH3 H H 72 -CH2CH3-(CH2)3CH3H H H -OCH3H H 73 -CH2CH3 -CH2-HC=CH2 H H H -OCH3 H H 74 -(CH2)2CH3-(CH2)2CH3H H H -OCH3H H 75 -(CH2)2CH3 -CH(CH3)2 H H H -OCH3 H H 76 -(CH2)2CH3 -(CH2)3CH3 H H H -OCH3 H H 77 -(CH2)2CH3-CH2-HC=CH2H H H -OCH3H H 78 -CH(CH3)2 -CH(CH3)2 H H H -OCH3 H H 79 -CH(CH3)2 -(CH2)3CH3 H H H -OCH3 H H 80 -CH(CH3)2-CH2-HC=CH2H H H -OCH3H H 81 -(CH2)3CH3 -(CH2)3CH3 H H H -OCH3 H H 82 -(CH2)3CH3-CH2-HC=CH2H H H -OCH3H H 83 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OCH3 H H 83b -CH3 -CH3 H H H -OH H H 84 -CH3-CH2CH3H H H -OH H H 85 -CH3 -(CH2)2CH3 H H H -OH H H 86 -CH3 -CH(CH3)2 H H H -OH H H 87 -CH3-(CH2)3CH3H H H -OH H H 88 -CH3 -CH2-HC=CH2 H H H -OH H H 89 -CH2CH3-CH2CH3H H H -OH H H 90 -CH2CH3-(CH2)2CH3H H H -OH H H 82 01312-0021-00PCT 91 -CH2CH3-CH(CH3)2H H H -OH H H 92 -CH2CH3 -(CH2)3CH3 H H H -OH H H 93 -CH2CH3-CH2-HC=CH2H H H -OH H H 94 -(CH2)2CH3 -(CH2)2CH3 H H H -OH H H 95 -(CH2)2CH3 -CH(CH3)2 H H H -OH H H 96 -(CH2)2CH3-(CH2)3CH3H H H -OH H H 97 -(CH2)2CH3 -CH2-HC=CH2 H H H -OH H H 98 -CH(CH3)2 -CH(CH3)2 H H H -OH H H 99 -CH(CH3)2-(CH2)3CH3H H H -OH H H 100 -CH(CH3)2 -CH2-HC=CH2 H H H -OH H H 101 -(CH2)3CH3-(CH2)3CH3H H H -OH H H 102 -(CH2)3CH3 -CH2-HC=CH2 H H H -OH H H 103 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OH H H 104 -CH3-CH3H H H -OC(O)CH3H H 105 -CH3 -CH2CH3 H H H -OC(O)CH3 H H 106 -CH3 -(CH2)2CH3 H H H -OC(O)CH3 H H 107 -CH3-CH(CH3)2H H H -OC(O)CH3H H 108 -CH3 -(CH2)3CH3 H H H -OC(O)CH3 H H 109 -CH3-CH2-HC=CH2H H H -OC(O)CH3H H 110 -CH2CH3-CH2CH3H H H -OC(O)CH3H H 111 -CH2CH3 -(CH2)2CH3 H H H -OC(O)CH3 H H 112 -CH2CH3-CH(CH3)2H H H -OC(O)CH3H H 113 -CH2CH3 -(CH2)3CH3 H H H -OC(O)CH3 H H 114 -CH2CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H H 115 -(CH2)2CH3-(CH2)2CH3H H H -OC(O)CH3H H 116 -(CH2)2CH3 -CH(CH3)2 H H H -OC(O)CH3 H H 117 -(CH2)2CH3 -(CH2)3CH3 H H H -OC(O)CH3 H H 118 -(CH2)2CH3-CH2-HC=CH2H H H -OC(O)CH3H H 119 -CH(CH3)2 -CH(CH3)2 H H H -OC(O)CH3 H H 120 -CH(CH3)2-(CH2)3CH3H H H -OC(O)CH3H H 121 -CH(CH3)2 -CH2-HC=CH2 H H H -OC(O)CH3 H H 122 -(CH2)3CH3 -(CH2)3CH3 H H H -OC(O)CH3 H H 123 -(CH2)3CH3-CH2-HC=CH2H H H -OC(O)CH3H H 124 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OC(O)CH3 H H 125 -CH3 -CH3 H H -OH H H -CH2CH3 126 -CH3-CH2CH3H H -OH H H -CH2CH3127 -CH3 -(CH2)2CH3 H H -OH H H -CH2CH3 128 -CH3-CH(CH3)2H H -OH H H -CH2CH3129 -CH3 -(CH2)3CH3 H H -OH H H -CH2CH3 130 -CH3 -CH2-HC=CH2 H H -OH H H -CH2CH3 131 -CH2CH3-CH2CH3H H -OH H H -CH2CH3132 -CH2CH3 -(CH2)2CH3 H H -OH H H -CH2CH3 133 -CH2CH3 -CH(CH3)2 H H -OH H H -CH2CH3 134 -CH2CH3-(CH2)3CH3H H -OH H H -CH2CH3135 -CH2CH3 -CH2-HC=CH2 H H -OH H H -CH2CH3 135 -(CH2)2CH3-(CH2)2CH3H H -OH H H -CH2CH3137 -(CH2)2CH3 -CH(CH3)2 H H -OH H H -CH2CH3 138 -(CH2)2CH3 -(CH2)3CH3 H H -OH H H -CH2CH3 139 -(CH2)2CH3-CH2-HC=CH2H H -OH H H -CH2CH3140 -CH(CH3)2 -CH(CH3)2 H H -OH H H -CH2CH3 141 -CH(CH3)2 -(CH2)3CH3 H H -OH H H -CH2CH3 142 -CH(CH3)2-CH2-HC=CH2H H -OH H H -CH2CH3143 -(CH2)3CH3 -(CH2)3CH3 H H -OH H H -CH2CH3 144 -(CH2)3CH3-CH2-HC=CH2H H -OH H H -CH2CH3145 -CH2-HC=CH2-CH2-HC=CH2H H -OH H H -CH2CH383 01312-0021-00PCT 145b -CH3-CH3H H -OH H -CH3H 46 -CH3 -CH2CH3 H H -OH H -CH3 H 47 -CH3-(CH2)2CH3H H -OH H -CH3H 148 -CH3 -CH(CH3)2 H H -OH H -CH3 H 149 -CH3 -(CH2)3CH3 H H -OH H -CH3 H 150 -CH3-CH2-HC=CH2H H -OH H -CH3H 151 -CH2CH3 -CH2CH3 H H -OH H -CH3 H 152 -CH2CH3 -(CH2)2CH3 H H -OH H -CH3 H 153 -CH2CH3-CH(CH3)2H H -OH H -CH3H 154 -CH2CH3 -(CH2)3CH3 H H -OH H -CH3 H 155 -CH2CH3-CH2-HC=CH2H H -OH H -CH3H 156 -(CH2)2CH3 -(CH2)2CH3 H H -OH H -CH3 H 157 -(CH2)2CH3 -CH(CH3)2 H H -OH H -CH3 H 158 -(CH2)2CH3-(CH2)3CH3H H -OH H -CH3H 159 -(CH2)2CH3 -CH2-HC=CH2 H H -OH H -CH3 H 160 -CH(CH3)2 -CH(CH3)2 H H -OH H -CH3 H 161 -CH(CH3)2-(CH2)3CH3H H -OH H -CH3H 162 -CH(CH3)2 -CH2-HC=CH2 H H -OH H -CH3 H 163 -(CH2)3CH3-(CH2)3CH3H H -OH H -CH3H 164 -(CH2)3CH3-CH2-HC=CH2H H -OH H -CH3H 165 -CH2-HC=CH2 -CH2-HC=CH2 H H -OH H -CH3 H 166 -CH3-CH3H H -OC(O)CH3H H -CH2CH3167 -CH3 -CH2CH3 H H -OC(O)CH3 H H -CH2CH3 168 -CH3 -(CH2)2CH3 H H -OC(O)CH3 H H -CH2CH3 169 -CH3-CH(CH3)2H H -OC(O)CH3H H -CH2CH3170 -CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH2CH3 171 -CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH2CH3 172 -CH2CH3-CH2CH3H H -OC(O)CH3H H -CH2CH3173 -CH2CH3 -(CH2)2CH3 H H -OC(O)CH3 H H -CH2CH3 174 -CH2CH3-CH(CH3)2H H -OC(O)CH3H H -CH2CH3175 -CH2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH2CH3 176 -CH2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH2CH3 177 -(CH2)2CH3-(CH2)2CH3H H -OC(O)CH3H H -CH2CH3178 -(CH2)2CH3 -CH(CH3)2 H H -OC(O)CH3 H H -CH2CH3 179 -(CH2)2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH2CH3 180 -(CH2)2CH3-CH2-HC=CH2H H -OC(O)CH3H H -CH2CH3181 -CH(CH3)2 -CH(CH3)2 H H -OC(O)CH3 H H -CH2CH3 182 -CH(CH3)2-(CH2)3CH3H H -OC(O)CH3H H -CH2CH3183 -CH(CH3)2 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH2CH3 184 -(CH2)3CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH2CH3 185 -(CH2)3CH3-CH2-HC=CH2H H -OC(O)CH3H H -CH2CH3186 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH2CH3 187 -CH3 -CH3 H H -OC(O)CH3 H -CH3 H 188 -CH3-CH2CH3H H -OC(O)CH3H -CH3H 189 -CH3 -(CH2)2CH3 H H -OC(O)CH3 H -CH3 H 190 -CH3-CH(CH3)2H H -OC(O)CH3H -CH3H 191 -CH3 -(CH2)3CH3 H H -OC(O)CH3 H -CH3 H 192 -CH3 -CH2-HC=CH2 H H -OC(O)CH3 H -CH3 H 193 -CH2CH3-CH2CH3H H -OC(O)CH3H -CH3H 194 -CH2CH3 -(CH2)2CH3 H H -OC(O)CH3 H -CH3 H 195 -CH2CH3 -CH(CH3)2 H H -OC(O)CH3 H -CH3 H 196 -CH2CH3-(CH2)3CH3H H -OC(O)CH3H -CH3H 197 -CH2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H -CH3 H 198 -(CH2)2CH3-(CH2)2CH3H H -OC(O)CH3H -CH3H 199 -(CH2)2CH3-CH(CH3)2H H -OC(O)CH3H -CH3H 84 01312-0021-00PCT 200 -(CH2)2CH3-(CH2)3CH3H H -OC(O)CH3H -CH3H 01 -(CH2)2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H -CH3 H 02 -CH(CH3)2-CH(CH3)2H H -OC(O)CH3H -CH3H 203 -CH(CH3)2 -(CH2)3CH3 H H -OC(O)CH3 H -CH3 H 204 -CH(CH3)2 -CH2-HC=CH2 H H -OC(O)CH3 H -CH3 H 205 -(CH2)3CH3-(CH2)3CH3H H -OC(O)CH3H -CH3H 206 -(CH2)3CH3 -CH2-HC=CH2 H H -OC(O)CH3 H -CH3 H 207 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H -CH3 H 207b -CH3-CH3H H H -OCH3H -CH2CH3208 -CH3 -CH2CH3 H H H -OCH3 H -CH2CH3 209 -CH3-(CH2)2CH3H H H -OCH3H -CH2CH3210 -CH3 -CH(CH3)2 H H H -OCH3 H -CH2CH3 211 -CH3 -(CH2)3CH3 H H H -OCH3 H -CH2CH3 212 -CH3-CH2-HC=CH2H H H -OCH3H -CH2CH3213 -CH2CH3 -CH2CH3 H H H -OCH3 H -CH2CH3 214 -CH2CH3 -(CH2)2CH3 H H H -OCH3 H -CH2CH3 215 -CH2CH3-CH(CH3)2H H H -OCH3H -CH2CH3216 -CH2CH3 -(CH2)3CH3 H H H -OCH3 H -CH2CH3 217 -CH2CH3-CH2-HC=CH2H H H -OCH3H -CH2CH3218 -(CH2)2CH3-(CH2)2CH3H H H -OCH3H -CH2CH3219 -(CH2)2CH3 -CH(CH3)2 H H H -OCH3 H -CH2CH3 220 -(CH2)2CH3-(CH2)3CH3H H H -OCH3H -CH2CH3221 -(CH2)2CH3 -CH2-HC=CH2 H H H -OCH3 H -CH2CH3 222 -CH(CH3)2 -CH(CH3)2 H H H -OCH3 H -CH2CH3 223 -CH(CH3)2-(CH2)3CH3H H H -OCH3H -CH2CH3224 -CH(CH3)2 -CH2-HC=CH2 H H H -OCH3 H -CH2CH3 225 -(CH2)3CH3 -(CH2)3CH3 H H H -OCH3 H -CH2CH3 226 -(CH2)3CH3-CH2-HC=CH2H H H -OCH3H -CH2CH3227 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OCH3 H -CH2CH3 228 -CH3-CH3H H H -OCH3-CH3H 229 -CH3 -CH2CH3 H H H -OCH3 -CH3 H 230 -CH3 -(CH2)2CH3 H H H -OCH3 -CH3 H 231 -CH3-CH(CH3)2H H H -OCH3-CH3H 232 -CH3 -(CH2)3CH3 H H H -OCH3 -CH3 H 233 -CH3 -CH2-HC=CH2 H H H -OCH3 -CH3 H 234 -CH2CH3-CH2CH3H H H -OCH3-CH3H 235 -CH2CH3 -(CH2)2CH3 H H H -OCH3 -CH3 H 236 -CH2CH3-CH(CH3)2H H H -OCH3-CH3H 237 -CH2CH3 -(CH2)3CH3 H H H -OCH3 -CH3 H 238 -CH2CH3 -CH2-HC=CH2 H H H -OCH3 -CH3 H 239 -(CH2)2CH3-(CH2)2CH3H H H -OCH3-CH3H 240 -(CH2)2CH3 -CH(CH3)2 H H H -OCH3 -CH3 H 241 -(CH2)2CH3 -(CH2)3CH3 H H H -OCH3 -CH3 H 242 -(CH2)2CH3-CH2-HC=CH2H H H -OCH3-CH3H 243 -CH(CH3)2 -CH(CH3)2 H H H -OCH3 -CH3 H 244 -CH(CH3)2-(CH2)3CH3H H H -OCH3-CH3H 245 -CH(CH3)2 -CH2-HC=CH2 H H H -OCH3 -CH3 H 246 -(CH2)3CH3 -(CH2)3CH3 H H H -OCH3 -CH3 H 247 -(CH2)3CH3-CH2-HC=CH2H H H -OCH3-CH3H 248 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OCH3 -CH3 H 249 H -CH3 H H H H H -CH2CH3 250 H -CH2CH3H H H H H -CH2CH3251 H -(CH2)2CH3 H H H H H -CH2CH3 252 H -CH(CH3)2H H H H H -CH2CH3253 H -(CH2)3CH3H H H H H -CH2CH385 01312-0021-00PCT 254 H -CH2-HC=CH2H H H H H -CH2CH355 H -CH3 H H -OH H H H 56 H -CH2CH3H H -OH H H H 257 H -(CH2)2CH3 H H -OH H H H 258 H -CH(CH3)2 H H -OH H H H 259 H -(CH2)3CH3H H -OH H H H 260 H -CH2-HC=CH2 H H -OH H H H 261 H -CH3 H H -OH H H -CH2CH3 262 H -CH2CH3H H -OH H H -CH2CH3263 H -(CH2)2CH3 H H -OH H H -CH2CH3 264 H -CH(CH3)2H H -OH H H -CH2CH3265 H -(CH2)3CH3 H H -OH H H -CH2CH3 266 H -CH2-HC=CH2 H H -OH H H -CH2CH3 267 H -CH3H H -OH H -CH3H 268 H -CH2CH3 H H -OH H -CH3 H 269 H -(CH2)2CH3 H H -OH H -CH3 H 270 H -CH(CH3)2H H -OH H -CH3H 271 H -(CH2)3CH3 H H -OH H -CH3 H 272 H -CH2-HC=CH2H H -OH H -CH3H 273 H -CH3H H H -OCH3-CH3H 274 H -CH2CH3 H H H -OCH3 -CH3 H 275 H -(CH2)2CH3H H H -OCH3-CH3H 276 H -CH(CH3)2 H H H -OCH3 -CH3 H 277 H -(CH2)3CH3 H H H -OCH3 -CH3 H 278 H -CH2-HC=CH2H H H -OCH3-CH3H 279 H -CH3 H H -OC(O)CH3 H H H 280 H -CH2CH3 H H -OC(O)CH3 H H H 281 H -(CH2)2CH3H H -OC(O)CH3H H H 282 H -CH(CH3)2 H H -OC(O)CH3 H H H 283 H -(CH2)3CH3H H -OC(O)CH3H H H 284 H -CH2-HC=CH2 H H -OC(O)CH3 H H H 285 H -CH3 H H H H -CH3 H 286 H -CH2CH3H H H H -CH3H 287 H -(CH2)2CH3 H H H H -CH3 H 288 H -CH(CH3)2 H H H H -CH3 H 289 H -(CH2)3CH3H H H H -CH3H 290 H -CH2-HC=CH2 H H H H -CH3 H 291 H -CH3H H H -OCH3H H 292 H -CH2CH3 H H H -OCH3 H H 293 H -(CH2)2CH3 H H H -OCH3 H H 294 H -CH(CH3)2H H H -OCH3H H 295 H -(CH2)3CH3 H H H -OCH3 H H 296 H -CH2-HC=CH2 H H H -OCH3 H H 297 cyclopropyl -CH3H H H H H H 298 cyclopropyl -CH2CH3 H H H H H H 299 cyclopropyl -(CH2)2CH3H H H H H H 300 cyclopropyl -CH(CH3)2 H H H H H H 301 cyclopropyl -(CH2)3CH3 H H H H H H 302 cyclopropyl -CH2-HC=CH2H H H H H H 303 cyclopropyl -CH3 H H -OCH3 H H H 304 cyclopropyl -CH2CH3 H H -OCH3 H H H 305 cyclopropyl -(CH2)2CH3H H -OCH3H H H 306 cyclopropyl -CH(CH3)2 H H -OCH3 H H H 307 cyclopropyl -(CH2)3CH3H H -OCH3H H H 308 cyclopropyl -CH2-HC=CH2H H -OCH3H H H 86 01312-0021-00PCT 309 cyclopropyl -CH3H H -OH H H H 10 cyclopropyl -CH2CH3 H H -OH H H H 11 cyclopropyl -(CH2)2CH3H H -OH H H H 312 cyclopropyl -CH(CH3)2 H H -OH H H H 313 cyclopropyl -(CH2)3CH3 H H -OH H H H 314 cyclopropyl -CH2-HC=CH2H H -OH H H H 315 cyclopropyl -CH3 H H -OC(O)CH3 H H H 316 cyclopropyl -CH2CH3 H H -OC(O)CH3 H H H 317 cyclopropyl -(CH2)2CH3H H -OC(O)CH3H H H 318 cyclopropyl -CH(CH3)2 H H -OC(O)CH3 H H H 319 cyclopropyl -(CH2)3CH3H H -OC(O)CH3H H H 320 cyclopropyl -CH2-HC=CH2 H H -OC(O)CH3 H H H 321 cyclopropyl -CH3 H H H H H -CH2CH3 322 cyclopropyl -CH2CH3H H H H H -CH2CH3323 cyclopropyl -(CH2)2CH3 H H H H H -CH2CH3 324 cyclopropyl -CH(CH3)2 H H H H H -CH2CH3 325 cyclopropyl -(CH2)3CH3H H H H H -CH2CH3326 cyclopropyl -CH2-HC=CH2 H H H H H -CH2CH3 327 cyclopropyl -CH3H H -OH H H -CH2CH3328 cyclopropyl -CH2CH3H H -OH H H -CH2CH3329 cyclopropyl -(CH2)2CH3 H H -OH H H -CH2CH3 330 cyclopropyl -CH(CH3)2H H -OH H H -CH2CH3331 cyclopropyl -(CH2)3CH3 H H -OH H H -CH2CH3 332 cyclopropyl -CH2-HC=CH2 H H -OH H H -CH2CH3 333 H -CH3H H H H H H 334 H -CH2CH3 H H H H H H 335 H -(CH2)2CH3 H H H H H H 336 H -CH(CH3)2H H H H H H 337 H -(CH2)3CH3 H H H H H H 338 H -CH2-HC=CH2H H H H H H 339 H cyclopropyl H H H H H H 340 H -CH3 H -CH3 H H H H 341 H -CH2CH3H -CH3H H H H 342 H -(CH2)2CH3 H -CH3 H H H H 343 H -CH(CH3)2 H -CH3 H H H H 344 H -(CH2)3CH3H -CH3H H H H 345 H -CH2-HC=CH2 H -CH3 H H H H 346 H cyclopropyl H -CH3H H H H 347 H -CH3 H -CH3 -OH H H H 348 H -CH2CH3 H -CH3 -OH H H H 349 H -(CH2)2CH3H -CH3-OH H H H 350 H -CH(CH3)2 H -CH3 -OH H H H 351 H -(CH2)3CH3 H -CH3 -OH H H H 352 H -CH2-HC=CH2H -CH3-OH H H H 353 H cyclopropyl H -CH3 -OH H H H 354 H -CH3H -CH3H H H -CH2CH3355 H -CH2CH3 H -CH3 H H H -CH2CH3 356 H -(CH2)2CH3 H -CH3 H H H -CH2CH3 357 H -CH(CH3)2H -CH3H H H -CH2CH3358 H -(CH2)3CH3 H -CH3 H H H -CH2CH3 359 H -CH2-HC=CH2 H -CH3 H H H -CH2CH3 360 H cyclopropyl H -CH3H H H -CH2CH3361 H -CH3 H -CH3 -OH H H -CH2CH3 362 H -CH2CH3H -CH3-OH H H -CH2CH3363 H -(CH2)2CH3H -CH3-OH H H -CH2CH387 01312-0021-00PCT 364 H -CH(CH3)2H -CH3-OH H H -CH2CH365 H -(CH2)3CH3 H -CH3 -OH H H -CH2CH3 66 H -CH2-HC=CH2H -CH3-OH H H -CH2CH3367 H cyclopropyl H -CH3 -OH H H -CH2CH3 368 H -CH3 H -CH3 H H -CH3 H 369 H -CH2CH3H -CH3H H -CH3H 370 H -(CH2)2CH3 H -CH3 H H -CH3 H 371 H -CH(CH3)2 H -CH3 H H -CH3 H 372 H -(CH2)3CH3H -CH3H H -CH3H 373 H -CH2-HC=CH2 H -CH3 H H -CH3 H 374 H cyclopropyl H -CH3H H -CH3H 375 H -CH3 H -CH3 H -OCH3 H H 376 H -CH2CH3 H -CH3 H -OCH3 H H 377 H -(CH2)2CH3H -CH3H -OCH3H H 378 H -CH(CH3)2 H -CH3 H -OCH3 H H 379 H -(CH2)3CH3 H -CH3 H -OCH3 H H 380 H -CH2-HC=CH2H -CH3H -OCH3H H 381 H cyclopropyl H -CH3 H -OCH3 H H 382 H -CH3H -CH3-OH H -CH3H 383 H -CH2CH3H -CH3-OH H -CH3H 384 H -(CH2)2CH3 H -CH3 -OH H -CH3 H 385 H -CH(CH3)2H -CH3-OH H -CH3H 386 H -(CH2)3CH3 H -CH3 -OH H -CH3 H 387 H -CH2-HC=CH2 H -CH3 -OH H -CH3 H 388 H cyclopropyl H -CH3-OH H -CH3H 389 H -CH3 H -CH3 -OC(O)CH3 H H H 390 H -CH2CH3 H -CH3 -OC(O)CH3 H H H 391 H -(CH2)2CH3H -CH3-OC(O)CH3H H H 392 H -CH(CH3)2 H -CH3 -OC(O)CH3 H H H 393 H -(CH2)3CH3H -CH3-OC(O)CH3H H H 394 H -CH2-HC=CH2 H -CH3 -OC(O)CH3 H H H 395 H cyclopropyl H -CH3 -OC(O)CH3 H H H 396 H H H -CH3H H H H 397 H H H -CH3 -OH H H H 398 H H H -CH3 H -OCH3 H H 399 H H H -CH3H H -CH3H 400 H H H -CH3 H H H -CH2CH3 401 H H H -CH3-OH H H -CH2CH3402 H H H -CH3 -OH H -CH3 H 403 H H H -CH3 -OH -OCH3 -CH3 H 404 H H H -CH3-OH F H H 405 H H H -CH3 -OH H H -CH3 406 -CH3 -CH3 H H H H H H 407 -CH3-CH2CH3H H H H H H 408 -CH3 -(CH2)2CH3 H H H H H H 409 -CH3-CH(CH3)2H H H H H H 410 -CH3 -(CH2)3CH3 H H H H H H 411 -CH3 -CH2-HC=CH2 H H H H H H 412 -CH2CH3-CH2CH3H H H H H H 413 -CH2CH3 -(CH2)2CH3 H H H H H H 414 -CH2CH3 -CH(CH3)2 H H H H H H 415 -CH2CH3-(CH2)3CH3H H H H H H 416 -CH2CH3 -CH2-HC=CH2 H H H H H H 417 -(CH2)2CH3-(CH2)2CH3H H H H H H 418 -(CH2)2CH3-CH(CH3)2H H H H H H 88 01312-0021-00PCT 419 -(CH2)2CH3-(CH2)3CH3H H H H H H 20 -(CH2)2CH3 -CH2-HC=CH2 H H H H H H 21 -CH(CH3)2-CH(CH3)2H H H H H H 422 -CH(CH3)2 -(CH2)3CH3 H H H H H H 423 -CH(CH3)2 -CH2-HC=CH2 H H H H H H 424 -(CH2)3CH3-(CH2)3CH3H H H H H H 425 -(CH2)3CH3 -CH2-HC=CH2 H H H H H H 426 -CH2-HC=CH2 -CH2-HC=CH2 H H H H H H 427 H -CD3H H H H H H 428 H -CD3 H H -OH H H H 429 H -CD3H H -OC(O)CH3H H H 430 H -CD3 H H H -OCH3 H H 431 H -CD3 H H H H H H 432 H -CD3H H -OH H H H 433 H -CD3 H H -OC(O)CH3 H H H 434 H -CD3 H H H -OCH3 H H 435 H -CD3H H H H -CH3H 436 H -CD3 H H -OH H -CH3 H 437 H -CD3H H -OC(O)CH3H -CH3H 438 H -CD3H H H -OCH3-CH3H 439 H -CD3 H H H H H -CH2CH3 440 H -CD3H H -OH H H -CH2CH3441 H -CD3 H H -OC(O)CH3 H H -CH2CH3 442 H -CD3 H H H -OCH3 H -CH2CH3 443 H -CD2CD3H H H H H H 444 H -CD2CD3 H H -OH H H H 445 H -CD2CD3 H H -OC(O)CH3 H H H 446 H -CD2CD3H H H -OCH3H H 447 H -CD2CD3 H H H H H H 448 H -CD2CD3H H -OH H H H 449 H -CD2CD3 H H -OC(O)CH3 H H H 450 H -CD2CD3 H H H -OCH3 H H 451 H -CD2CD3H H H H -CH3H 452 H -CD2CD3 H H -OH H -CH3 H 453 H -CD2CD3 H H -OC(O)CH3 H -CH3 H 454 H -CD2CD3H H H -OCH3-CH3H 455 H -CD2CD3 H H H H H -CH2CH3 456 H -CD2CD3H H -OH H H -CH2CH3457 H -CD2CD3 H H -OC(O)CH3 H H -CH2CH3 458 H -CD2CD3 H H H -OCH3 H -CH2CH3 458 H -CH3H D H H H H 459 H -CH2CH3 H D H H H H 460 H -(CH2)2CH3 H D H H H H 461 H -CH(CH3)2H D H H H H 462 H -(CH2)3CH3 H D H H H H 463 H -CH2-HC=CH2H D H H H H 464 H -CH3 H D -OH H H H 465 H -CH2CH3 H D -OH H H H 466 H -(CH2)2CH3H D -OH H H H 467 H -CH(CH3)2 H D -OH H H H 468 H -(CH2)3CH3 H D -OH H H H 469 H -CH2-HC=CH2H D -OH H H H 470 H -CH3 H D -OC(O)CH3 H H H 471 H -CH2CH3H D -OC(O)CH3H H H 472 H -(CH2)2CH3H D -OC(O)CH3H H H 89 01312-0021-00PCT 473 H -CH(CH3)2H D -OC(O)CH3H H H 74 H -(CH2)3CH3 H D -OC(O)CH3 H H H 75 H -CH2-HC=CH2H D -OC(O)CH3H H H 476 H -CH3 H D -OH H -CH3 H 477 H -CH2CH3 H D -OH H -CH3 H 478 H -(CH2)2CH3H D -OH H -CH3H 479 H -CH(CH3)2 H D -OH H -CH3 H 480 H -(CH2)3CH3 H D -OH H -CH3 H 481 H -CH2-HC=CH2H D -OH H -CH3H 482 H -CH3 H D H -OMe -CH3 H 483 H -CH2CH3H D H -OMe -CH3H 484 H -(CH2)2CH3 H D H -OMe -CH3 H 485 H -CH(CH3)2 H D H -OMe -CH3 H 486 H -(CH2)3CH3H D H -OMe -CH3H 487 H -CH2-HC=CH2 H D H -OMe -CH3 H 488 H -CH3 H D H -OMe H H 489 H -CH2CH3H D H -OMe H H 490 H -(CH2)2CH3 H D H -OMe H H 491 H -CH(CH3)2H D H -OMe H H 492 H -(CH2)3CH3H D H -OMe H H 493 H -CH2-HC=CH2 H D H -OMe H H 494 H -CH3H D H H -CH3H 495 H -CH2CH3 H D H H -CH3 H 496 H -(CH2)2CH3 H D H H -CH3 H 497 H -CH(CH3)2H D H H -CH3H 498 H -(CH2)3CH3 H D H H -CH3 H 499 H -CH2-HC=CH2 H D H H -CH3 H Other exemplary compounds of Formula I include those below in Table 7, which is also represented by Formula Ig: Formula Ig Table 7 ef. X Y R2R3R4R5R6R11 -CH3 -CH3 H H -OCH3 H H H 2 -CH3 -CH2CH3 H H -OCH3 H H H 3 -CH3-(CH2)2CH3H H -OCH3H H H 4 -CH3 -CH(CH3)2 H H -OCH3 H H H 5 -CH3-(CH2)3CH3H H -OCH3H H H 90 01312-0021-00PCT 6 -CH3-CH2-HC=CH2H H -OCH3H H H 7 -CH2CH3 -CH2CH3 H H -OCH3 H H H 8 -CH2CH3-(CH2)2CH3H H -OCH3H H H 9 -CH2CH3 -CH(CH3)2 H H -OCH3 H H H 10 -CH2CH3 -(CH2)3CH3 H H -OCH3 H H H 11 -CH2CH3-CH2-HC=CH2H H -OCH3H H H 12 -(CH2)2CH3 -(CH2)2CH3 H H -OCH3 H H H 13 -(CH2)2CH3 -CH(CH3)2 H H -OCH3 H H H 14 -(CH2)2CH3-(CH2)3CH3H H -OCH3H H H 15 -(CH2)2CH3 -CH2-HC=CH2 H H -OCH3 H H H 16 -CH(CH3)2-CH(CH3)2H H -OCH3H H H 17 -CH(CH3)2 -(CH2)3CH3 H H -OCH3 H H H 18 -CH(CH3)2 -CH2-HC=CH2 H H -OCH3 H H H 19 -(CH2)3CH3-(CH2)3CH3H H -OCH3H H H 20 -(CH2)3CH3 -CH2-HC=CH2 H H -OCH3 H H H 21 -CH2-HC=CH2 -CH2-HC=CH2 H H -OCH3 H H H 22 -CH3-CH2CH3H H -OH H H H 23 -CH3 -(CH2)2CH3 H H -OH H H H 24 -CH3-CH(CH3)2H H -OH H H H 25 -CH3-(CH2)3CH3H H -OH H H H 26 -CH3 -CH2-HC=CH2 H H -OH H H H 27 -CH2CH3-CH2CH3H H -OH H H H 28 -CH2CH3 -(CH2)2CH3 H H -OH H H H 29 -CH2CH3 -CH(CH3)2 H H -OH H H H 30 -CH2CH3-(CH2)3CH3H H -OH H H H 31 -CH2CH3 -CH2-HC=CH2 H H -OH H H H 32 -(CH2)2CH3 -(CH2)2CH3 H H -OH H H H 33 -(CH2)2CH3-CH(CH3)2H H -OH H H H 34 -(CH2)2CH3 -(CH2)3CH3 H H -OH H H H 35 -(CH2)2CH3-CH2-HC=CH2H H -OH H H H 36 -CH(CH3)2 -CH(CH3)2 H H -OH H H H 37 -CH(CH3)2 -(CH2)3CH3 H H -OH H H H 38 -CH(CH3)2-CH2-HC=CH2H H -OH H H H 39 -(CH2)3CH3 -(CH2)3CH3 H H -OH H H H 40 -(CH2)3CH3 -CH2-HC=CH2 H H -OH H H H 41 -CH2-HC=CH2-CH2-HC=CH2H H -OH H H H 42 -CH3 -CH3 H H -OC(O)CH3 H H H 43 -CH3-CH2CH3H H -OC(O)CH3H H H 44 -CH3 -(CH2)2CH3 H H -OC(O)CH3 H H H 45 -CH3 -CH(CH3)2 H H -OC(O)CH3 H H H 46 -CH3-(CH2)3CH3H H -OC(O)CH3H H H 47 -CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 48 -CH2CH3 -CH2CH3 H H -OC(O)CH3 H H H 49 -CH2CH3-(CH2)2CH3H H -OC(O)CH3H H H 50 -CH2CH3 -CH(CH3)2 H H -OC(O)CH3 H H H 51 -CH2CH3-(CH2)3CH3H H -OC(O)CH3H H H 52 -CH2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 53 -(CH2)2CH3 -(CH2)2CH3 H H -OC(O)CH3 H H H 54 -(CH2)2CH3-CH(CH3)2H H -OC(O)CH3H H H 55 -(CH2)2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H H 56 -(CH2)2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H H 57 -CH(CH3)2-CH(CH3)2H H -OC(O)CH3H H H 58 -CH(CH3)2 -(CH2)3CH3 H H -OC(O)CH3 H H H 59 -CH(CH3)2-CH2-HC=CH2H H -OC(O)CH3H H H 60 -(CH2)3CH3-(CH2)3CH3H H -OC(O)CH3H H H 91 01312-0021-00PCT 61 -(CH2)3CH3-CH2-HC=CH2H H -OC(O)CH3H H H 62 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H H H 63 -CH3-CH3H H H -OCH3H H 64 -CH3 -CH2CH3 H H H -OCH3 H H 65 -CH3 -(CH2)2CH3 H H H -OCH3 H H 66 -CH3-CH(CH3)2H H H -OCH3H H 67 -CH3 -(CH2)3CH3 H H H -OCH3 H H 68 -CH3 -CH2-HC=CH2 H H H -OCH3 H H 69 -CH2CH3-CH2CH3H H H -OCH3H H 70 -CH2CH3 -(CH2)2CH3 H H H -OCH3 H H 71 -CH2CH3-CH(CH3)2H H H -OCH3H H 72 -CH2CH3 -(CH2)3CH3 H H H -OCH3 H H 73 -CH2CH3 -CH2-HC=CH2 H H H -OCH3 H H 74 -(CH2)2CH3-(CH2)2CH3H H H -OCH3H H 75 -(CH2)2CH3 -CH(CH3)2 H H H -OCH3 H H 76 -(CH2)2CH3 -(CH2)3CH3 H H H -OCH3 H H 77 -(CH2)2CH3-CH2-HC=CH2H H H -OCH3H H 78 -CH(CH3)2 -CH(CH3)2 H H H -OCH3 H H 79 -CH(CH3)2-(CH2)3CH3H H H -OCH3H H 80 -CH(CH3)2-CH2-HC=CH2H H H -OCH3H H 81 -(CH2)3CH3 -(CH2)3CH3 H H H -OCH3 H H 82 -(CH2)3CH3-CH2-HC=CH2H H H -OCH3H H 83 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OCH3 H H 83b -CH3 -CH3 H H H -OH H H 84 -CH3-CH2CH3H H H -OH H H 85 -CH3 -(CH2)2CH3 H H H -OH H H 86 -CH3 -CH(CH3)2 H H H -OH H H 87 -CH3-(CH2)3CH3H H H -OH H H 88 -CH3 -CH2-HC=CH2 H H H -OH H H 89 -CH2CH3-CH2CH3H H H -OH H H 90 -CH2CH3 -(CH2)2CH3 H H H -OH H H 91 -CH2CH3 -CH(CH3)2 H H H -OH H H 92 -CH2CH3-(CH2)3CH3H H H -OH H H 93 -CH2CH3 -CH2-HC=CH2 H H H -OH H H 94 -(CH2)2CH3 -(CH2)2CH3 H H H -OH H H 95 -(CH2)2CH3-CH(CH3)2H H H -OH H H 96 -(CH2)2CH3 -(CH2)3CH3 H H H -OH H H 97 -(CH2)2CH3-CH2-HC=CH2H H H -OH H H 98 -CH(CH3)2 -CH(CH3)2 H H H -OH H H 99 -CH(CH3)2 -(CH2)3CH3 H H H -OH H H 100 -CH(CH3)2-CH2-HC=CH2H H H -OH H H 101 -(CH2)3CH3 -(CH2)3CH3 H H H -OH H H 102 -(CH2)3CH3 -CH2-HC=CH2 H H H -OH H H 103 -CH2-HC=CH2-CH2-HC=CH2H H H -OH H H 104 -CH3 -CH3 H H H -OC(O)CH3 H H 105 -CH3-CH2CH3H H H -OC(O)CH3H H 106 -CH3 -(CH2)2CH3 H H H -OC(O)CH3 H H 107 -CH3 -CH(CH3)2 H H H -OC(O)CH3 H H 108 -CH3-(CH2)3CH3H H H -OC(O)CH3H H 109 -CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H H 110 -CH2CH3 -CH2CH3 H H H -OC(O)CH3 H H 111 -CH2CH3-(CH2)2CH3H H H -OC(O)CH3H H 112 -CH2CH3 -CH(CH3)2 H H H -OC(O)CH3 H H 113 -CH2CH3-(CH2)3CH3H H H -OC(O)CH3H H 114 -CH2CH3-CH2-HC=CH2H H H -OC(O)CH3H H 92 01312-0021-00PCT 115 -(CH2)2CH3-(CH2)2CH3H H H -OC(O)CH3H H 16 -(CH2)2CH3 -CH(CH3)2 H H H -OC(O)CH3 H H 17 -(CH2)2CH3-(CH2)3CH3H H H -OC(O)CH3H H 118 -(CH2)2CH3 -CH2-HC=CH2 H H H -OC(O)CH3 H H 119 -CH(CH3)2 -CH(CH3)2 H H H -OC(O)CH3 H H 120 -CH(CH3)2-(CH2)3CH3H H H -OC(O)CH3H H 121 -CH(CH3)2 -CH2-HC=CH2 H H H -OC(O)CH3 H H 122 -(CH2)3CH3 -(CH2)3CH3 H H H -OC(O)CH3 H H 123 -(CH2)3CH3-CH2-HC=CH2H H H -OC(O)CH3H H 124 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OC(O)CH3 H H 125 -CH3-CH3H H -OH H H -CH2CH3126 -CH3 -CH2CH3 H H -OH H H -CH2CH3 127 -CH3 -(CH2)2CH3 H H -OH H H -CH2CH3 128 -CH3-CH(CH3)2H H -OH H H -CH2CH3129 -CH3 -(CH2)3CH3 H H -OH H H -CH2CH3 130 -CH3 -CH2-HC=CH2 H H -OH H H -CH2CH3 131 -CH2CH3-CH2CH3H H -OH H H -CH2CH3132 -CH2CH3 -(CH2)2CH3 H H -OH H H -CH2CH3 133 -CH2CH3-CH(CH3)2H H -OH H H -CH2CH3134 -CH2CH3-(CH2)3CH3H H -OH H H -CH2CH3135 -CH2CH3 -CH2-HC=CH2 H H -OH H H -CH2CH3 135 -(CH2)2CH3-(CH2)2CH3H H -OH H H -CH2CH3137 -(CH2)2CH3 -CH(CH3)2 H H -OH H H -CH2CH3 138 -(CH2)2CH3 -(CH2)3CH3 H H -OH H H -CH2CH3 139 -(CH2)2CH3-CH2-HC=CH2H H -OH H H -CH2CH3140 -CH(CH3)2 -CH(CH3)2 H H -OH H H -CH2CH3 141 -CH(CH3)2 -(CH2)3CH3 H H -OH H H -CH2CH3 142 -CH(CH3)2-CH2-HC=CH2H H -OH H H -CH2CH3143 -(CH2)3CH3 -(CH2)3CH3 H H -OH H H -CH2CH3 144 -(CH2)3CH3-CH2-HC=CH2H H -OH H H -CH2CH3145 -CH2-HC=CH2 -CH2-HC=CH2 H H -OH H H -CH2CH3 145b -CH3 -CH3 H H -OH H F H 146 -CH3-CH2CH3H H -OH H F H 147 -CH3 -(CH2)2CH3 H H -OH H F H 148 -CH3 -CH(CH3)2 H H -OH H F H 149 -CH3-(CH2)3CH3H H -OH H F H 150 -CH3 -CH2-HC=CH2 H H -OH H F H 151 -CH2CH3-CH2CH3H H -OH H F H 152 -CH2CH3 -(CH2)2CH3 H H -OH H F H 153 -CH2CH3 -CH(CH3)2 H H -OH H F H 154 -CH2CH3-(CH2)3CH3H H -OH H F H 155 -CH2CH3 -CH2-HC=CH2 H H -OH H F H 156 -(CH2)2CH3 -(CH2)2CH3 H H -OH H F H 157 -(CH2)2CH3-CH(CH3)2H H -OH H F H 158 -(CH2)2CH3 -(CH2)3CH3 H H -OH H F H 159 -(CH2)2CH3-CH2-HC=CH2H H -OH H F H 160 -CH(CH3)2 -CH(CH3)2 H H -OH H F H 161 -CH(CH3)2 -(CH2)3CH3 H H -OH H F H 162 -CH(CH3)2-CH2-HC=CH2H H -OH H F H 163 -(CH2)3CH3 -(CH2)3CH3 H H -OH H F H 164 -(CH2)3CH3 -CH2-HC=CH2 H H -OH H F H 165 -CH2-HC=CH2-CH2-HC=CH2H H -OH H F H 166 -CH3 -CH3 H H -OC(O)CH3 H H -CH2CH3 167 -CH3-CH2CH3H H -OC(O)CH3H H -CH2CH3168 -CH3-(CH2)2CH3H H -OC(O)CH3H H -CH2CH393 01312-0021-00PCT 169 -CH3-CH(CH3)2H H -OC(O)CH3H H -CH2CH370 -CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH2CH3 71 -CH3-CH2-HC=CH2H H -OC(O)CH3H H -CH2CH3172 -CH2CH3 -CH2CH3 H H -OC(O)CH3 H H -CH2CH3 173 -CH2CH3 -(CH2)2CH3 H H -OC(O)CH3 H H -CH2CH3 174 -CH2CH3-CH(CH3)2H H -OC(O)CH3H H -CH2CH3175 -CH2CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH2CH3 176 -CH2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH2CH3 177 -(CH2)2CH3-(CH2)2CH3H H -OC(O)CH3H H -CH2CH3178 -(CH2)2CH3 -CH(CH3)2 H H -OC(O)CH3 H H -CH2CH3 179 -(CH2)2CH3-(CH2)3CH3H H -OC(O)CH3H H -CH2CH3180 -(CH2)2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH2CH3 181 -CH(CH3)2 -CH(CH3)2 H H -OC(O)CH3 H H -CH2CH3 182 -CH(CH3)2-(CH2)3CH3H H -OC(O)CH3H H -CH2CH3183 -CH(CH3)2 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH2CH3 184 -(CH2)3CH3 -(CH2)3CH3 H H -OC(O)CH3 H H -CH2CH3 185 -(CH2)3CH3-CH2-HC=CH2H H -OC(O)CH3H H -CH2CH3186 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H H -CH2CH3 187 -CH3-CH3H H -OC(O)CH3H F H 188 -CH3-CH2CH3H H -OC(O)CH3H F H 189 -CH3 -(CH2)2CH3 H H -OC(O)CH3 H F H 190 -CH3-CH(CH3)2H H -OC(O)CH3H F H 191 -CH3 -(CH2)3CH3 H H -OC(O)CH3 H F H 192 -CH3 -CH2-HC=CH2 H H -OC(O)CH3 H F H 193 -CH2CH3-CH2CH3H H -OC(O)CH3H F H 194 -CH2CH3 -(CH2)2CH3 H H -OC(O)CH3 H F H 195 -CH2CH3 -CH(CH3)2 H H -OC(O)CH3 H F H 196 -CH2CH3-(CH2)3CH3H H -OC(O)CH3H F H 197 -CH2CH3 -CH2-HC=CH2 H H -OC(O)CH3 H F H 198 -(CH2)2CH3-(CH2)2CH3H H -OC(O)CH3H F H 199 -(CH2)2CH3 -CH(CH3)2 H H -OC(O)CH3 H F H 200 -(CH2)2CH3 -(CH2)3CH3 H H -OC(O)CH3 H F H 201 -(CH2)2CH3-CH2-HC=CH2H H -OC(O)CH3H F H 202 -CH(CH3)2 -CH(CH3)2 H H -OC(O)CH3 H F H 203 -CH(CH3)2 -(CH2)3CH3 H H -OC(O)CH3 H F H 204 -CH(CH3)2-CH2-HC=CH2H H -OC(O)CH3H F H 205 -(CH2)3CH3 -(CH2)3CH3 H H -OC(O)CH3 H F H 206 -(CH2)3CH3-CH2-HC=CH2H H -OC(O)CH3H F H 207 -CH2-HC=CH2 -CH2-HC=CH2 H H -OC(O)CH3 H F H 207b -CH3 -CH3 H H H -OCH3 H -CH2CH3 208 -CH3-CH2CH3H H H -OCH3H -CH2CH3209 -CH3 -(CH2)2CH3 H H H -OCH3 H -CH2CH3 210 -CH3 -CH(CH3)2 H H H -OCH3 H -CH2CH3 211 -CH3-(CH2)3CH3H H H -OCH3H -CH2CH3212 -CH3 -CH2-HC=CH2 H H H -OCH3 H -CH2CH3 213 -CH2CH3-CH2CH3H H H -OCH3H -CH2CH3214 -CH2CH3 -(CH2)2CH3 H H H -OCH3 H -CH2CH3 215 -CH2CH3 -CH(CH3)2 H H H -OCH3 H -CH2CH3 216 -CH2CH3-(CH2)3CH3H H H -OCH3H -CH2CH3217 -CH2CH3 -CH2-HC=CH2 H H H -OCH3 H -CH2CH3 218 -(CH2)2CH3 -(CH2)2CH3 H H H -OCH3 H -CH2CH3 219 -(CH2)2CH3-CH(CH3)2H H H -OCH3H -CH2CH3220 -(CH2)2CH3 -(CH2)3CH3 H H H -OCH3 H -CH2CH3 221 -(CH2)2CH3-CH2-HC=CH2H H H -OCH3H -CH2CH3222 -CH(CH3)2-CH(CH3)2H H H -OCH3H -CH2CH394 01312-0021-00PCT 223 -CH(CH3)2-(CH2)3CH3H H H -OCH3H -CH2CH324 -CH(CH3)2 -CH2-HC=CH2 H H H -OCH3 H -CH2CH3 25 -(CH2)3CH3-(CH2)3CH3H H H -OCH3H -CH2CH3226 -(CH2)3CH3 -CH2-HC=CH2 H H H -OCH3 H -CH2CH3 227 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OCH3 H -CH2CH3 228 -CH3-CH3H H H -OCH3F H 229 -CH3 -CH2CH3 H H H -OCH3 F H 230 -CH3 -(CH2)2CH3 H H H -OCH3 F H 231 -CH3-CH(CH3)2H H H -OCH3F H 232 -CH3 -(CH2)3CH3 H H H -OCH3 F H 233 -CH3-CH2-HC=CH2H H H -OCH3F H 234 -CH2CH3 -CH2CH3 H H H -OCH3 F H 235 -CH2CH3 -(CH2)2CH3 H H H -OCH3 F H 236 -CH2CH3-CH(CH3)2H H H -OCH3F H 237 -CH2CH3 -(CH2)3CH3 H H H -OCH3 F H 238 -CH2CH3 -CH2-HC=CH2 H H H -OCH3 F H 239 -(CH2)2CH3-(CH2)2CH3H H H -OCH3F H 240 -(CH2)2CH3 -CH(CH3)2 H H H -OCH3 F H 241 -(CH2)2CH3-(CH2)3CH3H H H -OCH3F H 242 -(CH2)2CH3-CH2-HC=CH2H H H -OCH3F H 243 -CH(CH3)2 -CH(CH3)2 H H H -OCH3 F H 244 -CH(CH3)2-(CH2)3CH3H H H -OCH3F H 245 -CH(CH3)2 -CH2-HC=CH2 H H H -OCH3 F H 246 -(CH2)3CH3 -(CH2)3CH3 H H H -OCH3 F H 247 -(CH2)3CH3-CH2-HC=CH2H H H -OCH3F H 248 -CH2-HC=CH2 -CH2-HC=CH2 H H H -OCH3 F H 249 H -CH3 H H H H H -CH2CH3 250 H -CH2CH3H H H H H -CH2CH3251 H -(CH2)2CH3 H H H H H -CH2CH3 252 H -CH(CH3)2H H H H H -CH2CH3253 H -(CH2)3CH3 H H H H H -CH2CH3 254 H -CH2-HC=CH2 H H H H H -CH2CH3 255 H -CH3H H -OH H H H 256 H -CH2CH3 H H -OH H H H 257 H -(CH2)2CH3 H H -OH H H H 258 H -CH(CH3)2H H -OH H H H 259 H -(CH2)3CH3 H H -OH H H H 260 H -CH2-HC=CH2H H -OH H H H 261 H -CH3 H H -OH H H -CH2CH3 262 H -CH2CH3 H H -OH H H -CH2CH3 263 H -(CH2)2CH3H H -OH H H -CH2CH3264 H -CH(CH3)2 H H -OH H H -CH2CH3 265 H -(CH2)3CH3 H H -OH H H -CH2CH3 266 H -CH2-HC=CH2H H -OH H H -CH2CH3267 H -CH3 H H -OH H F H 268 H -CH2CH3H H -OH H F H 269 H -(CH2)2CH3 H H -OH H F H 270 H -CH(CH3)2 H H -OH H F H 271 H -(CH2)3CH3H H -OH H F H 272 H -CH2-HC=CH2 H H -OH H F H 273 H -CH3 H H H -OCH3 F H 274 H -CH2CH3H H H -OCH3F H 275 H -(CH2)2CH3 H H H -OCH3 F H 276 H -CH(CH3)2H H H -OCH3F H 277 H -(CH2)3CH3H H H -OCH3F H 95 01312-0021-00PCT 278 H -CH2-HC=CH2H H H -OCH3F H 79 H -CH3 H H -OC(O)CH3 H H H 80 H -CH2CH3H H -OC(O)CH3H H H 281 H -(CH2)2CH3 H H -OC(O)CH3 H H H 282 H -CH(CH3)2 H H -OC(O)CH3 H H H 283 H -(CH2)3CH3H H -OC(O)CH3H H H 284 H -CH2-HC=CH2 H H -OC(O)CH3 H H H 285 H -CH3 H H H H F H 286 H -CH2CH3H H H H F H 287 H -(CH2)2CH3 H H H H F H 288 H -CH(CH3)2H H H H F H 289 H -(CH2)3CH3 H H H H F H 290 H -CH2-HC=CH2 H H H H F H 291 H -CH3H H H -OCH3H H 292 H -CH2CH3 H H H -OCH3 H H 293 H -(CH2)2CH3 H H H -OCH3 H H 294 H -CH(CH3)2H H H -OCH3H H 295 H -(CH2)3CH3 H H H -OCH3 H H 296 H -CH2-HC=CH2H H H -OCH3H H 297 cyclopropyl -CH3H H H H H H 298 cyclopropyl -CH2CH3 H H H H H H 299 cyclopropyl -(CH2)2CH3H H H H H H 300 cyclopropyl -CH(CH3)2 H H H H H H 301 cyclopropyl -(CH2)3CH3 H H H H H H 302 cyclopropyl -CH2-HC=CH2H H H H H H 303 cyclopropyl -CH3 H H -OCH3 H H H 304 cyclopropyl -CH2CH3 H H -OCH3 H H H 305 cyclopropyl -(CH2)2CH3H H -OCH3H H H 306 cyclopropyl -CH(CH3)2 H H -OCH3 H H H 307 cyclopropyl -(CH2)3CH3H H -OCH3H H H 308 cyclopropyl -CH2-HC=CH2 H H -OCH3 H H H 309 cyclopropyl -CH3 H H -OH H H H 310 cyclopropyl -CH2CH3H H -OH H H H 311 cyclopropyl -(CH2)2CH3 H H -OH H H H 312 cyclopropyl -CH(CH3)2 H H -OH H H H 313 cyclopropyl -(CH2)3CH3H H -OH H H H 314 cyclopropyl -CH2-HC=CH2 H H -OH H H H 315 cyclopropyl -CH3H H -OC(O)CH3H H H 316 cyclopropyl -CH2CH3 H H -OC(O)CH3 H H H 317 cyclopropyl -(CH2)2CH3 H H -OC(O)CH3 H H H 318 cyclopropyl -CH(CH3)2H H -OC(O)CH3H H H 319 cyclopropyl -(CH2)3CH3 H H -OC(O)CH3 H H H 320 cyclopropyl -CH2-HC=CH2 H H -OC(O)CH3 H H H 321 cyclopropyl -CH3H H H H H -CH2CH3322 cyclopropyl -CH2CH3 H H H H H -CH2CH3 323 cyclopropyl -(CH2)2CH3H H H H H -CH2CH3324 cyclopropyl -CH(CH3)2 H H H H H -CH2CH3 325 cyclopropyl -(CH2)3CH3 H H H H H -CH2CH3 326 cyclopropyl -CH2-HC=CH2H H H H H -CH2CH3327 cyclopropyl -CH3 H H -OH H H -CH2CH3 328 cyclopropyl -CH2CH3 H H -OH H H -CH2CH3 329 cyclopropyl -(CH2)2CH3H H -OH H H -CH2CH3330 cyclopropyl -CH(CH3)2 H H -OH H H -CH2CH3 331 cyclopropyl -(CH2)3CH3H H -OH H H -CH2CH3332 cyclopropyl -CH2-HC=CH2H H -OH H H -CH2CH396 01312-0021-00PCT 333 H -CH3H H H H H H 34 H -CH2CH3 H H H H H H 35 H -(CH2)2CH3H H H H H H 336 H -CH(CH3)2 H H H H H H 337 H -(CH2)3CH3 H H H H H H 338 H -CH2-HC=CH2H H H H H H 339 H cyclopropyl H H H H H H 340 H -CH3 H -CH3 H H H H 341 H -CH2CH3H -CH3H H H H 342 H -(CH2)2CH3 H -CH3 H H H H 343 H -CH(CH3)2H -CH3H H H H 344 H -(CH2)3CH3 H -CH3 H H H H 345 H -CH2-HC=CH2 H -CH3 H H H H 346 H cyclopropyl H -CH3H H H H 347 H -CH3 H -CH3 -OH H H H 348 H -CH2CH3 H -CH3 -OH H H H 349 H -(CH2)2CH3H -CH3-OH H H H 350 H -CH(CH3)2 H -CH3 -OH H H H 351 H -(CH2)3CH3H -CH3-OH H H H 352 H -CH2-HC=CH2H -CH3-OH H H H 353 H cyclopropyl H -CH3 -OH H H H 354 H -CH3H -CH3H H H -CH2CH3355 H -CH2CH3 H -CH3 H H H -CH2CH3 356 H -(CH2)2CH3 H -CH3 H H H -CH2CH3 357 H -CH(CH3)2H -CH3H H H -CH2CH3358 H -(CH2)3CH3 H -CH3 H H H -CH2CH3 359 H -CH2-HC=CH2 H -CH3 H H H -CH2CH3 360 H cyclopropyl H -CH3H H H -CH2CH3361 H -CH3 H -CH3 -OH H H -CH2CH3 362 H -CH2CH3H -CH3-OH H H -CH2CH3363 H -(CH2)2CH3 H -CH3 -OH H H -CH2CH3 364 H -CH(CH3)2 H -CH3 -OH H H -CH2CH3 365 H -(CH2)3CH3H -CH3-OH H H -CH2CH3366 H -CH2-HC=CH2 H -CH3 -OH H H -CH2CH3 367 H cyclopropyl H -CH3 -OH H H -CH2CH3 368 H -CH3H -CH3H H F H 369 H -CH2CH3 H -CH3 H H F H 370 H -(CH2)2CH3H -CH3H H F H 371 H -CH(CH3)2 H -CH3 H H F H 372 H -(CH2)3CH3 H -CH3 H H F H 373 H -CH2-HC=CH2H -CH3H H F H 374 H cyclopropyl H -CH3 H H F H 375 H -CH3 H -CH3 H -OCH3 H H 376 H -CH2CH3H -CH3H -OCH3H H 377 H -(CH2)2CH3 H -CH3 H -OCH3 H H 378 H -CH(CH3)2H -CH3H -OCH3H H 379 H -(CH2)3CH3 H -CH3 H -OCH3 H H 380 H -CH2-HC=CH2 H -CH3 H -OCH3 H H 381 H cyclopropyl H -CH3H -OCH3H H 382 H -CH3 H -CH3 -OH H F H 383 H -CH2CH3 H -CH3 -OH H F H 384 H -(CH2)2CH3H -CH3-OH H F H 385 H -CH(CH3)2 H -CH3 -OH H F H 386 H -(CH2)3CH3H -CH3-OH H F H 387 H -CH2-HC=CH2H -CH3-OH H F H 97 01312-0021-00PCT 388 H cyclopropyl H -CH3-OH H F H 89 H -CH3 H -CH3 -OC(O)CH3 H H H 90 H -CH2CH3H -CH3-OC(O)CH3H H H 391 H -(CH2)2CH3 H -CH3 -OC(O)CH3 H H H 392 H -CH(CH3)2 H -CH3 -OC(O)CH3 H H H 393 H -(CH2)3CH3H -CH3-OC(O)CH3H H H 394 H -CH2-HC=CH2 H -CH3 -OC(O)CH3 H H H 395 H cyclopropyl H -CH3 -OC(O)CH3 H H H 396 H H H -CH3H H H H 397 H H H -CH3 -OH H H H 398 H H H -CH3H -OCH3H H 399 H H H -CH3 H H F H 400 H H H -CH3 H H H -CH2CH3 401 H H H -CH3-OH H H -CH2CH3402 H H H -CH3 -OH H F H 403 H H H -CH3 -OH -OCH3 F H 404 H H H -CH3-OH F H H 405 H H H -CH3 -OH H H -CH3 406 -CH3-CH3H H H H H H 407 -CH3-CH2CH3H H H H H H 408 -CH3 -(CH2)2CH3 H H H H H H 409 -CH3-CH(CH3)2H H H H H H 410 -CH3 -(CH2)3CH3 H H H H H H 411 -CH3 -CH2-HC=CH2 H H H H H H 412 -CH2CH3-CH2CH3H H H H H H 413 -CH2CH3 -(CH2)2CH3 H H H H H H 414 -CH2CH3 -CH(CH3)2 H H H H H H 415 -CH2CH3-(CH2)3CH3H H H H H H 416 -CH2CH3 -CH2-HC=CH2 H H H H H H 417 -(CH2)2CH3-(CH2)2CH3H H H H H H 418 -(CH2)2CH3 -CH(CH3)2 H H H H H H 419 -(CH2)2CH3 -(CH2)3CH3 H H H H H H 420 -(CH2)2CH3-CH2-HC=CH2H H H H H H 421 -CH(CH3)2 -CH(CH3)2 H H H H H H 422 -CH(CH3)2 -(CH2)3CH3 H H H H H H 423 -CH(CH3)2-CH2-HC=CH2H H H H H H 424 -(CH2)3CH3 -(CH2)3CH3 H H H H H H 425 -(CH2)3CH3-CH2-HC=CH2H H H H H H 426 -CH2-HC=CH2 -CH2-HC=CH2 H H H H H H 427 -CH3 -CH3 H H H H -OMe H 428 -CH3-CH2CH3H H H H -OMe H 429 -CH3 -(CH2)2CH3 H H H H -OMe H 430 -CH3 -CH(CH3)2 H H H H -OMe H 431 -CH3-(CH2)3CH3H H H H -OMe H 432 -CH3 -CH2-HC=CH2 H H H H -OMe H 433 -CH2CH3-CH2CH3H H H H -OMe H 434 -CH2CH3 -(CH2)2CH3 H H H H -OMe H 435 -CH2CH3 -CH(CH3)2 H H H H -OMe H 436 -CH2CH3-(CH2)3CH3H H H H -OMe H 437 -CH2CH3 -CH2-HC=CH2 H H H H -OMe H 438 -(CH2)2CH3 -(CH2)2CH3 H H H H -OMe H 439 -(CH2)2CH3-CH(CH3)2H H H H -OMe H 440 -(CH2)2CH3 -(CH2)3CH3 H H H H -OMe H 441 -(CH2)2CH3-CH2-HC=CH2H H H H -OMe H 442 -CH(CH3)2-CH(CH3)2H H H H -OMe H 98 01312-0021-00PCT 443 -CH(CH3)2-(CH2)3CH3H H H H -OMe H 44 -CH(CH3)2 -CH2-HC=CH2 H H H H -OMe H 45 -(CH2)3CH3-(CH2)3CH3H H H H -OMe H 446 -(CH2)3CH3 -CH2-HC=CH2 H H H H -OMe H 447 -CH2-HC=CH2 -CH2-HC=CH2 H H H H -OMe H 448 -CH3-CH3H H H H -OMe -CH2CH3449 -CH3 -CH2CH3 H H H H -OMe -CH2CH3 450 -CH3 -(CH2)2CH3 H H H H -OMe -CH2CH3 451 -CH3-CH(CH3)2H H H H -OMe -CH2CH3452 -CH3 -(CH2)3CH3 H H H H -OMe -CH2CH3 453 -CH3-CH2-HC=CH2H H H H -OMe -CH2CH3454 -CH2CH3 -CH2CH3 H H H H -OMe -CH2CH3 455 -CH2CH3 -(CH2)2CH3 H H H H -OMe -CH2CH3 456 -CH2CH3-CH(CH3)2H H H H -OMe -CH2CH3457 -CH2CH3 -(CH2)3CH3 H H H H -OMe -CH2CH3 458 -CH2CH3 -CH2-HC=CH2 H H H H -OMe -CH2CH3 459 -(CH2)2CH3-(CH2)2CH3H H H H -OMe -CH2CH3460 -(CH2)2CH3 -CH(CH3)2 H H H H -OMe -CH2CH3 461 -(CH2)2CH3-(CH2)3CH3H H H H -OMe -CH2CH3462 -(CH2)2CH3-CH2-HC=CH2H H H H -OMe -CH2CH3463 -CH(CH3)2 -CH(CH3)2 H H H H -OMe -CH2CH3 464 -CH(CH3)2-(CH2)3CH3H H H H -OMe -CH2CH3465 -CH(CH3)2 -CH2-HC=CH2 H H H H -OMe -CH2CH3 466 -(CH2)3CH3 -(CH2)3CH3 H H H H -OMe -CH2CH3 467 -(CH2)3CH3-CH2-HC=CH2H H H H -OMe -CH2CH3468 -CH2-HC=CH2 -CH2-HC=CH2 H H H H -OMe -CH2CH3 469 -CH3 cyclopropyl H H H H -OMe H 470 -CH2CH3cyclopropyl H H H H -OMe H 471 -(CH2)2CH3 cyclopropyl H H H H -OMe H 472 -CH(CH3)2cyclopropyl H H H H -OMe H 473 -(CH2)3CH3 cyclopropyl H H H H -OMe H 474 -CH2-HC=CH2 cyclopropyl H H H H -OMe H 475 cyclopropyl cyclopropyl H H H H -OMe H 476 -CH3 cyclopropyl H H H H -OMe -CH2CH3 477 -CH2CH3 cyclopropyl H H H H -OMe -CH2CH3 478 -(CH2)2CH3cyclopropyl H H H H -OMe -CH2CH3479 -CH(CH3)2 cyclopropyl H H H H -OMe -CH2CH3 480 -(CH2)3CH3cyclopropyl H H H H -OMe -CH2CH3481 -CH2-HC=CH2 cyclopropyl H H H H -OMe -CH2CH3 482 cyclopropyl cyclopropyl H H H H -OMe -CH2CH3 483 H -CH3H H H H -OMe H 484 H -CH2CH3 H H H H -OMe H 485 H -(CH2)2CH3 H H H H -OMe H 486 H -CH(CH3)2H H H H -OMe H 487 H -(CH2)3CH3 H H H H -OMe H 488 H -CH2-HC=CH2H H H H -OMe H 489 H cyclopropyl H H H H -OMe H 490 H -CH3 H H H H -OMe -CH2CH3 491 H -CH2CH3H H H H -OMe -CH2CH3492 H -(CH2)2CH3 H H H H -OMe -CH2CH3 493 H -CH(CH3)2 H H H H -OMe -CH2CH3 494 H -(CH2)3CH3H H H H -OMe -CH2CH3495 H -CH2-HC=CH2 H H H H -OMe -CH2CH3 496 H cyclopropyl H H H H -OMe -CH2CH3497 H -CD3H H H H H H 99 01312-0021-00PCT 498 H -CD3H H -OH H H H 99 H -CD3 H H -OC(O)CH3 H H H 00 H -CD3H H H -OCH3H H 501 H -CD3 H H H H H H 502 H -CD3 H H -OH H H H 503 H -CD3H H -OC(O)CH3H H H 504 H -CD3 H H H -OCH3 H H 505 H -CD3 H H H H F H 506 H -CD3H H -OH H F H 507 H -CD3 H H -OC(O)CH3 H F H 508 H -CD3H H H -OCH3F H 509 H -CD3 H H H H H -CH2CH3 510 H -CD3 H H -OH H H -CH2CH3 511 H -CD3H H -OC(O)CH3H H -CH2CH3512 H -CD3 H H H -OCH3 H -CH2CH3 513 H -CD2CD3 H H H H H H 514 H -CD2CD3H H -OH H H H 515 H -CD2CD3 H H -OC(O)CH3 H H H 516 H -CD2CD3H H H -OCH3H H 517 H -CD2CD3H H H H H H 518 H -CD2CD3 H H -OH H H H 519 H -CD2CD3H H -OC(O)CH3H H H 520 H -CD2CD3 H H H -OCH3 H H 521 H -CD2CD3 H H H H F H 522 H -CD2CD3H H -OH H F H 523 H -CD2CD3 H H -OC(O)CH3 H F H 524 H -CD2CD3 H H H -OCH3 F H 525 H -CD2CD3H H H H H -CH2CH3526 H -CD2CD3 H H -OH H H -CH2CH3 527 H -CD2CD3H H -OC(O)CH3H H -CH2CH3528 H -CD2CD3 H H H -OCH3 H -CH2CH3 529 H -CH3 H D H H H H 530 H -CH2CH3H D H H H H 531 H -(CH2)2CH3 H D H H H H 532 H -CH(CH3)2 H D H H H H 533 H -(CH2)3CH3H D H H H H 534 H -CH2-HC=CH2 H D H H H H 535 H -CH3H D -OH H H H 536 H -CH2CH3 H D -OH H H H 537 H -(CH2)2CH3 H D -OH H H H 538 H -CH(CH3)2H D -OH H H H 539 H -(CH2)3CH3 H D -OH H H H 540 H -CH2-HC=CH2 H D -OH H H H 541 H -CH3H D -OH H F H 542 H -CH2CH3 H D -OH H F H 543 H -(CH2)2CH3H D -OH H F H 544 H -CH(CH3)2 H D -OH H F H 545 H -(CH2)3CH3 H D -OH H F H 546 H -CH2-HC=CH2H D -OH H F H 547 H -CH3 H D H -OMe F H 548 H -CH2CH3 H D H -OMe F H 549 H -(CH2)2CH3H D H -OMe F H 550 H -CH(CH3)2 H D H -OMe F H 551 H -(CH2)3CH3H D H -OMe F H 552 H -CH2-HC=CH2H D H -OMe F H 100 01312-0021-00PCT 553 H -CH3H D H -OMe H H 54 H -CH2CH3 H D H -OMe H H 55 H -(CH2)2CH3H D H -OMe H H 556 H -CH(CH3)2 H D H -OMe H H 557 H -(CH2)3CH3 H D H -OMe H H 558 H -CH2-HC=CH2H D H -OMe H H 559 H -CH3 H D -OC(O)CH3 H H H 560 H -CH2CH3 H D -OC(O)CH3 H H H 561 H -(CH2)2CH3H D -OC(O)CH3H H H 562 H -CH(CH3)2 H D -OC(O)CH3 H H H 563 H -(CH2)3CH3H D -OC(O)CH3H H H 564 H -CH2-HC=CH2 H D -OC(O)CH3 H H H 565 H -CH3 H D -OC(O)CH3 H F H 566 H -CH2CH3H D -OC(O)CH3H F H 567 H -(CH2)2CH3 H D -OC(O)CH3 H F H 568 H -CH(CH3)2 H D -OC(O)CH3 H F H 569 H -(CH2)3CH3H D -OC(O)CH3H F H 570 H -CH2-HC=CH2 H D -OC(O)CH3 H F H COMPOSITIONS AND METHODS As used herein, the term “5-HT1A” refers to a 5-HT1A receptor. As used herein, the term “5-HT2A” refers to a 5-HT2A receptor. As used herein, the term “effective amount” in connection with a compound disclosed herein means an amount capable of treating or preventing a disorder, disease or condition, or symptoms thereof, disclosed herein. As used herein, the term “hallucination” (and related terms such as “hallucinogenic” and “hallucinogen”) refers to a perception in the absence of external stimulus that has qualities of real perception. In some embodiments, hallucinations may be vivid, substantial, and are perceived to be located in external objective space. As used herein, hallucinations may occur in any sensory modality including, but not limited to visual, auditory, olfactory, gustatory, tactile, proprioceptive, equilibrioceptive, nociceptive, thermoceptive and chronoceptive. In some embodiments, the hallucinations are selected from visual hallucinations, auditory hallucinations, olfactory hallucinations, gustatory hallucinations, tactile hallucinations, proprioceptive hallucinations, equilibrioceptive hallucinations, nociceptive hallucinations, thermoceptive hallucinations, chronoceptive hallucinations and any combination thereof. In some embodiments, hallucinations are visual hallucinations. As used herein, the terms “prevent” or “preventing” refers to means a method of delaying and / or precluding the onset, recurrence or spread, in whole or in part, of a disorder, disease or condition; barring a subject from acquiring a disorder, disease, or condition; or reducing a subject’s risk of acquiring a disorder, disease, or condition. 101 01312-0021-00PCT As used herein, the term “treat” or “treating” refers to an alleviation, in whole or in part, of a disorder, disease or condition, or one or more of the symptoms associated with a disorder, disease, or condition, or slowing or halting of further progression or worsening of those symptoms, or alleviating or eradicating the cause(s) of the disorder, disease, or condition itself. In further embodiments of the present disclosure, described are methods of administering the compounds and compositions provided herein. In some embodiments, a compound or composition provided herein is for use in the methods provided herein. In some embodiments, the disclosure provides the use of a compound provided herein in the preparation of a medicament for treating one or more of the diseases or disorders provided herein. In certain embodiments, the method comprises administering a serotonin 5-HT1A agonist and a serotonin 5-HT2A agonist. Without being bound to any particular theory, in certain embodiments it has been surprisingly discovered that administering a serotonin 5-HT1A agonist and a serotonin 5-HT2A agonist can be effective in preventing or treating one or more of the conditions described herein. In certain embodiments, it has also been surprisingly discovered that administering a serotonin 5-HT1A agonist and a hallucinogenic 5-HT2A agonist can effectively treat patients without the patients experiencing the hallucinogenic effects of the 5-HT2A agonist. Without intending to be bound by any particular theory, it is believed that the patient can experience a therapeutic effect without experiencing a hallucinogenic manifestation that typically results from the administration of a 5-HT2A agonist because the 5-HT1A agonist can “turn off” the hallucinogenic effects of the of the 5-HT2A agonist without otherwise significantly altering its agonism at a 5-HT2A receptor. In some embodiments, the 5-HT1A agonist is a partial agonist. In some embodiments, the 5-HT1A agonist is a full agonist. In some embodiments, the 5-HT2A agonist is a partial agonist. In some embodiments, the 5- HT2A agonist is a full agonist. In some embodiments, the 5-HT1A and / or 5-HT2A agonists may be selected from compounds of Formula I herein. In some embodiments, the 5-HT1A and the 5-HT2A agonists are the same compound (e.g., a compound of Formula I). As defined herein, a “full agonist” shall mean an agonist having an Emax% of at least 90% for the relevant serotonin receptor agonist assay (e.g., BRET2, calcium mobilization, beta- arrestin) when compared to an industry-accepted control compound for that particular receptor assay (e.g., serotonin (5-OH-tryptamine)). In some embodiments, a “full agonist” will exhibit an Emax% of at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, or at least 99%. Also defined herein, a “partial agonist” shall mean an agonist having an Emax% of less than 90% for the relevant serotonin receptor when compared to an industry-accepted control compound for that particular receptor (e.g., serotonin (5-OH- tryptamine)). In some embodiments, a “partial agonist” will exhibit an Emax% of less than 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, or even less than 5%. In some 102 01312-0021-00PCT embodiments, a partial agonist will exhibit an Emax% of about 0.1 to about 89.9%, such as about 1 to about 89, about 5 to about 85, about 50 to about 88, about 40 to about 85, about 35 to about 75, about 25 to about 65, or about 20 to about 55%. In some embodiment, the 5-HT1A agonist as used herein is selected from buspirone (8- [4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8 -azaspiro[4.5]decane-7,9-dione), 5-OH-buspirone, 6- OH-buspirone, tandospirone ((1R,2R,6S,7S)-4-{4-[4-(pyrimidin -2-yl)piperazin-1-yl]butyl}-4- azatricyclo[5.2.1.02,6]decane-3,5-dione), gepirone (4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin- 1-yl)butyl]piperid- ine-2,6-dione), alnespirone ((+)-4-dihydro-2H-chromen-3-yl]- propylamino]butyl]-8-azaspiro[4.5]decane-- 7,9-dione), binospirone (8-[2-(2,3-dihydro-1,4- benzodioxin-2-ylmethylamino)ethyl]-8-azaspiro[4.5]-decane-7,9-dione), ipsapirone (9,9-dioxo-8- [4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-9.lamda.6-thia-8-azabicyclo[4.3.0]nona-1,3,5-trien-7- one), perospirone (3aR, 7aS) -2-{4-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]butyl} hexahydro- 1H-isoindole-1,3(2H)-dione, befiradol (F-13,640) (3-chloro-4-fluorophenyl-[4-fluoro-4-([(5- methylpyridin-2 -yl)methylamino]methyl)piperidin-1-yl]methanone, repinotan ((R)-(-)-2-[4- [(chroman-2 -ylmethyl)-amino]-butyl]-1,1-dioxo-benzo[d] isothiazolone), piclozotan (3-chloro-4- [4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]-1,4- -benzoxazepin-5(4H)-one), osemozotan (5-(3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy)-1,3-benzodioxole), flesinoxan (4-fluoro-N-[2-[4-[(3S)-3-(hydroxymethyl)-2,3-dihydro-1,4 -benzodioxin-8-yl]piperazin- 1-yl]ethyl]benzamide), flibanserin (1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3- dihydro-2H-- benzimidazol-2-one), 8-OH-DPAT (7-(Dipropylamino)-5,6,7,8- tetrahydronaphthalen-1-ol), and sarizotan (EMD-128,130) (1-[(2R)-3,4-dihydro-2H-chromen-2- yl]-N-([5-(4 -fluorophenyl)pyridin-3-yl]methyl)methanamine), a compound of Formula I, or a prodrug, salt, or derivative thereof. In some embodiments, the serotonin 5-HT1A agonist and 5-HT2A agonist are administered at the same time. In some embodiments, the serotonin 5-HT1A agonist and 5- HT2A agonist are administered at different times. In some embodiments, the serotonin 5-HT1A agonist and 5-HT2A agonist are administered sequentially. In some embodiments, the serotonin 5-HT1A agonist is administered first, and 5-HT2A agonist is administered second. In some embodiments, the serotonin 5-HT2A agonist is administered about 30 minutes to about 12hrs after administration of 5-HT1A agonist, such as about 1hr to about 6hrs afterwards. In some embodiments, the serotonin 5-HT1A agonist and 5-HT2A agonist are administered at the same time in the same composition. In some embodiments, 5-HT1A agonist is selected from buspirone, 5-OH-buspirone, 6-OH-buspirone, and 8-OH-DPAT. In some embodiments, the 5- HT1A agonist is buspirone. In some embodiments, the 5-HT1A agonist is selected from compounds of Formula I, such as for example compounds of Formula II. In some embodiments, the 5-HT2A agonist is hallucinogenic. In some embodiments, the 5-HT2A agonist is non-hallucinogenic. In some embodiments, the 5-HT2A agonist is selected from 103 01312-0021-00PCT compounds of Formula I, such as for example compounds of Formula II. In some embodiments, the 5-HT2A agonist and the 5-HT1A agonist may comprise the same compound. In some embodiments, the compounds of Formula I described herein (e.g., compounds of Formula II) can act as both 5-HT1A and 5-HT2A receptor agonists. In some embodiments, the compounds described herein are full agonists for both 5-HT1A and 5-HT2A. In some embodiments, the 5-HT1A agonist and 5-HT2A agonist are full agonists for a 5- HT1A receptor and a 5-HT2A receptor, respectively. In some embodiments, the 5-HT1A agonist exhibits a higher level of molar potency (i.e., lower EC50) for activating a 5-HT1A receptor than the 5-HT2A agonist exhibits for activating the 5-HT2A receptor. Without being bound to any particular scientific theory, in certain embodiments it has been surprisingly discovered that compounds that are agonists for 5-HT1A and 5-HT2A – but which exhibit a higher molar potency for 5-HT1A – may be useful to patients needing / desiring non-hallucinogenic 5-HT2A modulation. In other embodiments, the 5-HT1A agonist is a partial agonist (e.g., buspirone) and 5-HT2A agonist is a full agonist for a 5-HT1A receptor and a 5-HT2A receptors, respectively. In other embodiments, the 5-HT1A agonist is a partial agonist (e.g., buspirone) and 5-HT2A agonist is a partial agonist for a 5-HT1A receptor and a 5-HT2A receptors, respectively. In certain embodiments are described methods for treating, preventing, ameliorating, or curing a disease or disorder via a non-hallucinogenic therapeutic treatment regimen that includes modulation of a 5-HT1A receptor. In certain embodiments, the method comprises identifying a subject in need of treatment for a disease or condition associated with modulation of a 5-HT1A receptor; selecting a compound of Formula I (e.g., Formula II); and administering the compound to the subject in need of treatment, wherein the compound modulates activity at both a 5-HT1A and 5-HT2A receptor. In certain embodiments, the compound of Formula I is a full agonist of a 5-HT1A receptor. In certain embodiments, the compound of Formula I is a full agonist for both 5-HT1A and 5-HT2A receptors. In certain embodiments, the compound of Formula I is a partial agonist for a 5-HT1A receptor and a full agonist for a 5-HT2A receptor. In certain embodiments, the compound of Formula I is a partial agonist for a 5-HT1A receptor and a partial agonist for a 5-HT2A receptor. In certain embodiments, the compound of Formula I, exhibits a higher molar potency (lower EC50) for a 5-HT1A receptor when compared to a 5- HT2A receptor. In certain embodiments, the 5-HT1A agonist has an EC50 for activating a 5-HT1A receptor of less than about 100nM, such as less than about 75nm, less than about 50nm, less than about 25nm, less than about 15nm, less than about 10nm, or less than about 5nm. In certain embodiments, the 5-HT2A agonist has an has an EC50for activating a 5-HT2A receptor of less than about 100nM, such as less than about 75nm, less than about 50nm, less than about 25nm, less than about 15nm, less than about 10nm, or less than about 5nm. In certain 104 01312-0021-00PCT embodiments, the 5-HT1A agonist has an exhibits an EC50 for activating a 5-HT1A receptor of about 0.01nM to about 100nM, such as about 0.05 to about 50nm, about 0.1 to about 25nM, or about 0.5 to about 10nM. In certain embodiments, the 5-HT2A agonist has an exhibits an EC50 for activating a 5-HT2A receptor of about 0.01nM to about 100nM, such as about 0.05 to about 50nm, about 0.1 to about 25nM, or about 0.5 to about 10nM. In certain embodiments, the 5- HT2A agonist has an exhibits an EC50for activating a 5-HT2A receptor of about 5 to about 75nM, such as about 10 to about 60nm, about 15 to about 50nM, or about 20 to about 40nM. In some embodiments, the 5-HT1A agonist / 5-HT2A agonist exhibit 5-HT1A receptor: 5-HT2A receptor EC50 ratio range of about 1:2 to about 1:100, such as about 1:5 to about 1:50 or about 1:10 to about 1:40. In some embodiments, one or more of the compounds of Formula I independently exhibit a 5-HT1A receptor: 5-HT2A receptor EC50ratio range of about 1:2 to about 1:100, such as about 1:5 to about 1:50 or about 1:10 to about 1:40. Relevant testing parameters to determine full vs. partial agonism (Emax%) and molar potency (EC50) include those known to persons of skill in the art, such as the 5-HT Functional Assays described further below. In some embodiments, also described are novel compounds and compositions, as well as methods of administering the same. In certain embodiments, the method comprises administering a serotonin 5-HT2A agonist and a serotonin 5-HT2B antagonist. Without being bound to any particular theory, in certain embodiments it has been surprisingly discovered that administering a serotonin 5-HT2A agonist and a serotonin 5-HT2B antagonist can be effective in preventing or treating one or more of the conditions described herein. In some embodiments, it has been surprisingly discovered that administering a serotonin 5-HT2A agonist and a serotonin 5-HT2B antagonist can effectively treat patients while also reducing serotonin 5-HT2B-induced cardiotoxicity (e.g., heart valve fibrosis and hypertrophy). In certain embodiments, it has also been surprisingly discovered that administering a serotonin 5-HT2B antagonist and a 5-HT2A agonist can be safely and effectively used treat patients as described herein without the patients experiencing the hallucinogenic effects that can be associated with hallucinogenic 5-HT2A agonists. In some embodiments, the 5-HT2A agonist is a full agonist. In some embodiments, the 5-HT2A agonist is a partial agonist. In some embodiments, the 5-HT2B antagonist is a full antagonist. In some embodiments, the 5-HT2B antagonist is a partial antagonist. Exemplary serotonin 5-HT2B receptor antagonists include, but are not limited to, agomelatine, amisulpride, ariprazole, carprazine, clozapine, cyproheptadine, mCCP, sarpogrelate, lisuride, tegasurod, metadoxine, and promethazine. In certain embodiments, the 5-HT2B antagonist is not an antagonist at any of the other serotonin 5-HT type receptor subtypes, such as 5-HT1A and 5-HT2A. In certain embodiments, the 5-HT2B receptor antagonist will also be a full or partial agonist at a 5-HT1A and / or 5-HT2A receptor. 105 01312-0021-00PCT In some embodiments, the serotonin 5-HT2A agonist and 5-HT2B antagonist are administered at the same time. In some embodiments, the serotonin 5-HT2A agonist and 5- HT2B antagonist are administered at different times. In some embodiments, the serotonin 5- HT2A agonist and 5-HT2B antagonist are administered at the same time in the same composition. In some embodiments, the serotonin 5-HT1A agonist and 5-HT2B antagonist are administered sequentially. In some embodiments, the serotonin 5-HT2B antagonist is administered first, and 5-HT2A agonist is administered second. In some embodiments, the serotonin 5-HT2A agonist is administered about 30 minutes to about 12hrs after administration of 5-HT2B antagonist, such as about 1hr to about 6hrs afterwards. In some embodiments, the 5- HT2A agonist is hallucinogenic. In some embodiments, the 5-HT2A agonist is non- hallucinogenic. In some embodiments, the 5-HT2A agonist is selected from compounds of Formula I, such as for example compounds of Formula II. In some embodiments, also described are novel compounds and compositions, as well as methods of administering the same. In certain embodiments, the method comprises administering a serotonin 5-HT2A antagonist and a serotonin 5-HT2C agonist. Without being bound to any particular theory, in certain embodiments it has been surprisingly discovered that administering a serotonin 5-HT2A antagonist and a serotonin 5-HT2C agonist can be effective in preventing or treating one or more of the conditions described herein, including, e.g., drug addiction (e.g., cocaine or methamphetamine use disorders). In some embodiments, it has been surprisingly discovered that administering a serotonin 5-HT2A antagonist and a serotonin 5-HT2C agonist can effectively treat patients while also reducing serotonin 5-HT2B-induced cardiotoxicity (e.g., heart valve fibrosis and hypertrophy). In certain embodiments, it has also been surprisingly discovered that administering a serotonin 5-HT2A antagonist and a 5-HT2C agonist can be safely and effectively used treat patients as described herein without the patients experiencing the hallucinogenic effects that can be associated with hallucinogenic 5-HT2A agonists. In some embodiments, the 5-HT2A antagonist is a full agonist. In some embodiments, the 5-HT2A antagonist is a partial antagonist. In some embodiments, the 5- HT2C agonist is a full agonist. In some embodiments, the 5-HT2C agonist is a partial agonist. In some embodiments, the 5-HT2A antagonist and the 5-HT2C agonist are different compounds. In some embodiments, the 5-HT2A antagonist and the 5-HT2C agonist are the same compound, i.e., a single “bifunctional” ligand that blocks activity at the 5-HT2A receptor while activating the 5-HT2C receptor. In certain embodiments, the bifunctional compounds is selected from compounds of Formula I. In certain embodiments, the compound of Formula I is also a 5-HT2B receptor antagonist, i.e., a “trifunctional” ligand that blocks activity at the 5-HT2A and 5-HT2B receptors while activating the 5-HT2C receptor. In certain embodiments, the method comprises administering a serotonin 5-HT2A inverse agonist and a serotonin 5-HT2C agonist. Without being bound to any particular theory, 106 01312-0021-00PCT in certain embodiments it has been surprisingly discovered that administering a serotonin 5- HT2A inverse agonist and a serotonin 5-HT2C agonist can be effective in preventing or treating one or more of the conditions described herein, including, e.g., drug addiction (e.g., cocaine or methamphetamine use disorders). Exemplary serotonin 5-HT2A receptor antagonists include, but are not limited to, ketanserin, altanserin, M100,907, pimavanserin, ritanserin, risperidone, pirenperone, sisperone, trazadone, cyclobenzaprine, and brexpiprazole. In certain embodiments for compounds of Formula I, Applicant has discovered that size and nature of alkyl groups for X and / or Y can dramatically affect the metabolism of such compounds. For example, it has been theorized that compounds such as 5-MeO- Dimethyltryptamine (5-MeO-DMT) and Dimethyltryptamine (DMT) are inactive upon oral administration due to rapid metabolism of the methylamino residues by monoamine oxidase (MAO) enzymes. It has also been theorized that the oral stability of psilocin (4-OH- dimethyltryptamine), on the other hand, is due largely to intramolecular coordination (hydrogen bonding) between the 4-OH group and the dimethylamino residue, which effectively shields / inhibits rapid MAO degradation. Without being bound to any particular scientific theory, Applicant has surprisingly found that substituting the alkyl groups X and / or Y with substituents such as deuterium and fluorine can help inhibit MAO degradation of those groups, even in the absence of a hydrogen bond donor (e.g., -OH) at the 4-position (e.g., R4 in Formula I). In addition, or in the alternative, Applicant has discovered that using non-methyl alkyl groups such as ethyl or n-propyl for X and / or Y (or where W3 is –(CH2)n-, a, b and c are each hydrogen, and n is 1 or 2 in Formula II) can also slow or inhibit rapid MAO metabolism upon oral administration. This, in turn, permits the preparation of orally available compounds of Formula I that are highly active serotonergic drugs that do not require special formulating procedures (e.g., dosages containing MAO inhibitors), or the presence of hydrogen bond-forming donors at the 4-position that – in some cases – can negatively impact the properties of the underlying compound (e.g., reduction of 5- HT1A and / or 5-HT2A agonism). In some embodiments, Applicant has also surprisingly discovered that alpha-deuteration of the compounds of Formula I (wherein R3 and / or R3’ are deuterium) can dramatically improve the pharmacokinetics of those compounds. Without being bound to any particular scientific theory, it is believed that the heavier deuterium isotope disrupts the enzymatic metabolism of those compounds. However, in some embodiments it may not be desirable to “over deuterate” the compound, such as further including deuterated species for residues for X and Y or deuteration at the beta position (i.e., W2), which can further alter the compounds’ pharmacokinetic profiles (e.g., greatly extended half lives) in an undesirable manner. 107 01312-0021-00PCT Accordingly, in some embodiments, Applicant has discovered that minimal deuteration may be used to achieve the desired pharmacokinetic outcome. For example, in some embodiments adding a single deuterium atom at the alpha position (i.e., R3 or R3’) can greatly enhance the desired pharmacokinetic profile. It is theorized that this may be due, in part, to the creation of a stereocenter at the alpha position upon deuteration that impacts the enzymes’ ability to metabolize the compound (e.g., hindrance of MAO degradation and / or the ability of enzymes to oxidize the alpha position during metabolic processes). In one embodiment, the compounds of Formula I, the methods, and the pharmaceutical compositions described herein are used to modulate the activity of a neurotransmitter receptor by administering a therapeutically effective amount of a compound Formula I. Methods include the administration of a therapeutically effective amount of a compound of Formula I to prevent or treat an addiction or an overdose such as those discussed herein. Compounds of Formula I may be administered neat or as a pharmaceutical composition comprising a compound of Formula I as discussed below. In other embodiments, the methods and compositions disclosed herein comprise regulating the activity of a neurotransmitter receptor with a formulation comprising a compound of Formula I. In one embodiment, the methods and compositions disclosed herein comprise administering a first dosage formulation comprising at least one compound of Formula I and a second active compound. In some embodiments, the second active compound is a serotonin 5- HT2A receptor antagonist. In one embodiment, the methods disclosed herein comprise administering a first dosage formulation comprising a compound of Formula I and a neurotransmitter activity modulator (e.g., a second serotonergic drug). In one embodiment, the methods disclosed herein comprise administering a first dosage formulation comprising at least compound of Formula I and a second dosage form comprising at least one cannabinoid, at least one terpene, or a second serotonergic drug. The present disclosure relates to methods of treating addiction or overdose comprising administering, to a subject in need thereof, compositions comprising, consisting essentially of, or consisting of an effective amount of a compound of Formula I and an excipient. The terms “composition” and “formulation” are used interchangeably herein. Other embodiments relate to methods of treating addiction or overdose comprising administering, to a subject in need thereof, pharmaceutical compositions comprising, consisting essentially of, or consisting of a therapeutically effective amount of a compound of Formula I, including those discussed above, and a pharmaceutically acceptable excipient (also known as a pharmaceutically acceptable carrier). As discussed above, a compound of Formula I may be therapeutically useful to prevent and / or treat, for example, addictions and overdoses such as those described herein. In some embodiments, the compositions described herein may comprise at least one 108 01312-0021-00PCT compound of Formula I, and a second compound selected from at least one of a second serotonergic drug, a cannabinoid, a terpene, or an MAO inhibitor. In certain embodiments, the second compound may be derived from natural sources, such as fungi (e.g., Psilocybe mushrooms; Lion’s Mane mushrooms (containing terpenes such as erinacines and hericenones)) and plants (e.g., Cannabis). Accordingly, in certain embodiments the second compound may derived or “extracted” from fungus or plant material, meaning said second compound may or may not be “purified” depending on the manner in which it was sourced and extracted. Within the context of this disclosure, the term "purified" means separated from other compounds or materials, such as plant or fungal material, e.g., protein, chitin, cellulose, or water. In one embodiment, the term "purified" refers to a compound substantially free of other materials. In one embodiment, the term "purified" refers to a compound that is substantially free from a second compound (e.g. an enantiomeric compound of Formula I exhibiting 99% enantiomeric excess after resolution). In one embodiment, the term "purified" refers to a compound substantially free from a biological material, such as mold, fungus, plant mater, or bacteria. In one embodiment, the term "purified" refers to a compound or composition that has been crystallized. In one embodiment, the term "purified" refers to a compound or composition that has been chromatographed, for example by gas chromatography, liquid chromatography (e.g., LC, HPLC, etc.), etc. In one embodiment, the term "purified" refers to a compound or composition that has been distilled. In one embodiment, the term "purified" refers to a compound or composition that has been sublimed. In one embodiment, the term "purified" refers to a compound or composition that has been subject to two or more steps chosen from crystallization, chromatography, distillation, or sublimation. In one embodiment, the term "purified" refers to a compound that has a purity ranging from about 80% to about 100%, meaning that the compound makes up about 80% to about 100%of the total mass of the composition. In one embodiment, the term "purified" refers to a compound that is has a purity ranging from about 90% to about 100%, meaning that the compound makes up about 90% to about 100% of the total mass of the composition. In one embodiment, the term "purified" refers to a compound that has a purity ranging from about 95% to about 100%, meaning that the compound makes up about 95% to about 100% of the total mass of the composition. In one embodiment, the term "purified" refers to a compound that has a purity ranging from about 99% to about 100% pure, meaning that the compound makes up about 99% to about 100% of the total mass of the composition. In one embodiment, the term "purified" refers to a compound that has a purity ranging from about 99.9% to about 100%, meaning that the compound makes up about 99.9% to about 100% of the total mass of the composition. 109 01312-0021-00PCT As used herein, the term "particular ratio" refers to the amount of a compound in relation to the amount of another compound or compounds. In one embodiment, there is about 1:1 ratio of a 4-acetoxy-3-[2-(dimethylamino)ethyl]-benzo[b]thiophene) to 4-hydroxy-N,N- dimethyltryptamine. In one embodiment, a particular ratio of compounds is measured by the same unit, e.g., grams, kilograms, pounds, ounces, etc. In one embodiment, a particular ratio of compounds is measured in moles, i.e., molar proportions or molar ratios. As used herein, the term "particular amount" refers to the quantity of a compound or compounds. In one embodiment, a particular amount is the combined quantity of two compounds within a sample. In one embodiment, a particular amount is measured by dry weight. In one embodiment, the particular amount has 1, 2, 3, or 4 significant figures. Disclosed herein are compositions comprising a compound of Formula I and a second compound. In one embodiment, the compositions disclosed herein comprise a molar ratio ranging from about 10:1 to about 1:10 of the compound of Formula I (e.g., a 5-HT2A receptor agonist) to the second compound (e.g., a 5-HT1A receptor agonist). In one embodiment, the compositions disclosed herein comprise a molar ratio ranging from about 100:1 to about 1:100 of the compound of Formula I to the second compound. In one embodiment, the compositions disclosed herein comprise a molar ratio ranging from about 1,000:1 to about 1:1,000 of the compound of Formula I to the second compound. In one embodiment, the compositions disclosed herein comprise a molar ratio ranging from about 10,000:1 to about 1:10,000 of the compound of Formula I to the second compound. Within the context of this disclosure, unless otherwise specified, the serotonergic compounds (e.g., tryptamine compounds) described herein may be present in their protonated or deprotonated (salt or freebase) forms or mixtures thereof depending on the context, for example, the pH of the solution or composition. However, in certain embodiments, the serotonergic compounds described herein will be lipophilic, meaning they will tend to combine with lipids and fats and can readily pass though biological membranes in the body of an animal or human (e.g., blood brain barrier). In certain embodiments, the serotonergic compound in free base form will be lipophilic. As used herein, the term "salt" refers to a neutralized ionic compound. In one embodiment, a salt is formed from the neutralization of acids and bases. In one embodiment, a salt is electrically neutral. In one embodiment, the compositions and methods disclosed herein comprise administering a first cannabinoid. In one embodiment, a first cannabinoid is a first purified cannabinoid. As used herein, the term "cannabinoid" refers to a compound from a class of molecules commonly found in plants of the genus cannabis and their derivatives. In one embodiment, the 110 01312-0021-00PCT cannabinoid is endogenous to an animal, i.e., an endocannabinoid. In one embodiment, the cannabinoid is derived from a plant, e.g., a plant of genus cannabis, e.g., a phytocannabinoid. In one embodiment, the cannabinoid is artificially made in a lab, i.e., a synthetic cannabinoid. Many cannabinoids can be identified by the "cannabi" text in their chemical name. There are at least 113 different cannabinoids isolated from cannabis, exhibiting varied (similar and different) effects. Examples of cannabinoids within the context of this disclosure include the following molecules: Cannabichromene (CBC), Cannabichromenic acid (CBCA), Cannabichromevarin (CBCV), Cannabichromevarinic acid (CBCVA), Cannabicyclol (CBL), Cannabicyclolic acid (CBLA), Cannabicyclovarin (CBLV), Cannabidiol (CBD), Cannabidiol monomethylether (CBDM), Cannabidiolic acid (CBDA), Cannabidiorcol (CBD-C1), Cannabidivarin (CBDV), Cannabidivarinic acid (CBDVA), Cannabielsoic acid B (CBEA-B), Cannabielsoin (CBE), Cannabielsoin acid A (CBEA-A), Cannabigerol (CBG), Cannabigerol monomethylether (CBGM), Cannabigerolic acid (CBGA), Cannabigerolic acid monomethylether (CBGAM), Cannabigerovarin (CBGV), Cannabigerovarinic acid (CBGVA), Cannabinodiol (CBND), Cannabinodivarin (CBDV), Cannabinol (CBN), Cannabinol methylether (CBNM), Cannabinol-C2 (CBN-C2), Cannabinol-C4 (CBN-C4), Cannabinolic acid (CBNA), Cannabiorcool (CBN-C1), Cannabivarin (CBV), Cannabitriol (CBT), Cannabitriolvarin (CBTV), 10-Ethoxy-9-hydroxy-delta- 6a-tetrahydrocannabinol, Cannbicitran (CBT), Cannabiripsol (CBR), 8,9-Dihydroxy-delta-6a- tetrahydrocannabinol, Delta-8-tetrahydrocannabinol (.DELTA.8-THC), Delta-8- tetrahydrocannabinolic acid (.DELTA.8-THCA), Delta-9-tetrahydrocannabinol (THC), Delta-9- tetrahydrocannabinol-C4 (THC-C4), Delta-9-tetrahydrocannabinolic acid A (THCA-A), Delta-9- tetrahydrocannabinolic acid B (THCA-B), Delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4), Delta-9-tetrahydrocannabiorcol (THC-C1), Delta-9-tetrahydrocannabiorcolic acid (THCA-C1), Delta-9-tetrahydrocannabivarin (THCV), Delta-9-tetrahydrocannabivarinic acid (THCVA), 10- Oxo-delta-6a-tetrahydrocannabinol (OTHC), Cannabichromanon (CBCF), Cannabifuran (CBF), Cannabiglendol, Delta-9-cis-tetrahydrocannabinol (cis-THC), Tryhydroxy-delta-9- tetrahydrocannabinol (triOH-THC), Dehydrocannabifuran (DCBF), and 3,4,5,6-Tetrahydro-7- hydroxy-alpha-alpha-2-trimethyl-9-n-propyl-2,6-metha- no-2H-1-benzoxocin-5-methanol. In one embodiment, the term "cannabinoid" refers to a compound chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBGV, or CBGVA. Within the context of this disclosure, the term "THC" comprises any derivative of Delta-9- tetrahydrocannabinol and / or salts thereof. In one embodiment, the compositions disclosed herein comprise THC and a compound of Formula I. In one embodiment, the THC is purified THC. In one embodiment, methods disclosed herein comprise administering a composition comprising THC and a compound of Formula I. In one embodiment, the THC is purified THC. 111 01312-0021-00PCT Within the context of this disclosure, the term "THCA" comprises any derivative of tetrahydrocannabinolic acid and / or salts thereof. In one embodiment, the compositions disclosed herein comprise THCA and a compound of Formula I. In one embodiment, the THCA is purified THCA. In one embodiment, the methods disclosed herein comprise administering a composition comprising THCA and a compound of Formula I. In one embodiment, the THCA is purified THCA . Within the context of this disclosure, the term "THCV" comprises any derivative of Delta- 9-tetrahydrocannabivarin and / or salts thereof. In one embodiment, the compositions disclosed herein comprise THCV and a compound of Formula I. In one embodiment, the THCV is purified THCV . In one embodiment, the methods disclosed herein comprise administering a composition comprising THCV and a compound of Formula I. In one embodiment, the THCV is purified THCV. Within the context of this disclosure, the term "THCVA" comprises any derivative of Delta-9-tetrahydrocannabivarinic acid and / or salts thereof. In one embodiment, the compositions disclosed herein comprise THCVA and a compound of Formula I. In one embodiment, the THCVA is purified THCVA . In one embodiment, the methods disclosed herein comprise administering a composition comprising THCVA and a compound of Formula I. In one embodiment, the THCVA is purified THCVA. Within the context of this disclosure, the term "CBC" comprises any derivative of Cannabichromene and / or salts thereof. In one embodiment, the compositions disclosed herein comprise CBC and a compound of Formula I. In one embodiment, the CBC is purified CBC . In one embodiment, the methods disclosed herein comprise administering a composition comprising CBC and a compound of Formula I. In one embodiment, the CBS is purified CBC. Within the context of this disclosure, the term "CBCA" comprises any derivative of Cannabichromenic acid and / or salts thereof. In one embodiment, the compositions disclosed herein comprise CBCA and a compound of Formula I. In one embodiment, the CBCA is purified CBCA. In one embodiment, the methods disclosed herein comprise administering a composition comprising CBCA and a compound of Formula I. In one embodiment, the CBCA is purified CBCA. Within the context of this disclosure, the term "CBCV" comprises any derivative of Cannabichromevarin and / or salts thereof. In one embodiment, the disclosed herein comprise CBCV and a compound of Formula I. In one embodiment, the CBCV is purified CBCV. In one embodiment, the methods disclosed herein comprise administering a composition comprising CBCV and a compound of Formula I. In one embodiment, the CBCV is purified CBCV. Within the context of this disclosure, the term "CBCVA" comprises any derivative of Cannabichromevarinic acid and / or salts thereof. In one embodiment, the compositions disclosed 112 01312-0021-00PCT herein comprise CBCVA and a compound of Formula I. In one embodiment, the CBCVA is purified CBCVA. In one embodiment, the methods disclosed herein comprise administering a composition comprising CBCVA and a compound of Formula I. In one embodiment, the CBCVA is purified CBCVA . Within the context of this disclosure, the term "CBD" comprises any derivative of Cannabidiol and / or salt thereof. In one embodiment, the compositions disclosed herein comprise CBD and a compound of Formula I. In one embodiment, the CBD is purified CBD. In one embodiment, the methods disclosed herein comprise administering a composition comprising CBD and a compound of Formula I. In one embodiment, the CBD is purified CBD. Within the context of this disclosure, the term "CBDA" comprises any derivative of Cannabidiolic acid and / or salts thereof. In one embodiment, the compositions disclosed herein comprise CBDA and a compound of Formula I. In one embodiment, the CBDA is purified CBDA. In one embodiment, the methods disclosed herein comprise administering a composition comprising CBDA and a compound of Formula I. In one embodiment, the CBDA is purified CBDA. Within the context of this disclosure, the term "CBDV" comprises any derivative of Cannabidivarin and / or salts thereof. In one embodiment, the compositions disclosed herein comprise CBDV and a compound of Formula I. In one embodiment, the CBDV is purified CBDV. In one embodiment, the methods disclosed herein comprise administering a composition comprising CBDV and a compound of Formula I. In one embodiment, the CBDV is purified CBDV. Within the context of this disclosure, the term "CBDVA" comprises any derivative of Cannabidivarinic acid and / or salts thereof. In one embodiment, the compositions disclosed herein comprise CBDVA and a compound of Formula I. In one embodiment, the CBDVA is purified CBDVA. In one embodiment, the methods disclosed herein comprise administering a composition comprising CBDVA and a compound of Formula I. In one embodiment, the CBDVA is purified CBDVA. Within the context of this disclosure, the term "CBG" comprises any derivative of Cannabigerol and / or salts thereof. In one embodiment, the compositions disclosed herein comprise CBG and a compound of Formula I. In one embodiment, the CBG is purified CBG. In one embodiment, the methods disclosed herein comprise administering a composition comprising CBG and a compound of Formula I. In one embodiment, the CBG is purified CBG. Within the context of this disclosure, the term "CBGA" comprises any derivative of Cannabigerolic acid and / or salts thereof. In one embodiment, the compositions disclosed herein comprise CBGA and a compound of Formula I. In one embodiment, the CBGA is purified CBGA. In one embodiment, the methods disclosed herein comprise administering a 113 01312-0021-00PCT composition comprising CBGA and a compound of Formula I. In one embodiment, the CBGA is purified CBGA. Within the context of this disclosure, the term "CBGV" comprises any derivative of Cannabigerovarin and / or salts thereof. In one embodiment, the compositions disclosed herein comprise CBGV and a compound of Formula I. In one embodiment, the CBGV is purified CBGV. In one embodiment, the methods disclosed herein comprise administering a composition comprising CBGV and a compound of Formula I. In one embodiment, the CBGV is purified CBGV. Within the context of this disclosure, the term "CBGVA" comprises any derivative of Cannabigerovarinic acid and / or salts thereof. In one embodiment, the compositions disclosed herein comprise CBGVA and a compound of Formula I. In one embodiment, the CBGVA is purified CBGVA. In one embodiment, the methods disclosed herein comprise administering a composition comprising CBGVA and a compound of Formula I. In one embodiment, the CBGVA is purified CBGVA. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 100:1 to about 1:100 of the compound of Formula I and a purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 75:1 to about 1:75 of the compound of Formula I and a purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 50:1 to about 1:50 of the compound of Formula I and a purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 25:1 to about 1:25 of the compound of Formula I and a purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 10:1 to about 1:10 of the compound of Formula I and a purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 5:1 to about 1:5 of the compound of Formula I and a purified cannabinoid. In one embodiment, the compositions and methods disclosed herein comprise a compound of Formula I, a first purified cannabinoid, and a second purified cannabinoid. In one embodiment, the second purified cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBGV, or CBGVA. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 100:1 to about 1:100 of the compound of Formula I and the sum of the first purified cannabinoid and the second purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 75:1 to about 1:75 of a compound of Formula I and the sum of the first purified cannabinoid and the second purified cannabinoid. In one embodiment, the compositions 114 01312-0021-00PCT disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 50:1 to about 1:50 of a compound of Formula I and the sum of the first purified cannabinoid and the second purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 25:1 to about 1:25 of the compound of Formula I and the sum of the first purified cannabinoid and the second purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 10:1 to about 1:10 of a compound of Formula I and the sum of the first purified cannabinoid and the second purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 5:1 to about 1:5 of a compound of Formula I and the sum of the first purified cannabinoid and the second purified cannabinoid. In one embodiment, the compositions and methods disclosed herein comprise administering a compound of Formula I and a terpene. In one embodiment, the terpene is a purified terpene. As used herein, the term "terpene" refers to a compound belonging to a large class of compounds often biosynthesized from 5-carbon isoprene units. In one embodiment, a terpene is isolated from a plant, e.g., conifers, cannabis, basil, etc. In one embodiment, a terpene is produced by an insect, e.g., termites or swallowtail butterflies. In one embodiment, a terpene is a volatile compound. In one embodiment, a terpene produces an odor. In one embodiment, a terpene is a major component of a natural resin, e.g., turpentine produced from resin. In one embodiment, a terpene is derived biosynthetically from units of isoprene, which has the molecular formula C5H8. In one embodiment, the molecular formula of terpenes are multiples of (C5H8)n, where n is the number of linked isoprene units, such as 1 to 5. Within the context of this disclosure when a terpene is modified chemically, such as by oxidation or rearrangement of the carbon skeleton, the resulting compound is referred to as a “terpenoid.” In the relevant arts, terpenoids are sometimes referred to as isoprenoids. In one embodiment, a terpene is the primary constituent or constituents of an essential oil from a plant and / or flower. Essential oils are used widely as fragrances in perfumery, medicine, and alternative medicines, e.g., aromatherapy. In one embodiment, a terpene is categorized according to the number of isoprene (C5H8) units in the compound, for example, a monoterpene (C10H16), a sesquiterpene (C15H24), a diterpene (C20H32), a triterpene (C30H48), or a tetraterpene (C40H64). Examples of terpenes within the context of this disclosure include acetanisole, acetyl cedrene, anethole, anisole, benzaldehyde, bornyl acetate, borneol, cadinene, cafestol, caffeic acid, camphene, camphor, capsaicin, carene, carotene, carvacrol, carvone, alpha- 115 01312-0021-00PCT caryophyllene, beta-caryophyllene, caryophyllene oxide, cedrene, cedrene epoxide, cecanal, cedrol, cembrene, cinnamaldehyde, cinnamic acid, citronellal, citronellol, cymene, eicosane, elemene, estragole, ethyl acetate, ethyl cinnamate, ethyl maltol, eucalyptol / 1,8-cineole, eudesmol, eugenol, euphol, farnesene, farnesol, fenchone, geraniol, geranyl acetate, guaia- 1(10),11-diene, guaiacol, guaiol, guaiene, gurjunene, herniarin, hexanaldehyde, hexanoic acid, humulene, ionone, ipsdienol, isoamyl acetate, isoamyl alcohol, isoamyl formate, isoborneol, isomyrcenol, isoprene, isopulegol, isovaleric acid, lavandulol, limonene, gamma-linolenic acid, linalool, longifolene, lycopene, menthol, methyl butyrate, 3-mercapto-2-methylpentanal, beta- mercaptoethanol, mercaptoacetic acid, methyl salicylate, methylbutenol, methyl-2- methylvalerate, methyl thiobutyrate, beta-myrcene, gamma-muurolene, nepetalactone, nerol, nerolidol, neryl acetate, nonanaldehyde, nonanoic acid, ocimene, octanal, octanoic acid, pentyl butyrate, phellandrene, phenylacetaldehyde, phenylacetic acid, phenylethanethiol, phytol, pinene, propanethiol, pristimerin, pulegone, retinol, rutin, sabinene, squalene, taxadiene, terpineol, terpine-4-ol, terpinolene, thujone, thymol, umbelliferone, undecanal, verdoxan, and vanillin. In one embodiment, a purified terpene is chosen from bornyl acetate, alpha-bisabolol, borneol, camphene, camphor, carene, beta-caryophyllene, cedrene, cymene, elemene, eucalyptol, eudesmol, farnesene, fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalool, menthol, beta-myrcene, nerolidol, ocimene, phellandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene, or valencene. Within the context of this disclosure, the term "bornyl acetate" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise bornyl acetate and a compound of Formula I. In one embodiment, the bornyl acetate is purified bornyl acetate. In one embodiment, the methods disclosed herein comprise administering a composition comprising bornyl acetate and a compound of Formula I. In one embodiment, the bornyl acetate is purified bornyl acetate. Within the context of this disclosure, the term "alpha-bisabolol" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise alpha-bisabolol and a compound of Formula I. In one embodiment, the alpha-bisabolol is purified alpha-bisabolol. In one embodiment, the methods disclosed herein comprise administering a composition comprising alpha-bisabolol and a compound of Formula I. In one embodiment, the alpha-bisabolol is purified alpha-bisabolol. Within the context of this disclosure, the term "borneol" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise borneol and a compound of Formula 116 01312-0021-00PCT I. In one embodiment, the borneol is purified borneol. In one embodiment, the methods disclosed herein comprise administering a composition comprising borneol and a compound of Formula I. In one embodiment, the borneol is purified borneol. Within the context of this disclosure, the term "camphene" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise camphene and a compound of Formula I. In one embodiment, the camphene is purified camphene. In one embodiment, the methods disclosed herein comprise administering a composition comprising camphene and a compound of Formula I. In one embodiment, the camphene is purified camphene. Within the context of this disclosure, the term "camphor" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise camphor and a compound of Formula I. In one embodiment, the camphor is purified camphor. In one embodiment, the methods disclosed herein comprise administering a composition comprising camphor and a compound of Formula I. In one embodiment, the camphor is purified camphor. Within the context of this disclosure, the term "carene" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise carene and a compound of Formula I. In one embodiment, the carene is purified carene. In one embodiment, the methods disclosed herein comprise administering a composition comprising carene and a compound of Formula I. In one embodiment, the carene is purified carene. Within the context of this disclosure, the term "beta-caryophyllene" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise beta-caryophyllene and a compound of Formula I. In one embodiment, the beta-caryophyllene is purified beta- caryophyllene. In one embodiment, the methods disclosed herein comprise administering a composition comprising beta-caryophyllene and a compound of Formula I. In one embodiment, the beta-caryophyllene is purified beta-caryophyllene. Within the context of this disclosure, the term "cedrene" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise cedrene and a compound of Formula I. In one embodiment, the cedrene is purified cedrene. In one embodiment, the methods disclosed herein comprise administering a composition comprising cedrene and a compound of Formula I. In one embodiment, the cedrene is purified cedrene. Within the context of this disclosure, the term "cymene" comprises any derivative and / or salt to thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one 117 01312-0021-00PCT embodiment, the compositions disclosed herein comprise cymene and a compound of Formula I. In one embodiment, the cymene is purified cymene. In one embodiment, the methods disclosed herein comprise administering a composition comprising cymene and a compound of Formula I. In one embodiment, the cymene is purified cymene. Within the context of this disclosure, the term "elemene" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise elemene and a compound of Formula I. In one embodiment, the elemene is purified elemene. In one embodiment, the methods disclosed herein comprise administering a composition comprising elemene and a compound of Formula I. In one embodiment, the elemene is purified elemene. Within the context of this disclosure, the term "eucalyptol" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise eucalyptol and a compound of Formula I. In one embodiment, the eucalyptol is purified eucalyptol. In one embodiment, the methods disclosed herein comprise administering a composition comprising eucalyptol and a compound of Formula I. In one embodiment, the eucalyptol is purified eucalyptol. Within the context of this disclosure, the term "eudesmol" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise eudesmol and a compound of Formula I. In one embodiment, the eudesmol is purified eudesmol. In one embodiment, the methods disclosed herein comprise administering a composition comprising eudesmol and a compound of Formula I. In one embodiment, the eudesmol is purified eudesmol. Within the context of this disclosure, the term "farnesene" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise farnesene and a compound of Formula I. In one embodiment, the farnesene is purified farnesene. In one embodiment, the methods disclosed herein comprise administering a composition comprising farnesene and a compound of Formula I. In one embodiment, the farnesene is purified farnesene. Within the context of this disclosure, the term "fenchol" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise fenchol and a compound of Formula I. In one embodiment, the fenchol is purified fenchol. In one embodiment, the methods disclosed herein comprise administering a composition comprising fenchol and a compound of Formula I. In one embodiment, the fenchol is purified fenchol. Within the context of this disclosure, the term "geraniol" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one 118 01312-0021-00PCT embodiment, the compositions disclosed herein comprise geraniol and a compound of Formula I. In one embodiment, the geraniol is purified geraniol. In one embodiment, the methods disclosed herein comprise administering a composition comprising geraniol and a compound of Formula I. In one embodiment, the geraniol is purified geraniol. Within the context of this disclosure, the term "guaiacol" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise guaiacol and a compound of Formula I. In one embodiment, the guaiacol is purified guaiacol. In one embodiment, the methods disclosed herein comprise administering a composition comprising guaiacol and a compound of Formula I. In one embodiment, the guaiacol is purified guaiacol. Within the context of this disclosure, the term "humulene" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise humulene and a compound of Formula I. In one embodiment, the humulene is purified humulene. In one embodiment, the methods disclosed herein comprise administering a composition comprising humulene and a compound of Formula I. In one embodiment, the humulene is purified humulene. Within the context of this disclosure, the term "isoborneol" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise isoborneol and a compound of Formula I. In one embodiment, the isoborneol is purified isoborneol. In one embodiment, the methods disclosed herein comprise administering a composition comprising isoborneol and a compound of Formula I. In one embodiment, the isoborneol purified isoborneol. Within the context of this disclosure, the term "limonene" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise limonene and a compound of Formula I. In one embodiment, the limonene is purified limonene. In one embodiment, the methods disclosed herein comprise administering a composition comprising limonene and a compound of Formula I. In one embodiment, the limonene is purified limonene. Within the context of this disclosure, the term "linalool" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise linalool and a compound of Formula I. In one embodiment, the linalool is purified linalool. In one embodiment, the methods disclosed herein comprise administering a composition comprising linalool and a compound of Formula I. In one embodiment, the linalool is purified linalool. Within the context of this disclosure, the term "menthol" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one 119 01312-0021-00PCT embodiment, the compositions disclosed herein comprise menthol and a compound of Formula I. In one embodiment, the menthol is purified menthol. In one embodiment, the methods disclosed herein comprise administering a composition comprising menthol and a compound of Formula I. In one embodiment, the menthol is purified menthol. Within the context of this disclosure, the term "beta-myrcene" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise beta-myrcene and a compound of Formula I. In one embodiment, the beta-myrcene is purified beta-myrcene. In one embodiment, the methods disclosed herein comprise administering a composition comprising beta-myrcene and a compound of Formula I. In one embodiment, the beta-myrcene is purified beta-myrcene. Within the context of this disclosure, the term "nerolidol" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise nerolidol and a compound of Formula I. In one embodiment, the nerolidol is purified nerolidol. In one embodiment, the methods disclosed herein comprise administering a composition comprising nerolidol and a compound of Formula I. In one embodiment, the nerolidol is purified nerolidol. Within the context of this disclosure, the term "ocimene" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise ocimene and a compound of Formula I. In one embodiment, the ocimene is purified ocimene. In one embodiment, the methods disclosed herein comprise administering a composition comprising ocimene and a compound of Formula I. In one embodiment, the ocimene is purified ocimene. Within the context of this disclosure, the term "phellandrene" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise phellandrene and a compound of Formula I. In one embodiment, the phellandrene is purified phellandrene. In one embodiment, the methods disclosed herein comprise administering a composition comprising phellandrene and a compound of Formula I. In one embodiment, the phellandrene is purified phellandrene. Within the context of this disclosure, the term "phytol" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise phytol and a compound of Formula I. In one embodiment, the phytol is purified phytol. In one embodiment, the methods disclosed herein comprise administering a composition comprising phytol and a compound of Formula I. In one embodiment, the phytol is purified phytol. Within the context of this disclosure, the term "pinene" comprises any derivative and / or 120 01312-0021-00PCT salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise pinene and a compound of Formula I. In one embodiment, the pinene is purified pinene. In one embodiment, the methods disclosed herein comprise administering a composition comprising pinene and a compound of Formula I. In one embodiment, the pinene is purified pinene. Within the context of this disclosure, the term "pulegone" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise pulegone and a compound of Formula I. In one embodiment, the pulegone is purified pulegone. In one embodiment, the methods disclosed herein comprise administering a composition comprising pulegone and a compound of Formula I. In one embodiment, the pulegone is purified pulegone. Within the context of this disclosure, the term "sabinene" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise sabinene and a compound of Formula I. In one embodiment, the sabinene is purified sabinene. In one embodiment, the methods disclosed herein comprise administering a composition comprising sabinene and a compound of Formula I. In one embodiment, the sabinene is purified sabinene. Within the context of this disclosure, the term "terpineol" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise terpineol and a compound of Formula I. In one embodiment, the terpineol is purified terpineol. In one embodiment, the methods disclosed herein comprise administering a composition comprising terpineol and a compound of Formula I. In one embodiment, the terpineol is purified terpineol. Within the context of this disclosure, the term "terpinolene" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise terpinolene and a compound of Formula I. In one embodiment, the terpinolene is purified terpinolene. In one embodiment, the methods disclosed herein comprise administering a composition comprising terpinolene and a compound of Formula I. In one embodiment, the terpinolene is purified terpinolene. Within the context of this disclosure, the term "valencene" comprises any derivative and / or salt thereof, including any isomeric, structural, and / or enantiomeric, variations thereof. In one embodiment, the compositions disclosed herein comprise valencene and a compound of Formula I. In one embodiment, the valencene is purified valencene. In one embodiment, the methods disclosed herein comprise administering a composition comprising valencene and a compound of Formula I. In one embodiment, the valencene is purified valencene. In one embodiment, the compositions and methods disclosed herein include one or 121 01312-0021-00PCT more erinacine molecules, which are optionally purified. In one embodiment, the compositions and methods disclosed herein comprise erinacine A. In one embodiment, the compositions and methods disclosed herein comprise erinacine B. In one embodiment, the compositions and methods disclosed herein comprise erinacine C. In one embodiment, the compositions and methods disclosed herein comprise erinacine D. In one embodiment, the compositions and methods disclosed herein comprise erinacine E. In one embodiment, the compositions and methods disclosed herein comprise erinacine F. In one embodiment, the compositions and methods disclosed herein comprise erinacine G. In one embodiment, the compositions and methods disclosed herein comprise erinacine H. In one embodiment, the compositions and methods disclosed herein comprise erinacine I. In one embodiment, the compositions and methods disclosed herein comprise erinacine J. In one embodiment, the compositions and methods disclosed herein comprise erinacine K. In one embodiment, the compositions and methods disclosed herein comprise erinacine P. In one embodiment, the compositions and methods disclosed herein comprise erinacine Q. In one embodiment, the compositions and methods disclosed herein comprise erinacine R. In one embodiment, the compositions and methods disclosed herein comprise erinacine S. In one embodiment, the erinacine molecule is a purified erinacine molecule. In one embodiment, the compositions and methods disclosed herein comprise one or more purified erinacine molecules and purified pyridine-3-carboxylic acid. In one embodiment, the compositions and methods disclosed herein comprise one or more purified erinacine molecules and a purified cannabinoid, such as CBD. Within the context of this disclosure, the term "erinacine A" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine A and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine A and a compound of Formula I. Within the context of this disclosure, the term "erinacine B" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine B and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine B and a compound of Formula I. Within the context of this disclosure, the term "erinacine C" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine C and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine C and 122 01312-0021-00PCT a compound of Formula I. Within the context of this disclosure, the term "erinacine D" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine D and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine D a compound of Formula I. Within the context of this disclosure, the term "erinacine E" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine E and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine E and a compound of Formula I. Within the context of this disclosure, the term "erinacine F" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine F and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine F and a compound of Formula I. Within the context of this disclosure, the term "erinacine G" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine G and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine G and a compound of Formula I. Within the context of this disclosure, the term "erinacine H" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine H and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine H and a compound of Formula I. Within the context of this disclosure, the term "erinacine I" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine I and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine I and a 123 01312-0021-00PCT compound of Formula I. Within the context of this disclosure, the term "erinacine J" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine J and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine J and a compound of Formula I. Within the context of this disclosure, the term "erinacine K" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine K and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine K and a compound of Formula I. Within the context of this disclosure, the term "erinacine P" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine P and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine P and a compound of Formula I. Within the context of this disclosure, the term "erinacine Q" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine Q and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine Q and a compound of Formula I. Within the context of this disclosure, the term "erinacine R" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine R and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine R and a compound of Formula I. Within the context of this disclosure, the term "erinacine S" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of erinacine S and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified erinacine S and 124 01312-0021-00PCT a compound of Formula I. The erinacine chemical structures are taken from Li I-C, Lee L-Y, Tzeng T W, et al. Neurohealth properties of Hericium erinaceus mycelia enriched with erinacines. In: Behavioural Neurology. 2018. doi:10.1155 / 2018 / 5802634 In one embodiment, the compositions and methods disclosed herein include one or more hericenone molecules, optionally purified. In one embodiment, the compositions and methods disclosed herein comprise hericenone A. In one embodiment, the compositions and methods disclosed herein comprise hericenone B. In one embodiment, the compositions and methods disclosed herein comprise hericenone C. In one embodiment, the compositions and methods disclosed herein comprise hericenone D. In one embodiment, the compositions and methods disclosed herein comprise hericenone E. In one embodiment, the compositions and methods disclosed herein comprise hericenone F. In one embodiment, the compositions and methods disclosed herein comprise hericenone G. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone H. Within the context of this disclosure, the term "hericenone A" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of hericenone A and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified hericenone A and a compound of Formula I. Within the context of this disclosure, the term "hericenone B" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of hericenone B and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified hericenone B and a compound of Formula I. Within the context of this disclosure, the term "hericenone C" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of hericenone C and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified hericenone C and a compound of Formula I. Within the context of this disclosure, the term "hericenone D" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of hericenone D and a compound of Formula I. In one embodiment, the 125 01312-0021-00PCT compositions and methods disclosed herein comprise administering a formulation of purified hericenone D a compound of Formula I. Within the context of this disclosure, the term "hericenone E" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of hericenone E and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified hericenone E and a compound of Formula I. Within the context of this disclosure, the term "hericenone F" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of hericenone F and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified hericenone F and a compound of Formula I. Within the context of this disclosure, the term "hericenone G" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of hericenone G and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified hericenone G and a compound of Formula I. Within the context of this disclosure, the term "hericenone H" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of hericenone H and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified hericenone H and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise one or more purified hericenone molecules and purified pyridine-3-carboxylic acid. In one embodiment, the compositions and methods disclosed herein comprise one or more purified hericenone molecules and a purified cannabinoid, such as CBD. Within the context of this disclosure, the term "pyridine-3-carboxylic acid" comprises any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric, variations thereof. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of pyridine-3-carboxylic acid and a compound of Formula I. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation of purified pyridine-3-carboxylic acid and a compound of Formula I. 126 01312-0021-00PCT In one embodiment, the compositions and methods disclosed herein include one or more purified hericenone molecules and one or more purified erinacine molecules. In one embodiment, the compositions and methods disclosed herein include one or more purified serotonergic derivatives, one or more purified hericenone molecules and one or more purified erinacine molecules. In one embodiment, the compositions and methods disclosed herein include one or more purified serotonergic derivatives, one or more purified hericenone molecules, one or more purified erinacine molecules and one or more purified cannabinoids. In one embodiment, the compositions and methods disclosed herein include one or more purified serotonergic derivatives, one or more purified hericenone molecules, one or more purified erinacine molecules and purified pyridine-3-carboxylic acid. In one embodiment, the compositions and methods disclosed herein include one or more compounds of Formula I and one or more purified molecules attained by extracting and subsequently purifying one or more compounds from an organism chosen from Bacopa monnieri (for example, the purified molecule bacoside A3), Centella asiatica (for example, the purified molecule asiaticoside), Gingko biloba (for example, the purified molecule myricetin), Zingiber officinale (for example, the purified molecule zingerone), Ocimum sanctum (for example, the purified molecule linalool), Polygonum cuspidatum (for example, the purified molecule resveratrol), Origanum vulgare (for example, the purified molecule carvacrol), Origanum onites (for example, the purified molecule thymol), Rosmarinus officinalis (for example, the purified molecule rosmarinic acid), Rosmarinus eriocalyx (for example, the purified molecule camphor), Curcuma longa (for example, the purified molecule curcumin), Camellia sinensis (for example, the purified molecule theobromine), Lavandula spica (for example, the purified molecule caryophyllene), Scutellaria lateriflora (for example, the purified molecule baicalin), Avena sativa (for example, the purified molecule avenalin), Avena byzantina (for example, the purified molecule beta-glucan), Salvia divinorum (for example, the purified molecule salvinorin A), Banisteriopsis caapi (for example, the purified molecule harmine), Psychotria species (for example, the purified molecule dimethyltryptamine), Tabernanthe iboga (for example, the purified molecule ibogaine), Voacanga africana (for example, the purified molecule voacangine), Tabernaemontana undulata (for example, the purified molecule ibogamine), Lophophora williamsii (for example, the purified molecule mescaline), Ipomoea tricolor (for example, the purified molecule ergonovine), and / or Argyreia nervosa (for example, the purified molecule ergine). In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 100:1 to about 1:100 of the compound of Formula I derivative and a purified terpene. 127 01312-0021-00PCT In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 75:1 to about 1:75 of the compound of Formula I and a purified terpene. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 50:1 to about 1:50 of the compound of Formula I and a purified terpene. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 25:1 to about 1:25 of the compound of Formula I and a purified terpene. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 10:1 to about 1:10 of the compound of Formula I and a purified terpene. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 5:1 to about 1:5 of the compound of Formula I and a purified terpene. In one embodiment, the compositions and methods disclosed herein comprise a compound of Formula I, a purified cannabinoid, and a purified terpene. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 100:1 to about 1:100 of the compound of Formula I and a purified cannabinoid and a particular ratio (e.g., a molar ratio) ranging from about 100:1 to about 1:100 of the compound of Formula I and a purified terpene. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 75:1 to about 1:75 of compound of Formula I and a purified cannabinoid and a particular ratio (e.g., a molar ratio) ranging from about 75:1 to about 1:75 of the compound of Formula I and a purified terpene. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 50:1 to about 1:50 of the compound of Formula I and a purified cannabinoid and a particular ratio (e.g., a molar ratio) ranging from about 50:1 to about 1:50 of the compound of Formula I and a purified terpene. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 25:1 to about 1:25 of the compound of Formula I and a purified cannabinoid and a particular ratio (e.g., a molar ratio) ranging from about 25:1 to about 1:25 of the compound of Formula I and a purified terpene. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 10:1 to about 1:10 of compound of Formula I and a purified 128 01312-0021-00PCT cannabinoid and a particular ratio (e.g., a molar ratio) ranging from about 10:1 to about 1:10 of the compound of Formula I and a purified terpene. In one embodiment, the compositions disclosed herein comprise a particular ratio (e.g., a molar ratio) ranging from about 5:1 to about 1:5 of the compound of Formula I and a purified cannabinoid and a particular ratio (e.g., a molar ratio) ranging from about 5:1 to about 1:5 of the compound of Formula I and a purified terpene. In one embodiment, a purified terpene modulates the activity of a neurotransmitter activity modulator, e.g., a compound of Formula I, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a psilocybin derivative, etc. As used herein, the term "serotonergic drug" refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor. In one embodiment, a serotonergic drug binds to a serotonin receptor. In one embodiment, a serotonergic drug indirectly affects a serotonin receptor, e.g., via interactions affecting the reactivity of other molecules at the serotonin receptor. In one embodiment, a serotonergic drug is an agonist, e.g., a compound activating a serotonin receptor. In one embodiment, a serotonergic drug is an antagonist, e.g., a compound binding but not activating a serotonin receptor, e.g., blocking a receptor. In one embodiment, a serotonergic drug is an effector molecule, e.g., a compound binding to an enzyme for allosteric regulation. In one embodiment, a serotonergic drug acts (either directly or indirectly) at more than one type of receptor (e.g., SHT, dopamine, adrenergic, acetylcholine, etc.). In one embodiment, a serotonergic drug is an antidepressant. In one embodiment, a serotonergic drug is an anxiolytic. In one embodiment, a serotonergic drug is a selective serotonin reuptake inhibitor. In one embodiment, a serotonergic drug is a selective serotonin norepinephrine reuptake inhibitor. In some embodiments, the compounds of Formula I are serotonergic drugs. In some embodiments, at least one compound of Formula I is administered with a second serotonergic drug, such as one of the serotonergic drugs identified below. Some exemplary serotonergic drugs include the following molecules: 4-hydroxy-N- methyltryptamine (aka 3[2-(methylamino)ethyl]-1H-indol-4-ol), aeruginascin (aka [3-[2- (trimethylazaniumyl)ethyl]-1H-indol-4-yl] hydrogen phosphate), baeocystin (aka [3-[2- (methylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate), bufotenidine (aka 3-[2- (trimethylazaniumypethyl]-1H-indol-5-olate), bufotenin (aka 3-[2-(dimethylamino)ethyl]-1H-indol- 5-ol), ethocybin (aka [3-[2-(diethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate), norbaeocystin (aka [3-(2-aminoethyl)-1H-indol-4-yl] dihydrogen phosphate), norpsilocin, psilocin 129 01312-0021-00PCT (aka 3-[2-(dimethylamino)ethyl]-1H-indol-4-ol), psilocybin (aka [3-[2-(dimethylamino)ethyl]-1H- indol-4-yl] dihydrogen phosphate), serotonin (aka 3-(2-aminoethyl)-1H-indol-5-ol), 1P-LSD (aka (6aR,9R)-N,N-diethyl-7-methyl-4-propanoyl-6,6a,8,9-tetrahydroindolo [4,3-fg] quinoline-9- carboxamide), ALD-52 (aka (6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-6,6a,8,9- tetrahydroindolo[4,3-fg]q- uinoline-9-carboxamide), AL-LAD (aka (6aR,9R)-N,N-diethyl-7-prop-2- enyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]q- uinoline-9-carboxamide), BU-LAD (aka (6aR,9R)-7- butyl-N,N-diethyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoli- ne-9-carboxamide), DAL (aka (6aR,9R)-7-methyl-N,N-bis(prop-2-enyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-- fg]quinoline-9- carboxamide), DAM-57 (aka (6aR,9R)-N,N,7-trimethyl-6,6a,8,9-tetrahydro-4H-indolo[4,3- fg]quinoline-9- -carboxamide), EIPLA (aka (6aR,9R)-N-ethyl-7-methyl-N-propan-2-yl-6,6a,8,9- tetrahydro-4H-indolo[4,3- -fg]quinoline-9-carboxamide), ETH-LAD (aka (6aR,9R)-N,N,7-triethyl- 6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-- carboxamide), LAE-32 (aka (6aR,9R)-N-ethyl- 7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-- 9-carboxamide), LPD-824 (aka [(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-yl]-p- yrrolidin-1- ylmethanone), LSB (aka (6aR,9R)-N-butan-2-yl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3- fg]quino- line-9-carboxamide), LSA (aka (6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3- fg]quinoline-9-carbox- amide), LSD-25 (aka (6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro- 4H-indolo[4,3-fg]quinol- ine-9-carboxamide), LSD-PiP (aka (7-methyl-6,6a,8,9-tetrahydro-4H- indolo[4,3-fg]quinoline-9-yl)-piperidin-- 1-ylmethanone), LSM-775 (aka [(6aR,9R)-7-methyl- 6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-yl]-m- orpholin-4-ylmethanone), LSP (aka (6aR,9R)-7-methyl-N-pentan-3-yl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9- carboxamide), LSZ (aka [(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-yl]- [- (2S,4S)-2,4-dimethylazetidin-1-yl]methanone), methergine (aka (6aR,9R)-N-(1-hydroxybutan- 2-yl)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4-,3-fg]quinoline-9-carboxamide), MiPLA (aka (6aR,9R)-N,7-dimethyl-N-propan-2-yl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]- quinoline-9- carboxamide), NDTDI, PARGY-LAD, PRO-LAD (aka (6aR,9R)-N,N-diethyl-7-propyl-6,6a,8,9- tetrahydro-4H-indolo[4,3-fg]quinol- ine-9-carboxamide), 2-Me-DET (aka N,N-diethyl-2-(2-methyl- 1H-indol-3-yl)ethanamine), 2-Me-DMT (aka N,N-dimethyl-2-(2-methyl-1H-indol-3- yl)ethanamine), 2,alpha-DMT (aka 1-(2-methyl-1H-indol-3-yl)propan-2-amine), 4-AcO-DALT (aka [3-[2-[bis(prop-2-enyl)amino]ethyl]-1H-indol-4-yl] acetate), 4-AcO-DET (aka [3-[2- (diethylamino)ethyl]-1H-indol-4-yl] acetate), 4-AcO-DIPT (aka 3-[2-(Diisopropylamino)ethyl]-1H- indol-4-yl acetate), 4-AcO-DMT (aka [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] acetate), 4-AcO- DPT (aka [3-[2-(dipropylamino)ethyl]-1H-indol-4-yl] acetate), 4-AcO-EPT (aka 3-{2- [Ethyl(propyl)amino]ethyl}-1H-indol-4-yl acetate), 4-AcO-MET (aka [3-[2- [ethyl(methyl)amino]ethyl]-1H-indol-4-yl] acetate), 4-AcO-MIPT (aka [3-[2-[methyl(propan-2- yl)amino]ethyl]-1H-indol-4-yl] acetate), 4-AcO-MPT, 4-HO-DBT (aka 3-[2-(dibutylamino)ethyl]- 1H-indol-4-ol), 4-HO-DET (aka 3-[2-(diethylamino)ethyl]-1H-indol-4-ol), 4-HO-DIPT (aka 3-[2- [di(propan-2-yl)amino]ethyl]-1H-indol-4-ol), 4-HO-DPT (aka 3-[2-(dipropylamino)ethyl]-1H-indol- 130 01312-0021-00PCT 4-ol), 4-HO-EPT, 4-HO-MCPT, 4-HO-MET (aka 3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-ol), 4- HO-MIPT (aka 3-[2-[methyl(propan-2-yl)amino]ethyl]-1H-indol-4-ol), 4-HO-MPMI (aka 3-[(1- methylpyrrolidin-2-yl)methyl]-1H-indol-4-ol), 4-HO-MPT (aka 3-[2-[methyl(propyl)amino]ethyl]- 1H-indol-4-ol), 4-HO-pyr-T (aka 3-(2-pyrrolidin-1-ylethyl)-1H-indol-4-ol), 4-MeO-MIPT (aka N-[2- (4-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine), 4,5-MDO-DIPT (aka N-[2-(6H- [1,3]dioxolo[4,5-e]indol-8-yl)ethyl]-N-propan-2-ylpropan-2-amine- ), 4,5-MDO-DMT (aka 2-(6H- [1,3]dioxolo[4,5-e]indol-8-yl)-N,N-dimethylethanamine), 5-BROMO-DMT (aka 2-(5-bromo-1H- indol-3-yl)-N,N-dimethylethanamine), 5-chloro-alpha-MT (aka 1-(5-chloro-1H-indol-3-yl)propan- 2-amine), 5-fluoro-AMT (aka 1-(5-fluoro-1H-indol-3-yl)propan-2-amine), 5-MeO-AET (aka 1-(5- methoxy-1H-indol-3-yl)butan-2-amine), 5-MeO-AMT (aka 1-(5-methoxy-1H-indol-3-yl)propan-2- amine), 5-MeO-DALT (aka N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enylprop-2-en-1- amine), 5-MeO-DET (aka N,N-diethyl-2-(5-methoxy-1H-indol -3- yl)ethanamine), 5-MeO-DiPT (aka N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propan-2-ylpropan-2-amine), 5-MeO-DMT (aka 2- (5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine), 5-MeO -DPT (aka N-[2-(5-methoxy-1H- indol-3-yl)ethyl]-N-propylpropan-1-amine), 5-MeO-EiPT (aka N-ethyl-N-[2-(5-methoxy-1H-indol- 3-yl)ethyl]propan-2-amine), 5-MeO-MALT (aka N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-N- methylprop-2-en-1-amine), 5-MeO-MiPT (aka N-[2-(5-methoxy-1H-indol -3-yl)ethyl]-N- methylpropan-2-amine), 5-MeO-NMT (aka 2-(5-methoxy-1H-indol-3-yl)-N- methylethanamine;hydrochloride), 5-MeO-pyr-T (aka 4-fluoro-5-methoxy-3-(2-pyrrolidin-1- ylethyl)-1H-indole), 5-MeO-TMT (aka 2-(5-methoxy-2-methyl-1H-indol-3-yl)-N,N- dimethylethanamine), 5-MeS-DMT (aka N,N-dimethyl-2-(5-methylsulfanyl-1H-indol-3- yl)ethanamine), 5,6-MDO-DIPT (aka N-[2-(5H-[1,3]dioxolo[4,5-f]indol-7-yl)ethyl]-N-propan-2- ylpropan-2-amine- ), 5,6-MDO-DMT (aka 2-(5H-[1,3]dioxolo[4,5-f]indol-7-yl)-N,N- dimethylethanamine), 5,6-MDO-MIPT (aka N-[2-(5H-[1,3]dioxolo[4,5-f]indol-7-yl)ethyl]-N- ethylpropan-2-amine), 5,6-MeO-MIPT (aka N-[2-(5,6-dimethoxy-1H-indol-3-yl)ethyl]-N- methylpropan-2-amine), 5,N,N-TMT (aka N,N-dimethyl-2-(5-methyl-1H-indol-3-ethanamine), 6- MeO-THH (aka 6-methoxy-1-methyl-2,3,4,9-tetrahydro-1H-pyrido [3,4-b]indole), alpha-ET (aka 1-(1H-indol-3-yl)butan-2-amine), alpha-MT (aka 1-(1H-indol-3-yl)propan-2-amine), alpha-TMT (aka 1-(1H-indol-3-yl)-N,N-dimethylpropan-2-amine), alpha,N-DMT (aka 2-(1H-indol-3-yl)-N,N- dimethylethanamine), alpha,N,O-TMS (aka 1-(5-methoxy-1H-indol-3-yl)-N-methylpropan-2- amine), alpha,O-DMS (aka 1-(5-methoxy-1H-indol-3-yl)propan-2-amine), DALT (aka N-[2-(1H- indol-3-ypethyl]-N-prop-2-enylprop-2-en-1-amine), DBT (aka N-butyl-N-[2-(1H-indol-3- yl)ethyl]butan-1-amine), DET (aka N,N-diethyl-2-(1H-indol-3-yl)ethanamine), DiPT (aka N-[2-(5- methoxy-1H-indol-3-yl)ethyl]-N-propan-2-ylpropan-2-amine), DMT (aka 2-(1H-indol-3-yl)-N,N- dimethylethanamine), DPT (aka N-[2-(1H-indol-3-yl)ethyl]-N-propylpropan-1-amine), EiPT (aka N-ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-2-amine), Harmaline (aka 7-methoxy-1-methyl-3,4- dihydro-2H-pyrido [3,4-b]indole), Harmine (aka 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole), MALT, MBT (aka 3H-1,3-benzothiazole-2-thione), Melatonin (aka N-[2-(5-methoxy-1H-indol-3- 131 01312-0021-00PCT yl)ethyl]acetamide), MET (aka N-ethyl-2-(1H-indol-3-yl)-N-methylethanamine), MiPT (aka N-[2- (1H-indol-3-yl)ethyl]-N-methylpropan-2-amine), MPT (aka 3-[2-[methyl(propyl)amino]ethyl]-1H- indol-4-ol), NET (aka N-ethyl-2-(1H-indol-3-yl)ethanamine), NMT (aka 2-(1H-indol-3-yl)-N- methylethanamine), PiPT (aka N-[2-(1H-indol-3-yl)ethyl]-N-propan-2-ylpropan-1-amine), pyr-T (aka 3-(2-pyrrolidin-1-ylethyl)-1H-indole), T (aka 2-(1H-indol-3-yl)ethanamine), Tetrahydroharmine (aka 7-methoxy-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole), 2-Br- 4,5-MDA (aka 1-(6-bromo-1,3-benzodioxol-5-yl)propan-2-amine), 2-TIM (aka 2-(3,4-dimethoxy- 2-methylsulfanylphenyl)ethanamine), 2-TOET (aka 1-(4-ethyl-5-methoxy-2- methylsulfanylphenyl)propan-2-amine), 2-TOM (aka 1-(5-methoxy-4-methyl-2- methylsulfanylphenyl)propan-2-amine), 2,4-DMA (aka 1-(2,4-dimethoxyphenyl)propan-2-amine), 2,5-DMA (aka 1-(2,5-dimethoxyphenyl)propan-2-amine), 2C-B (aka 2-(4-bromo-2,5- dimethoxyphenyl)ethanamine), 2C-C (aka 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine), 2C-D (aka 2-(2,5-dimethoxy-4-methylphenyl)ethanamine), 2C-E (aka 2-(4-ethyl-2,5- dimethoxyphenyl)ethanamine), 2C-F (aka 2-(4-fluoro-2,5-dimethoxyphenyl)ethanamine), 2C-G (aka 2-(2,5-dimethoxy-3,4-dimethylpheny)ethanamine), 2C-G-3 (aka 2-(4,7-dimethoxy-2,3- dihydro-1H-inden-5-yl)ethanamine), 2C-G-4 (aka 2-(1,4-dimethoxy-5,6,7,8- tetrahydronaphthalen-2-yl)ethanamine), 2C-G-5 (aka CAS 207740-20-3), 2C-G-N (aka 2-(1,4- dimethoxynaphthalen-2-yl)ethanamine), 2C-H (aka 2-(2,5-dimethoxyphenyl)ethanamine), 2C-I (aka 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine), 2C-N (aka 2-(2,5-dimethoxy-4- nitrophenyl)ethanamine), 2C-O-4 (aka 2-(2,5-dimethoxy-4-propan-2-yloxyphenyl)ethanamine), 2C-P (aka 2-(2,5-dimethoxy-4-propylphenyl)ethanamine), 2C-SE (aka 2-(2,5-dimethoxy-4- methylselanylphenyl)ethanamine), 2C-T (aka 2-(2,5-dimethoxy-4- methylsulfanylphenyl)ethanamine), 2C-T-13 (aka 2-[2,5-dimethoxy-4-(2- methoxyethylsulfanyl)phenyl]ethanamine), 2C-T-15 (aka 2-(4-cyclopropylsulfanyl-2,5- dimethoxyphenyl)ethanamine), 2C-T-17 (aka 2-(4-butan-2-ylsulfanyl-2,5- dimethoxyphenyl)ethanamine), 2C-T-2 (aka 2-(4-ethylsulfanyl-2,5- dimethoxypheny)ethanamine), 2C-T-2 (aka 2-[4-(2-fluoroethylsulfanyl)-2,5- dimethoxyphenyl]ethanamine), 2C-T-4 (aka 2-(2,5-dimethoxy-4-propan-2- ylsulfanylpheny)ethanamine), 2C-T-7 (aka 2-(2,5-dimethoxy-4- propylsulfanylphenyl)ethanamine), 2C-T-8 (aka 2-[4-(cyclopropylmethylsulfanyl)-2,5- dimethoxyphenyl]ethanamine), 2C-T-9 (aka 2-(4-butylsulfanyl-2,5- dimethoxypheny)ethanamine), 2C-TFM (aka 2-[2,5-dimethoxy-4- (trifluoromethyl)phenyl]ethanamine), 2T-MMDA-3a (aka 1-(4-methylsulfanyl-1,3-benzodioxol-5- yl)propan-2-amine), 3-T-TRIS (aka 2-(3,4-diethoxy-5-ethylsulfanylphenyl)ethanamine), 3-TASB (aka 2-(3-ethoxy-4-ethylsulfanyl-5-methoxyphenyl)ethanamine), 3-TE (aka 2-(4-ethoxy-3- methoxy-5-methylsulfanylphenyl)ethanamine), 3-TFM (aka 2-(2,4-dimethoxy-3- methylsulfanylphenyl)ethanamine), 3-TM (aka 2-(3,4-dimethoxy-5- methylsulfanylpheny)ethanamine), 3-TME (aka 2-(3-ethylsulfanyl-4,5- 132 01312-0021-00PCT dimethoxyphenyl)ethanamine), 3-TSB (aka 2-(3-ethoxy-5-ethylsulfanyl-4- methoxyphenyl)ethanamine), 3,4-DMA (aka 1-(3,4-dimethoxyphenyl)propan-2-amine), 3C-BZ (aka 1-(3,5-dimethoxy-4-phenylmethoxyphenyl)propan-2-amine), 3C-E (aka 1-(4-ethoxy-3,5- dimethoxyphenyl)propan-2-amine), 4-Br-3,5-DMA (aka 1-(4-bromo-3,5- dimethoxyphenyl)propan-2-amine), 4-D (aka CAS 1020518-87-9), 4-MA (aka 1-(4- methoxyphenyl)propan-2-amine), 4-T-TRIS (aka 2-(3,5-diethoxy-4- ethylsulfanylphenyl)ethanamine), 4-TASB (aka 2-(3-ethoxy-4-ethylsulfanyl-5- methoxypheny)ethanamine), 4-TE (aka 2-(4-ethylsulfanyl-3,5-dimethoxyphenyl)ethanamine), 4- TIM (aka 2-(2,3-dimethoxy-4-methylsulfanylphenyl)ethanamine), 4-TM (aka 2-(3,5-dimethoxy-4- methylsulfanylphenyl)ethanamine), 4-TME (aka 2-(3-ethoxy-5-methoxy-4- methylsulfanylpheny)ethanamine), 4-TSB (aka 2-(3,5-diethoxy-4- methylsulfanylphenyl)ethanamine), 4T-MMDA-2 (aka 1-(5-methoxy-1,3-benzoxathiol-6- yl)propan-2-amine), 5-TASB (aka 2-(3,4-diethoxy-5-methylsulfanylphenyl)ethanamine), 5-TME (aka 2-(3-ethoxy-4-methoxy-5-methylsulfanylphenyl)ethanamine), 5-TOET (aka 1-(4-ethyl-2- methoxy-5-methylsulfanylphenyl)propan-2-amine), 5-TOM (aka 1-(2-methoxy-4-methyl-5- methylsulfanylphenyl)propan-2-amine), 25B-NBF (aka 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2- fluorophenyl)methyl]ethanamine- ), 25B-NBOH (aka 2-[[2-(4-bromo-2,5- dimethoxypheny)ethylaminolmethyl]phenol), 25B-NBOMe (aka 2-(4-bromo-2,5- dimethoxyphenyl)-N[(2-methoxyphenyl)methyl]ethanamine- ), 25C-NB3OMe (aka 2-(4-chloro- 2,5-dimethoxyphenyl)-N-[((3-methoxypheny)methyl]ethanamine), 25C-NB4OMe (aka 2-(4- chloro-2,5-dimethoxyphenyl)-N-[(4-methoxyphenyl)methyl]ethanamine), 25C-NBF (aka 2-(4- chloro-2,5-dimethoxyphenyl)-N-[(2-fluorophenyl)methyl]ethanamine), 25C-NBOH (aka 2-(4- chloro-2,5-dimethoxyphenyl)ethylaminolmethyl]phenol), 25C-NBOMe (aka 2-(4-chloro-2,5- dimethoxyphenyl)-N[(2-methoxyphenyl)methyl]ethanamine), 25CN-NBOH (aka 4-[2-[(2- hydroxyphenyl)methylaminolethyl]-2,5-dimethoxybenzonitrile), 25CN-NBOMe (aka CAS 1354632-16-8), 25D-NBOMe (aka 2-(2,5-dimethoxy-4-methylphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine), 25E-NBOMe (aka 2-(4-ethyl-2,5-dimethoxyphenyl)-N4(2- methoxyphenyl)methyl]ethanamine), 25G-NBOMe (aka 2-(2,5-dimethoxy-3,4-dimethylphenyl)- N-[(2-methoxyphenyl)methyl]ethanamin- e), 25H-NBOMe (aka 2-(2,5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine), 25H-NB34MD (aka N-(1,3-benzodioxol-5-ylmethyl)-2-(4- iodo-2,5-dimethoxyphenyl)ethanamine), 25I-NB3OMe (aka 2-(4-iodo-2,5-dimethoxyphenyl)-N- [(3-methoxyphenyl)methyl]ethanamine), 25I-NB4OMe (aka 2-(4-iodo-2,5-dimethoxyphenyl)-N- [(4-methoxyphenyl)methyl]ethanamine), 25I-NBF (aka N-[(2-fluorophenyl)methyl]-2-(4-iodo-2,5- dimethoxyphenyl)ethanamine), 25I-NBMD (aka N-(1,3-benzodioxol-4-ylmethyl)-2-(4-iodo-2,5- dimethoxyphenyl)ethanamine), 25I-NBOH (aka 2-[[2-(4-iodo-2,5- dimethoxypheny)ethylamino]methyl]phenol), 25I-NBOMe (aka 2-(4-iodo-2,5-dimethoxyphenyl)- N-[(2-methoxyphenyl)methyl]ethanamine), 25iP-NBOMe (aka 2-(2,5-dimethoxy-4-propan-2- ylphenyl)-N-[(2-methoxypheny)methyl]ethanamin- e), 25N-NBOMe (aka 2-(2,5-dimethoxy-4- 133 01312-0021-00PCT nitrophenyl)-N-[(2-methoxypheny)methyl]ethanamine), 25P-NBOMe (aka 2-(2,5-dimethoxy-4- propylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine), 25TFM-NBOMe (aka 2-[2,5- dimethoxy-4-(trifluoromethyl)phenyl]-N-[(2-methoxyphenyl)methyl]et- hanamine), 2CBCB- NBOMe (aka 1-[(7R)-3-bromo-2,5-dimethoxy-7-bicyclo[4.2.0]octa-1(6),2,4-trienyl]-N-[(- 2- methoxypheny)methyl]methanamine), 2CBFly-NBOMe (aka 2-(4-bromo-2,3,6,7- tetrahydrofuro[2,3-f][1]benzofuran-8-yl)-N-[(2-methoxy- phenyl)methyl]thanamine), AEM (aka 1- (3,4,5-trimethoxyphenyl)butan-2-amine), AL (aka 2-(3,5-dimethoxy-4-prop-2- enoxyphenyl)ethanamine), ALEPH (aka 1-(2,5-dimethoxy-4-methylsulfanylphenyl)propan-2- amine; hydrochloride), ALEPH-2 (aka 1-(4-ethylsulfanyl-2,5-dimethoxyphenyl)propan-2-amine), ALEPH-4 (aka 1-(2,5-dimethoxy-4-propan-2-ylsulfanylphenyl)propan-2-amine), ALEPH-6 (aka 1-(2,5-dimethoxy-4-phenylsulfanylphenyl)propan-2-amine), ALEPH-7 (aka 1-(2,5-dimethoxy-4- propylsulfanylphenyl)propan-2-amine), ARIADNE (aka (2R)-1-(2,5-dimethoxy-4- methylphenyl)butan-2-amine), ASB (aka 2-(3,4-diethoxy-5-methoxyphenyl)ethanamine), B (aka 2-(4-butoxy-3,5-dimethoxyphenyl)ethanamine), BEATRICE (aka 1-(2,5-dimethoxy-4- methylphenyl)-N-methylpropan-2-amine), beta-D (aka 2,2-dideuterio-2-(3,4,5- trimethoxyphenyl)ethanamine), BIS-TOM (aka 1-[4-methyl-2,5- bis(methylsulfanyl)phenyl]propan-2-amine), bk-2C-B (aka 2-amino-1-(4-bromo-2,5- dimethoxyphenyl)ethanone), BOB (aka 2-(4-bromo-2,5-dimethoxyphenyl)-2- methoxyethanamine), BOD (aka 2-(2,5-dimethoxy-4-methylphenyl)-2-methoxyethanamine), BOH (aka 2-(1,3-benzodioxol-5-yl)-2-methoxyethanamine), BOHD (aka 2-amino-1-(2,5- dimethoxy-4-methylpheny)ethanol), BOM (aka 2-methoxy-2-(3,4,5- trimethoxyphenyl)ethanamine), bromo-dragonFLY (aka 1-(4-bromofuro[2,3-f][1]benzofuran-8- yl)propan-2-amine), butylone (aka 1-(1,3-benzodioxl-5-yl)-2-(methylamino)butan-1-one), CPM (aka 2-[4-(cyclopropylmethoxy)-3,5-dimethoxyphenyl]ethanamine), DESOXY (aka 2-(3,5- dimethoxy-4-methylpheny)ethanamine), DMCPA (aka 2-(2,5-dimethoxy-4- methylphenyl)cyclopropan-1-amine), DME (aka 2-amino-1-(3,4-dimethoxyphenyl)ethanol), DMMDA (aka 1-(4,7-dimethoxy-1,3-benzodioxol-5-yl)propan-2-amine), DMMDA-2 (aka 1-(6,7- dimethoxy-1,3-benzodioxol-5-yl)propan-2-amine), DMPEA (aka 2-(3,4- dimethoxyphenyl)ethanamine), DOAM (aka 1-(2,5-dimethoxy-4-pentylphenyl)propan-2-amine), DOB (aka 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine), DOBU (aka 1-(4-butyl-2,5- dimethoxyphenyl)propan-2-amine), DOC (aka 1-(4-chloro-2,5-dimethoxyphenyl)propan-2- amine), DOEF (aka 1-[4-(2-fluoroethyl)-2,5-dimethoxyphenyl]propan-2-amine), DOET (aka 1-(4- ethyl-2,5-dimethoxyphenyl)propan-2-amine), DOF (aka 1-(4-fluoro-2,5-dimethoxyphenyl)propan- 2-amine), DOI (aka 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine), DOM (aka 1-(2,5- dimethoxy-4-methylphenyl)propan-2-amine), DON (aka 1-(2,5-dimethoxy-4-nitrophenyl)propan- 2-amine), DOPR (aka 1-(2,5-dimethoxy-4-propylphenyl)propan-2-amine), DOTFM (aka 1-[2,5- dimethoxy-4-(trifluoromethyl)phenyl]propan-2-amine), E (aka 2-(4-ethoxy-3,5- dimethoxyphenyl)ethanamine), EBDP (aka 1-(1,3-benzodioxol-5-yl)-N-ethylpentan-2-amine), 134 01312-0021-00PCT EEE (aka 1-(2,4,5-triethoxyphenyl)propan-2-amine), EEM (aka 1-(2,4-diethoxy-5- methoxyphenyl)propan-2-amine), EME (aka 1-(2,5-diethoxy-4-methoxyphenyl)propan-2-amine), EMM (aka 1-(2-ethoxy-4,5-dimethoxyphenyl)propan-2-amine), ETHYL-J (aka 1-(1,3- benzodioxol-5-yl)-N-ethylbutan-2-amine), ETHYL-K (aka 1-(1,3-benzodioxol-5-yl)-N- ethylpentan-2-amine), F-2 (aka 1-(5-methoxy-2-methyl-2,3-dihydro-1-benzofuran-6-yl)propan-2- amine), F-22 (aka 1-(5-methoxy-2,2-dimethyl-3H-1-benzofuran-6-yl)propan-2-amine), FLEA (aka N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]-N-methylhydroxylamine), G-3 (aka 1-(4,7- dimethoxy-2,3-dihydro-1H-inden-5-yl)propan-2-amine), G-4 (aka 1-(1,4-dimethoxy-5,6,7,8- tetrahydronaphthalen-2-yl)propan-2-amine), G-5 (aka 3,6-dimethoxy-4-(2- aminopropyl)benzonorbornane), G-N (aka 1-(1,4-dimethoxynaphthalen-2-yl)propan-2-amine), GANESHA (aka 1-(2,5-dimethoxy-3,4-dimethylphenyl)propan-2-amine), HOT-17 (aka N-[2-(4- butan-2-ylsulfanyl-2,5-dimethoxypheny)ethyl]hydroxylamine), HOT-2 (aka N-[2-(4-ethylsulfanyl- 2,5-dimethoxypheny)ethyl]hydroxylamine), HOT-7 (aka N-[2-(2,5-dimethoxy-4- propylsulfanylpheny)ethyl]hydroxylamine), IDNNA (aka 1-(4-iodo-2,5-dimethoxyphenyl)-N,N- dimethylpropan-2-amine), IM (aka 2-(2,3,4-trimethoxyphenyl)e thanamine), IP (aka 2-(3,5- dimethoxy-4-propan-2-yloxyphenyl)ethanamine), IRIS (aka 1-(5-ethoxy-2-methoxy-4- methylphenyl)propan-2-amine), J (aka 1-(1,3-benzodioxol-5-yl)butan-2-amine), jimscaline (aka [(1R)-4,5,6-trimethoxy-2,3-dihydro-1H-inden-1-yl]methanamine), LOPHOPHINE (aka 2-(7- methoxy-1,3-benzodioxol-5-yl)ethanamine), M (aka 2-(3,4,5-trimethoxypheny)ethanamine), MADAM-6 (aka N-methyl-1-(6-methyl-1,3-benzodioxol-5-yl)propan-2-amine), MAL (aka 2-[3,5- dimethoxy-4-(2-methylprop-2-enoxy)phenyl]ethanamine), MDA (aka 1-(1,3-benzodioxol-5- yl)propan-2-amine), MDAL (aka 1-(1,3-benzodioxol-5-yl)-N-prop-2-enylpropan-2-amine), MDBU (aka N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]butan-1-amine), MDBZ (aka 1-(1,3-benzodioxol-5- yl)-N-benzylpropan-2-amine), MDCPM (aka 1-(3a,7a-dihydro-1,3-benzodioxol-5-yl)-N- (cyclopropylmethyl)propan-2-amin- e), MDDM (aka 1-(1,3-benzodioxol-5-yl)-N,N- dimethylpropan-2-amine), MDE (aka 1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine), MDHOET (aka 2-[1-(1,3-benzodioxol-5-yl)propan-2-ylamino]ethanol), MDIP (aka 1-(1,3- benzodioxol-5-yl)-N-propan-2-ylpropan-2-amine), MDMA (aka 1-(1,3-benzodioxol-5-yl)-N- methylpropan-2-amine), MDMC (aka 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-methylpropan-2- amine), MDMEO (aka 1-(1,3-benzodioxol-5-yl)-N-methoxypropan-2-amine), MDMEOET (aka 1- (1,3-benzodioxol-5-yl)-N-(2-methoxyethyl)propan-2-amine), MDMP (aka 1-(1,3-benzodioxol-5- yl)-N,2-dimethylpropan-2-amine), MDOH (aka N-[1-(1,3-benzodioxol-5-yl)propan-2- yl]hydroxylamine), MDPEA (aka 2-(1,3-benzodioxol-5-yl)ethanamine), MDPH (aka 1-(1,3- benzodioxol-5-yl)-2-methylpropan-2-amine), MDPL (aka 1-(1,3-benzodioxol-5-yl)-N-prop-2- ynylpropan-2-amine), MDPR (aka 1-(1,3-benzodioxol-5-yl)-N-propylpropan-2-amine), ME (aka 2-(3-ethoxy-4,5-dimethoxyphenyl)ethanamine), MEDA (aka 1-(5-methoxy-2,3-dihydro-1,4- benzodioxin-7-yl)propan-2-amine), MEE (aka 1-(4,5-diethoxy-2-methoxyphenyl)propan-2- amine), MEM (aka 1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine), MEPEA (aka 2-(4- 135 01312-0021-00PCT ethoxy-3-methoxyphenyl)ethanamine), META-DOB (aka 1-(5-bromo-2,4- dimethoxyphenyl)propan-2-amine), META-DOT (aka 1-(2,4-dimethoxy-5- methylsulfanylphenyl)propan-2-amine), METHYL-DMA (aka 1-(2,5-dimethoxyphenyl)-N- methylpropan-2-amine), METHYL-DOB (aka 1-(4-bromo-2,5-dimethoxyphenyl)-N- methylpropan-2-amine), METHYL-J (aka 1-(1,3-benzodioxol-5-yl)-N-methylbutan-2-amine), METHYL-K (aka 1-(1,3-benzodioxol-5-yl)-N-methylpentan-2-amine), METHYL-MA (aka 1-(4- methoxyphenyl)-N-methylpropan-2-amine), METHYL-MMDA-2 (aka 1-(6-methoxy-1,3- benzodioxol-5-yl)-N-methylpropan-2-amine), MMDA (aka 1-(7-methoxy-1,3-benzodioxol-5- yl)propan-2-amine), MMDA-2 (aka 1-(6-methoxy-1,3-benzodioxol-5-yl)propan-2-amine), MMDA- 3a (aka 1-(4-methoxy-1,3-benzodioxol-5-yl)propan-2-amine), MMDA-3b (aka 1-(7-methoxy-1,3- benzodioxol-4-yl)propan-2-amine), MME (aka 1-(5-ethoxy-2,4-dimethoxyphenyl)propan-2- amine), MP (aka 2-(3,4-dimethoxy-5-propoxyphenyl)ethanamine), MPM (aka 1-(2,4-dimethoxy- 5-propoxyphenyl)propan-2-amine), NBOMe-mescaline (aka N-[(2-methoxyphenyl)methyl]-2- (3,4,5-trimethoxypheny)ethanamine), ORTHO-DOT (aka 1-(4,5-dimethoxy-2- methylsulfanylphenyl)propan-2-amine), P (aka 2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine), PE (aka 2-[3,5-dimethoxy-4-(2-phenylethoxy)phenyl]ethanamine), PEA (aka 2- phenylethanamine), PROPYNYL (aka 2-(3,5-dimethoxy-4-prop-2-ynoxyphenyl)ethanamine), psi-2C-T-4, psi-DOM (aka 1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine), SB (aka 2-(3,5- diethoxy-4-methoxyphenyl)ethanamine), TA (aka 1-(2,3,4,5-tetramethoxyphenyl)propan-2- amine), TB (aka 2-(4-butylsulfanyl-3,5-dimethoxypheny)ethanamine), TCB-2 (aka (3-bromo-2,5- dimethoxy-7-bicyclo[4.2.0]octa-1(6), 2,4-trienyl)methanamine;hydrobromide), TMA (aka 1- (3,4,5-trimethoxyphenyl)propan-2-amine), TMA-2 (aka 1-(2,4,5-trimethoxyphenyl)propan-2- amine), TMA-3 (aka 1-(2,3,4-trimethoxyphenyl)propan-2-amine), TMA-4 (aka 1-(2,3,5- trimethoxyphenyl)propan-2-amine), TMA-5 (aka 1-(2,3,6-trimethoxyphenyl)propan-2-amine), TMA-6 (aka 1-(2,4,6-trimethoxyphenyl)propan-2-amine), TMPEA (aka 2-(2,4,5- trimethoxyphenyl)ethanamine), TOMSO (aka 1-(2-methoxy-4-methyl-5- methylsulfinylphenyl)propan-2-amine), TP (aka 2-(3,5-dimethoxy-4- propylsulfanylphenyl)ethanamine), and TRIS (aka 2-(3,4,5-triethoxyphenyl)ethanamine). In one embodiment, a serotonergic drug is chosen from alprazolam, amphetamine, aripiprazole, azapirone, a barbiturate, bromazepam, bupropion, buspirone, a cannabinoid, chlordiazepoxide, citalopram, clonazepam, clorazepate, dextromethorphan, diazepam, duloxetine, escitalopram, fluoxetine, flurazepam, fluvoxamine, lorazepam, lysergic acid diethylamide, lysergamide, 3,4-methylenedioxymethamphetamine, milnacipran, mirtazapine, naratriptan, paroxetine, pethidine, phenethylamine, psicaine, oxazepam, reboxetine, serenic, serotonin, sertraline, temazepam, tramadol, triazolam, a tryptamine, venlafaxine, vortioxetine, and / or derivatives thereof. In one embodiment, serotonin acts at a serotonin receptor, e.g., by acting as a ligand at a 5-HT receptor. In one embodiment, serotonin is produced by an organism for use as a 136 01312-0021-00PCT neurotransmitter within that organism. In one embodiment, the compositions and methods disclosed herein increase the activity at a serotonin receptor. In one embodiment, the compositions and methods disclosed herein decrease the activity at a serotonin receptor. As used herein, the term "serotonin receptor" refers to a collection of proteins outside a cell capable of receiving signals and activating internal signal transduction pathways causing a cellular response. In one embodiment, a serotonin receptor is found on a cell within the central nervous system of an organism. In one embodiment, a serotonin receptor is found on a cell within the peripheral nervous system of an organism. In one embodiment, serotonin is the natural ligand for a serotonin receptor. In one embodiment, a serotonin receptor modulates the release of a neurotransmitter, e.g., glutamate, gamma-Aminobutyric acid, dopamine, epinephrine (a.k.a. norepinephrine), acetylcholine, etc. In one embodiment, a serotonin receptor modulates the release of a hormone, e.g., oxytocin, prolactin, vasopressin, cortisol, corticotropin, substance P, etc. Examples of serotonin receptors include, but are not limited to, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A, 5-HT5B, 5-HT6, and 5-HT7. As used herein, the term "adrenergic drug" refers to a compound that binds, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at an adrenergic receptor. In one embodiment, an adrenergic drug binds to an adrenergic receptor. In one embodiment, an adrenergic drug indirectly affects an adrenergic receptor, e.g., via interactions affecting the reactivity of other molecules at the adrenergic receptor. In one embodiment, an adrenergic drug is an agonist, e.g., a compound activating an adrenergic receptor. In one embodiment, an adrenergic drug is an antagonist, e.g., a compound binding but not activating an adrenergic receptor, e.g., blocking a receptor. In one embodiment, an adrenergic drug is an effector molecule, e.g., a compound binding to an enzyme for allosteric regulation. In one embodiment, an adrenergic drug acts (either directly or indirectly) at more than one type of receptor (e.g., 5HT, dopamine, adrenergic, acetylcholine, etc.). In one embodiment, an adrenergic drug is an antidepressant. In one embodiment, an adrenergic drug is a norepinephrine transporter inhibitor. In one embodiment, an adrenergic drug is a vesicular monoamine transporter inhibitor. In one embodiment, an adrenergic drug is chosen from adrenaline, agmatine, amoxapine, aptazapine, atomoxetine, bupropion, clonidine, doxepin, duloxetine, esmirtazpine, mianserin, mirabegron, mirtazapine, norepinephrine, phentolamine, phenylephrine, piperoxan, reserpine, ritodrine, setiptiline, tesofensine, timolol, trazodone, trimipramine, or xylazine. In one embodiment, an adrenergic drug acts at an adrenergic receptor, e.g., by acting as a ligand at an adrenergic receptor. In one embodiment, adrenaline is produced by an organism for use as a neurotransmitter within that organism. In one embodiment, norepinephrine is 137 01312-0021-00PCT produced by an organism for use as a neurotransmitter within that organism. In one embodiment, the compositions and methods disclosed herein increase the activity at an adrenergic receptor. In one embodiment, the compositions and methods disclosed herein decrease the activity at an adrenergic receptor. As used herein, the term "adrenergic receptor" refers to a collection of proteins outside a cell capable of receiving signals and activating internal signal transduction pathways causing a cellular response. In one embodiment, an adrenergic receptor is found on a cell within the central nervous system of an organism. In one embodiment, an adrenergic receptor is found on a cell within the sympathetic nervous system of an organism. As used herein, the term "dopaminergic drug" refers to a compound that binds, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a dopamine receptor. In one embodiment, a dopaminergic drug binds to a dopamine receptor. In one embodiment, a dopaminergic drug indirectly affects a dopamine receptor, e.g., via interactions affecting the reactivity of other molecules at the dopamine receptor. In one embodiment, a dopaminergic drug is an agonist, e.g., a compound activating a dopamine receptor. In one embodiment, a dopaminergic drug is an antagonist, e.g., a compound binding but not activating a dopamine receptor, e.g., blocking a receptor. In one embodiment, a dopaminergic drug is an effector molecule, e.g., a compound binding to an enzyme for allosteric regulation. In one embodiment, a dopaminergic drug acts (either directly or indirectly) at more than one type of receptor (e.g., 5HT, dopamine, adrenergic, acetylcholine, etc.). In one embodiment, a dopaminergic drug is a dopamine transporter inhibitor. In one embodiment, a dopaminergic drug is a vesicular monoamine transporter inhibitor. In one embodiment, a dopaminergic drug is chosen from amineptine, apomorphine, benzylpiperazine, bromocriptine, cabergoline, chlorpromazine, clozapine, dihydrexidine, domperidone, dopamine, fluphenazine, haloperidol, ketamine, loxapine, methamphetamine, olanzapine, pemoline, perphenazine, pergolide, phencyclidine, phenethylamine, phenmetrazine, pimozide, piribedil, a psychostimulant, reserpine, risperidone, ropinirole, tetrabenazine, or thioridazine. In one embodiment, a dopaminergic drug acts at a dopamine receptor, e.g., by acting as a ligand at a dopamine receptor. In one embodiment, dopamine is produced by an organism for use as a neurotransmitter within that organism. In one embodiment, the compositions and methods disclosed herein increase the activity at a dopamine receptor. In one embodiment, the compositions and methods disclosed herein decrease the activity at a dopamine receptor. As used herein, the term "dopamine receptor" refers to a collection of proteins outside a cell capable of receiving signals and activating internal signal transduction pathways causing a cellular response. In one embodiment, a dopamine receptor is found on a cell within the central 138 01312-0021-00PCT nervous system of an organism. In one embodiment, a purified terpene modulates the activity of a neurotransmitter at its native receptor, e.g., serotonin at a serotonin receptor, dopamine at a dopaminergic drug, norephedrine at an adrenergic receptor, etc. In one embodiment, a purified terpene is active at one or more receptors, e.g., a serotonin receptor, an adrenergic receptor, a dopamine receptor, a GABAergic receptor, a glutaminergic receptor, a histaminergic receptor, a cholinergic receptor, an opioid receptor, or a glycinergic receptor. In one embodiment, the compositions disclosed herein comprise a monoamine oxidase inhibitor. As used herein, the term "monoamine oxidase inhibitor" refers to a molecule binding to a monoamine oxidase enzyme thereby reducing the activity of the monoamine oxidase enzyme. Within the context of this disclosure, examples of monoamine oxidase inhibitors include aurorix, deprenyl, eldepryl, emsam, humoryl, hydracarbazine, isocarboxazid, linezolid, manerix, nydrazid, phenelzine, pirazidol, procarbazine, rasagiline, and tranylcypromine. In one embodiment, monoamine oxidase catalyzes the oxidation of a monoamine, e.g., serotonin, dopamine, norepinephrine, amphetamine, adrenaline, etc. In one embodiment, the compositions disclosed herein comprise a stabilizer. As used herein, the term "stabilizer" refers to a compound useful for preventing the degradation of an active ingredient, e.g., a compound of Formula I, a psilocybin derivative, a cannabinoid, a terpene, etc. In one embodiment, a stabilizer prevents an active ingredient from degrading. In one embodiment, a stabilizer prevents a serotonergic drug from reacting with other compounds in the composition, e.g., a cannabinoid, a terpene, a base, an acid, etc. In one embodiment, a stabilizer prevents a serotonergic drug from reacting with the ambient atmosphere, e.g., heat, light, water, and / or oxygen. In one embodiment, a stabilizer comprises an antioxidant. In one embodiment, a stabilizer comprises a pH buffer. In one embodiment, the methods and compositions disclosed herein comprise an antioxidant. As used herein, the term "antioxidant" refers to a compound and / or a composition useful for preventing oxidation. In one embodiment, an antioxidant protects an active ingredient from "free radicals". Within the context of this disclosure, a "free radical" is an atom, molecule, or an ion with an unpaired valence electron. In one embodiment, an antioxidant is an electron donor. In one embodiment, an antioxidant is chosen from ascorbic acid, lycopene, tocopherol, melatonin, retinol, astaxanthin, lutein, apigenin, carnosine, selenium, zinc, cucurmin, and / or a salt or derivative thereof. In one embodiment, an antioxidant is ascorbic acid and / or its salts or derivatives. Within 139 01312-0021-00PCT the context of this disclosure, the term "ascorbic acid" comprises Vitamin C and / or a salt or derivative thereof. In one embodiment, an antioxidant prevents the oxidation of a composition comprising one or more compounds disclosed herein, e.g., compounds of Formula I, psilocybin derivatives, cannabinoids, terpenes, and / or mixtures thereof. For example, preventing the oxidation of a phenolic group attached to a psilocybin derivative. As used herein, the term "oxidation" refers to the formal loss of electrons and / or the increase of the formal oxidation state and / or the addition of an oxygen atom or atoms. As used herein, "reduction" refers to the formal gain of electrons and / or the decrease of the formal oxidation state. Zumdahl, Steven S., et al. Chemistry, 7th. Cengage Learning, 2018. In one embodiment, the methods and compositions disclosed herein comprise a pH buffer. As used herein, the term "pH buffer" refers to a compound or a composition useful for maintaining the pH of a composition. In one embodiment, a pH buffer comprises a weak acid and a corresponding conjugate base. In one embodiment, a pH buffer comprises a weak base and a corresponding conjugate acid. In one embodiment, a pH buffer does not change the pH of a composition with the addition of a strong acid and / or base. In one embodiment, a pH buffer maintains the pH of a composition around 7. In one embodiment, a pH buffer maintains the pH of a composition below about 7. In one embodiment, a pH buffer maintains the pH of a composition above about 7. In one embodiment, a pH buffer maintains the pH of a composition ranging from about 2 to about 6. In one embodiment, a pH buffer maintains the pH of a composition ranging from about 5 to about 7. In one embodiment, a pH buffer maintains the pH of a composition ranging from about 6 to about 8. In one embodiment, a pH buffer maintains the pH of a composition ranging from about 7 to about 10. In one embodiment, a pH buffer comprises citric acid, acetic acid, monosodium phosphate, N-Cyclohexyl-2-aminoethanesulfonic acid, borate, hydrochloric acid, and / or sodium hydroxide. In one embodiment, the methods disclosed herein comprise administering a composition comprising an acid. As used herein, the term "acid" refers to a molecule or ion capable of donating a proton, i.e., H+and / or accepting electrons. In one embodiment, an "acid" refers to a Lewis acid. In one embodiment, an "acid" refers to a Bronsted acid. In one embodiment, an acid is determined by a composition’s pH. In one embodiment, a pH below 7 indicates the presence of an acid. In one embodiment, the compositions and methods disclosed herein comprise administering a formulation comprising a base. 140 01312-0021-00PCT As used herein, the term "base" refers to a molecule or ion capable of accepting a proton, i.e., an H+. In one embodiment, a "base" refers to a molecule capable of donating an electron pair, i.e., a Lewis base. In one embodiment, the presence of a base is determined by a compound's pH. In one embodiment, a pH above 7 indicates the presence of a base. In one embodiment, the compositions and methods disclosed herein comprise administering a non water soluble composition. In some embodiments, the compositions described herein are non-aqueous. As used herein, the term "water soluble" refers to a compound or composition capable of dissolving in water at standard temperature and pressure. In one example, 1 g of a compound dissolves in 1 L of water. In one example, 2 g of a compound dissolves in 1 L of water. In one example, 5 g of a compound dissolves in 1 L of water. In one example, 10 g of a compound dissolves in 1 L of water. In one embodiment, a compound's solubility in water is an inherent property of a compound. In one embodiment, a compound's solubility in water is facilitated by another compound, e.g., an excipient. In one embodiment, the compositions and methods disclosed herein comprise administering a compound of Formula I present as and / or within a homogenous mixture within a dosage formulation. In one embodiment, the compositions and methods disclosed herein comprise administering a compound of Formula I and at least one second compound (e.g., serotonergic drug, cannabinoid, terpene, excipient, stabilizer, antioxidant, etc.) present as and / or within a homogenous mixture within a dosage formulation. As used herein, the term "homogeneous mixture" refers to a solid, liquid, or gaseous composition that has two or more compounds present within one state or thing, e.g., a clear, colorless solution. In one embodiment, the homogeneous mixtures disclosed herein have the same proportion, concentration, and / or ratio of its components across different samples. In one embodiment, the components in the homogeneous mixture are in the same state of matter. In one embodiment, a homogeneous mixture comprises one or more compounds within a solution, e.g., a compound of Formula I and a cannabinoid within a clear solution. In one embodiment, the compositions disclosed herein are present as a homogenous mixture, e.g., a solution with no particulates, a solution with equal concentrations across samples, a powder of similar particle size, etc. Disclosed herein is a method of modulating activity at a neurotransmitter receptor, comprising: administering a neurotransmitter activity modulator; and administering a dosage formulation comprising a compound of Formula I to the person in 141 01312-0021-00PCT need of treatment, wherein the dosage formulation modulates activity at a neurotransmitter receptor. As used herein, the term "modulating activity of the neurotransmitter activity modulator" refers to changing, manipulating, and / or adjusting the ability of a compound or composition to affect a neurotransmitter receptor. In one embodiment, modulating the activity of a neurotransmitter activity modulator comprises administering an agonist at a neurotransmitter receptor. In one embodiment, modulating the activity of a neurotransmitter activity modulator comprises administering an antagonist at a neurotransmitter receptor. As used herein, the term "administering" (e.g., administering a drug) refers to dosing, treating, giving, and / or providing. In one embodiment, administering a neurotransmitter activity modulator comprises providing a neurotransmitter activity modulator to an organism (, e.g., a human being) with a neurotransmitter receptor. In one embodiment, administering a neurotransmitter activity modulator comprises providing a neurotransmitter activity modulator along with a compound of Formula I, e.g., a formulation having each of a neurotransmitter activity modulator and a compound of Formula I in a single dosage. In one embodiment, administering a neurotransmitter activity modulator comprises applying a transdermal composition, e.g., applying a topical composition to the skin having each of a neurotransmitter activity modulator and a compound of Formula I. In one embodiment, administering a neurotransmitter activity modulator comprises giving a transmucosal preparation, e.g., providing rapidly dissolving a tablet with an absorption enhancer having each of a neurotransmitter activity modulator and a compound of Formula I. In one embodiment, the methods disclosed herein comprise administering a composition by inhalation for crossing a blood-brain barrier. As used herein, the term "neurotransmitter activity modulator" refers to a compound or composition that reacts or influences activity at a neurotransmitter receptor, e.g., a compound of Formula I, a serotonergic drug, an adrenergic receptor, a dopamine receptor, a GABAergic receptor, a glutaminergic receptor, a histaminergic receptor, a cholinergic receptor, an opioid receptor, or a glycinergic receptor, etc. In one embodiment, a neurotransmitter activity modulator binds on a neurotransmitter receptor. In one embodiment, a neurotransmitter activity modulator indirectly affects a neurotransmitter receptor, e.g., via interactions affecting the reactivity of other molecules at a neurotransmitter receptor. In one embodiment, a neurotransmitter activity modulator is an agonist. In one embodiment, a neurotransmitter activity modulator is an antagonist. In one embodiment, a neurotransmitter activity modulator acts (either directly or indirectly) at more than one type of neurotransmitter receptor. In one embodiment, a neurotransmitter activity modulator is chosen from aripiprazole, bupropion, citalopram, clomipramine, dextroamphetamine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, quetiapine, reboxetine, risperidone, 142 01312-0021-00PCT sertraline, and venlafaxine. As used herein, the term "first dosage formulation" refers to a compound or compounds selected for the purposes of causing a reaction, effect, and / or result, e.g., causing activity at a neurotransmitter receptor, reacting with other compounds, enhancing the effects of other active ingredients, inhibiting the biosynthesis of a compound, etc., within an organism. In one embodiment, a first dosage formulation comprises a compound of Formula I. In one embodiment, a first dosage formulation comprises a first purified cannabinoid. In one embodiment, a first dosage formulation comprises a first purified terpene. In one embodiment, a first dosage formulation comprises a compound of Formula I and a purified serotonergic derivative. In one embodiment, a first dosage formulation comprises a compound of Formula I and a first purified cannabinoid. In one embodiment, a first dosage formulation a compound of Formula I and a first purified terpene. In one embodiment, a first dosage formulation comprises a compound of Formula I, a first purified cannabinoid, and first purified terpene. In one embodiment, a first dosage formulation comprises a compound of Formula I and a neurotransmitter activity modulator. In one embodiment, a second dosage formulation comprises a compound of Formula I. In one embodiment, a second dosage formulation comprises a second compound of Formula I. In one embodiment, a second dosage formulation comprises a second serotonergic drug. In one embodiment, the methods disclosed herein comprise administering a second dosage formulation. In one embodiment, the methods disclosed herein comprise administering a third dosage formulation. In one embodiment, the methods disclosed herein comprise administering a fourth dosage formulation. In one embodiment, the methods disclosed herein comprise administering more than four dosage formulations. In certain embodiments, the dosage formulation contains a desired amount of at least one compound of Formula I. In certain embodiments, the dosage formulation contains about 0.01 to about 1,000mg of the compound, such as about 0.1 to about 500mg, about 0.5 to about 100mg, or about 1 to about 50mg. In certain embodiments, the dosage formulation is calculated to contain an amount of a compound of Formula I based on mg of compound per kg of the subject (mg / kg). In certain embodiments, the mg / kg range can be about 0.001 to about 10mg / kg, such as about 0.01 to about 5, about 0.05 to about 4, about 0.05 to about 3, about 0.05 to about 3, about 0.05 to about 2, or about 0.05 to about 1mg / kg. In some embodiments, the compound is dosed in an amount that is less than about 1mg / kg, such as about 0.001 to about 0.99, about 0.01 to about 0.85, about 0.05 to about 0.75, about 0.01 to about 0.50, about 0.01 to about 0.25 or about 0.01 to about 0.10mg / kg. In one embodiment, the methods disclosed herein comprise administering one or more active ingredients, e.g., a compound(s) of Formula I, cannabinoids, terpenes, neurotransmitter activity modulators, etc., in more than two doses. 143 01312-0021-00PCT As used herein, the term "identifying a person in need of treatment" refers to analyzing, diagnosing, and / or determining whether a person requires treatment for a disease or condition. In one embodiment, identifying a person in need of treatment comprises diagnosing a person with a medical condition, e.g., a methamphetamine addiction or overdose, opioid addiction or overdose, etc. In one embodiment, identifying a person in need of treatment comprises performing a psychiatric evaluation. In one embodiment, identifying a person in need of treatment comprises performing a blood test. In one embodiment, identifying a person in need of treatment comprises determining whether a person has a compulsive disorder. In one embodiment, identifying a person in need of treatment comprises self-identifying as having a compulsive disorder. In one embodiment, the methods and compositions disclosed herein comprise administering an anxiolytic drug. As used herein, the term "anxiolytic drug" refers to a compound or composition that reacts or influences activity at a neurotransmitter receptor, e.g., a compound of Formula I, a serotonergic drug, an adrenergic receptor, a dopamine receptor, a GABAergic receptor, a glutaminergic receptor, a histaminergic receptor, a cholinergic receptor, an opioid receptor, or a glycinergic receptor, etc. In one embodiment, an anxiolytic drug binds on a neurotransmitter receptor. In one embodiment, an anxiolytic drug indirectly affects a neurotransmitter receptor, e.g., via interactions affecting the reactivity of other molecules at a neurotransmitter receptor. In one embodiment, an anxiolytic drug is an agonist. In one embodiment, an anxiolytic drug is an antagonist. In one embodiment, an anxiolytic drug acts (either directly or indirectly) at more than one type of neurotransmitter receptor. In one embodiment, an anxiolytic drug is chosen from alprazolam, an alpha blocker, an antihistamine, a barbiturate, a beta blocker, bromazepam, a carbamate, chlordiazepoxide, clonazepam, clorazepate, diazepam, flurazepam, lorazepam, an opioid, oxazepam, temazepam, or triazolam. In one embodiment, the methods and compositions disclosed herein comprise administering an antidepressant. As used herein, the term "antidepressant" refers to a compound or compounds that reacts or influences activity at a neurotransmitter receptor, e.g., a compound of Formula I, a serotonergic drug, an adrenergic receptor, a dopamine receptor, a GABAergic receptor, a glutaminergic receptor, a histaminergic receptor, a cholinergic receptor, an opioid receptor, or a glycinergic receptor, etc. In one embodiment, an antidepressant binds on a neurotransmitter receptor. In one embodiment, an antidepressant indirectly affects a neurotransmitter receptor, e.g., via interactions affecting the reactivity of other molecules at a neurotransmitter receptor. In one embodiment, an antidepressant is an agonist. In one embodiment, an antidepressant is an antagonist. In one embodiment, an antidepressant acts (either directly or indirectly) at more than 144 01312-0021-00PCT one type of neurotransmitter receptor. In one embodiment, an antidepressant is chosen from bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine. Disclosed herein is a method of treating nicotine addiction, comprising administering a compound of Formula I or a composition disclosed herein to the person in need of treatment. Disclosed herein is a method of treating drug addiction, comprising administering a compound of Formula I or a composition disclosed herein to the person in need of treatment. In certain embodiments, the drug addiction is selected from amphetamine addiction, methamphetamine addiction, opioid addiction (e.g., oxycodone, fentanyl, or heroin addiction), and cocaine addiction. In certain embodiments, the drug addiction is amphetamine addiction. In certain embodiments, the amphetamine is methamphetamine. Disclosed herein is a method of treating alcohol addiction, comprising administering a compound of Formula I or a composition disclosed herein to the person in need of treatment. As used herein, the term "addiction" refers to a physical and / or psychological dependence on a substance, activity, and / or any other habit. In one embodiment, an addiction is caused by the altered brain chemistry of an individual in response to a stimulus, e.g., a substance releasing large amounts of serotonin, an activity releasing large amounts of adrenaline, etc. In one embodiment, an addiction is a dependence on a substance, e.g., a drug, an alcohol, nicotine, a food, etc. In one embodiment, an addiction is a dependence on an activity, e.g., gambling, eating, shopping, etc. Disclosed herein is a method of treating drug overdose, comprising administering a compound of Formula I or a composition disclosed herein to the person in need of treatment. In certain embodiments, the drug overdose comprises the overuse of a drug that modulates trace amine-associated receptor 1 (TAAR1). In certain embodiments, the drug comprises a TAAR1 agonist. In certain embodiments, the drug comprises amphetamine. In certain embodiments, the drug comprises methamphetamine. In certain embodiments, the drug overdose comprises an opioid overdose. In some embodiments, the opioid comprises oxycodone, heroin or fentanyl. In certain embodiments, described herein is a method of treating or reducing the effects of methamphetamine overdose. In certain embodiments, the method comprises administering a compound of Formula I or composition disclosed herein to a person in need of treatment for methamphetamine overdose. In certain embodiments, the effects of methamphetamine overdose are selected from at least one of hyperthermia, convulsions, and seizures. Without being bound to any particular scientific theory, it is believed that one or more of the compounds of Formula I may be effective at treating methamphetamine addiction, methamphetamine overdose and its associated side effects by modulation via 5-HT2C and / or 5-HT2A receptors. In 145 01312-0021-00PCT some embodiments, it is believed that compounds of Formula I can effectively treat methamphetamine overdose (e.g., acute methamphetamine toxicity that results in death or negative neurological outcomes) by reducing or eliminating the side effects of methamphetamine toxicity, including (but not limited to) reducing at least one of hyperthermia, convulsions, or seizures. As used herein, the term “overdose” refers to a condition that arises when a subject ingests, injects, applies, or otherwise internalizes an amount of a substance, such as a drug, that leads to unwanted effects. In some instances, an overdose refers to the internalization of a drug or other substance in quantities much greater than are recommended or are much greater than the amount typically used to achieve a desired effect. In some embodiments, the substance is a prescription medication, an over-the-counter medication, or an illegal substance. In some instances, the overdose is accidental. In some instances, the overdose is intentional. In some embodiments, the compositions described herein further comprise at least one compound not acting on a serotonin receptor. In some embodiments, the compositions described herein comprise a serotonergic drug, wherein the serotonergic drug is selected from Formula I. In some embodiments, the composition comprises a single serotonergic drug. In some embodiments, the serotonergic drug consists essentially of a compound of Formula I. Although the disclosed disclosure has been described with reference to various exemplary embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present disclosure. Those having skill in the art would recognize that various modifications to the exemplary embodiments may be made, without departing from the scope of the disclosure. Where reference is made to a particular compound, it should be understood that this disclosure also contemplates salts and derivatives of that compound as well as degradation products, such as oxidized versions of explicitly disclosed molecules. Moreover, it should be understood that various features and / or characteristics of differing embodiments herein may be combined with one another. It is, therefore, to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the scope of the disclosure. Furthermore, other embodiments of the disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the disclosure disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a scope and spirit being indicated by the claims. In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range 146 01312-0021-00PCT and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. As used herein, the terms “about” and “approximately” mean ± 20%, ± 10%, ± 5%, or ± 1% of the indicated range, value, or structure, unless otherwise indicated. Examples Synthetic Scheme A: Benzothiophene and thienopyridine analogs Benzothiophene and thienopyridine compounds of Formula I can be synthesized in the following exemplary manner: Scheme 1A Compound A, a thiophenol starting compound, is alkylated with chloroacetone and the resulting thioether (Compound B) is cyclized under dehydrating acidic conditions to yield 3- methylbenzothiophene intermediate (Compound C). Compound C is then mono-brominated with N-bromosuccinimide (NBS) to provide the 3-bromomethylbenzothiophene, Compound D. 147 01312-0021-00PCT Scheme 2A The nitrile intermediate, Compound E, is prepare...

Claims

01312-0021-00PCT WHAT IS CLAIMED IS:

1. A method of treating a disease or condition comprising administering, to a subject in need thereof, a composition comprising, or consisting essentially of, a 5-HT2A receptor antagonist and a 5-HT2C receptor agonist.

2. The method of claim 1, wherein the disease or condition is an addiction and an overdose.

3. The method of any one of the preceding claims, wherein the subject in need thereof is a human subject.

4. The method of any one of the preceding claims, further comprising administering a 5-HT2B receptor antagonist.

5. The method of any one of the preceding claims, wherein the 5-HT2A receptor antagonist and the 5-HT2C receptor agonist are different compounds.

6. The method of claim 5, wherein the 5-HT2C receptor agonist is bexicaserin.

7. The method of claim 5 or 6, wherein the 5-HT2A receptor antagonist is ketanserin.

8. The method of any one of claims 1-4, wherein the 5-HT2A receptor antagonist and the 5- HT2C receptor agonist are the same compound.

9. The method of claim 8, wherein the compound is selected from compounds of Formula I Formula I wherein is a single or double bond as needed to satisfy atom valences; X and Y are each independently selected from hydrogen, deuterium, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2- C8 alkynyl, or Y is taken together with X and the nitrogen atom therebetween to form a 3- to 7- membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected 22401312-0021-00PCT from O, S, S(O), SO2, and NR9; W1is selected from O, Se, Se(O), SeO2,S, S(O), NR1a, C(R50)(R51), and SO2when the to which W1 is attached is a single bond, and W1 is selected from C(R50) and N when the to which W1 is attached is a double bond; W2is selected from –C(R30)(R31)– and –(C(R30)(R31))2–; W4is selected from C(R2)(R2’) and NR1cwhen a to which W4is attached is a single bond, and W4 is selected from C(R2) and N when a to which W4 is attached is a double bond; W5is selected from C(R51’) and N when the to which W5is attached is a single bond, and W5is C when the to which W5is attached is a double bond; Z4 is selected from N and CR4; Z5 is selected from N and CR5; Z6 is selected from N and CR6; Z7 is selected from N and CR7; R1aand R1care each independently selected from hydrogen, deuterium, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, -C(O)R8, -C(O)OR8, -P(O)(OR9)2, -C(O)N(R9)2, -SOR8, and -SO2R8; R2, R2’, R3, R3’, R4, R5, R6, R7, R30, R31, R50, R51, and R51’are each independently selected from hydrogen, deuterium, -N(R9)2, -C(O)R8, -OC(O)OR8, -C(O)OR8, -OC(O)R8, -SR9, -P(O)(OR9)2, -C(O)N(R9)2, halo, hydroxyl, optionally substituted C1- C8alkyl, optionally substituted -C1-C8alkoxy, optionally substituted C2-C8alkenyl and optionally substituted C2-C8alkynyl, or Y is absent and R3is taken together with the carbon to which it is attached and the nitrogen atom to which X is attached to form an optionally substituted 3- to 9- membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9, or Y is absent and R2 is taken together with the carbon to which it is attached and the nitrogen atom to which X is attached to form an optionally substituted 5- to 9-membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9; R8 is, independently for each occurrence, selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted heteroaryl, and optionally substituted aryl; and 22501312-0021-00PCT R9 is, independently for each occurrence, selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted heteroaryl, and optionally substituted aryl; and salts, solvates, hydrates, and prodrugs thereof.

10. The method of any one of claims 8-9, wherein the compound is also a 5-HT2B receptor antagonist.

11. The method of any one of the preceding claims, wherein the 5-HT2C receptor agonist exhibits a 5-HT2C receptor EC50 of about 0.1 to about 500 nM when measured in a Gq- mediated calcium flux functional assay in an HEK293 cell line.

12. The method of claim 11, wherein the 5-HT2C receptor agonist exhibits a 5-HT2C receptor EC50 of about 0.1 to about 250 nM.

13. The method of any one of claims 11-12, wherein the 5-HT2C receptor agonist exhibits a 5- HT2C receptor EC50 of about 0.1 to about 100 nM.

14. The method of any one of the preceding claims, wherein the 5-HT2A receptor antagonist exhibits an IC50 of about 0.1 to about 1000 nM when measured in an inositol phosphate 1 functional assay in an HEK293 cell line.

15. The method of any one of the preceding claims, wherein the 5-HT2B receptor antagonist exhibits an IC50 of about 0.1 to about 1000 nM when measured in an inositol phosphate 1 functional assay in an HEK293 cell line.

16. The method of claim 15, wherein the 5-HT2B receptor antagonist exhibits an IC50 of about 0.1 to about 500 nM.

17. The method of any one of claims 8-16, wherein the compound is selected from:22618. The method of any one of the preceding claims, wherein the disease or condition comprises addiction.

19. The method of claim 18, wherein the addiction comprises addiction to at least one drug. 22701312-0021-00PCT 20. The method of claim 18, wherein the at least one drug is selected from ethanol, methamphetamine, heroin, cocaine, fentanyl, and oxycodone.

21. The method of claim 18, wherein the addiction comprises addiction to food intake.

22. The method of any one of claims 8-21, wherein the compound is administered to a human subject in need thereof in an amount of about 0.1 to about 10 mg / kg.

23. The method of claim 22, wherein the compound is administered in an amount of about 0.1 to about 5 mg / kg.

24. The method of claim 22, wherein the compound is administered in an amount of about 0.5 to about 3.5 mg / kg. 228